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Abstract 
Environmental Etiology of Polycythemia Vera, Essential Thrombocythemia and Primary 
Myelofibrosis: A Case-Control Study in Northeast Pennsylvania 
Carol Ann Gross-Davis, MS 
Advisors: Craig Newschaffer, PhD., Igor Burstyn PhD 
 
 
 
Objectives 
The etiology of a rare category of myeloproliferative neoplasms (MPN), bone marrow 
diseases with an excess of blood cells, is currently unknown.  An MPN cluster in 
Northeastern Pennsylvania allowed investigation of effects of environmental risk factors 
and to assess the potential for gene-environment interactions.  Since no strong 
hypothesis could be advanced, we focused on known occupational and environmental 
carcinogens, especially those previously implicated in blood tumors, in our investigation 
(e.g. benzene, polycyclic aromatic hydrocarbons (PAH), aromatic & heterocyclic amines).  
The aims of this dissertation were to evaluate the associations between lifestyle and 
environmental risk factors for the most common myeloproliferative neoplasms (MPNs) 
(PV, ET, and PMF), with and without JAK2 V617FV617F. We also explore an interaction 
between known susceptibility genotypes for a subset of cases and controls and potential 
mutagenic chemical exposures, including PAHs.   
 
Methods 
This 2011 population based case-control study assessed residential, smoking and dietary 
history by telephone interview in Schuylkill, Luzerne and Carbon counties in 
Pennsylvania.  Cases (n=55) were identified from the Pennsylvania cancer registry and a 
previous MPN study in Pennsylvania.  Controls (n=473) were selected based on 
eligibility screening using random digit dialing.  Blood samples for genotyping were 
collected from a subset of 31 cases and 292 controls.  
x 
 
 
 
Results 
Cases were older (median age=71 vs. 61years) and more likely to be male (49% vs. 39%) 
compared to controls but otherwise demographically similar.  We found no relationships 
between MPNs and smoking history, residential history, diet, and lifestyle behaviors with 
presumed exposure to aromatic and heterocyclic amines.  After studying the main effects 
of 14 environmentally sensitive genes, we found that only the NAT2, CYP1A2, GSTA1, 
and GSTM3 variants were associated with an average of 3-to 5-fold increased odds of 
having an MPN.  
 
Conclusion 
While these results do not confirm a gene environment interaction effect for one specific 
chemical, the findings encourage further exploration of the interaction hypothesis with 
respect to NAT2, GST, and CYP gene biological pathway and chemical exposures.  These 
same genes appear to be implicated in cases with the somatic mutation believed to be 
involved in the etiology of MPNs, especially PV. Although no association was found 
between exposures related to aromatic and heterocyclic amines and MPNs, our findings 
suggest that genotypes that modify the toxicity of these exposures may play a role in 
MPNs. 
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Chapter 1: Background and the Overview of the Thesis 
 
Myeloproliferative neoplasms (MPNs) 
MPNs are diseases of the bone marrow, with myeloproliferative meaning the excess of 
blood cells.  MPNs are characterized by an overproduction of mature erythrocytes, often 
platelets (James et al. 2005).  These diseases were previously called myeloproliferative 
disorders and the classification of their related diseases has changed numerous times.  
 
MPNs as classified by the World Health Organization (WHO) include polycythemia vera 
(PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).  PV is a 
condition that results in the overproduction of red blood cells, >25% above predicted red 
cell mass (Campbell & Green, 2005).  ET is an overproduction of platelets in the bone 
marrow.  PMF includes bone marrow fibrosis (or scarring of the bone)and is the most 
severe of the three (Tefferi & Vardiman, 2007) .   
 
In 2008, the WHO’s revised diagnostic criterion to include molecular testing for MPN 
diagnosis.  Prior to the revised diagnostic criteria in 2001 Kutti and Ridell calculated a 
yearly incidence of PV at 2.8 per 100,000 persons per year (Kutti &Ridell, 2001).  For ET 
the incidence rate was estimated at 1.5 cases per 100,000 per year (Kutti &Ridell, 2001).  
The rarest of the MPNs is PMF, with an incidence rate of only 0.4 cases per 100,000 
persons per year (Kutti &Ridell, 2001).   
 
Incidence and prevalence reporting of these MPNs are improving each year.  However, 
after only one decade of reporting and diagnostic criteria evolution, there is still an 
ongoing effort by the CDC to improve reporting.  Since 2001, PV, ET, and PMF were 
required to be reported to the state cancer registries (Seaman et al., 2009).  However, 
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only hospital cases were required to be reported and, because treatments of MPNs 
typically do not require hospitalization, physicians did not report cases to the Cancer 
Registries such as Pennsylvania Cancer Registry (PCR).  In 2006, Seaman et al. found 
53% (20 of 38) of the cases that participated and were reported to the PCR either did not 
have enough information to confirm a PV diagnosis or did not meet the case definition of 
PV. 
 
The outcomes and demographics for patients with PV, ET, and PMF differ.  Patients with 
PV and ET can expect to have a near-normal life expectancy if the disease and potential 
complications are managed properly.  PV patients may progress to myelofibrosis and 
acute leukemia (Tefferi, 2007). For PV the median age of diagnosis is 60 years, with a 
slight male predominance (Tefferi, 2007)..  However, the outcome for PMF patients is 
worse than for PV and ET.  PMF patients have a lower quality of life and survival rate.  
No effective therapy is available for PMF, with survival of  60 % at five years (Tefferi & 
Vainchenker, 2011).  
 
Janus Kinase 2 (JAK2 6V17F) point mutation 
An acquired somatic point mutation in Janus Kinase 2 (JAK2 6V17F) on chromosome 
9p, is seen in nearly all PV patients (>95%) and about half of those with ET or PMF.  This 
mutation is suspected to be pathognomonic.  JAK2 is a signalling protein that acts as an 
on-and-off switch regulating bone marrow activity.  This mutation disrupts the normal 
inhibition of growth, thus increasing blood cell production (Baxter et al., 2005). While 
the MPN types differ phenotypically, they commonly share the same de-novo somatic 
JAK2 V617F point mutation (JAK2) thought to be at least partly responsible for disease 
initiation and/or progression (Baxter et al., 2005). 
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The etiologies of MPNs and the causes of JAK2 V617Facquired mutations are unclear 
(Baxter, 2005).  The WHO included the JAK2 V617F mutation as a major diagnostic 
criterion for PV, ET, and PMF in 2008, although confirmed cases of PV, ET, and PMF 
can be JAK2 V617Fnegative if other criteria are satisfied (Seaman et al., 2009; Tefferi et 
al., 2007).  
 
Familial clustering of PV, ET, and PMF 
There is strong evidence for an increased risk of developing an MPN in people who have 
a family member with an MPN (Anderson et al., 2012, Landgren et al., 2008).  Familial 
clustering has been documented in a large Swedish population-based study of 24,577 
first-degree relatives of 11,039 MPN patients diagnosed from 1958 to 2005.  This study 
showed a 5-7-fold increase in risk of developing an MPN for first-degree relatives of 
MPN patients (Landgren et al., 2008).  However, this study could include false positive 
cases, as it included cases before the molecular diagnostic tool for the JAK2 V617F 
mutation was used. 
 
Inherited genetics have also been suspected to influence both MPN phenotype and 
susceptibility, including potential germ-line mutations, some yet to be identified 
(Andrikovics et al., 2010).  Recently, a germ-line haplotype, a sequence of single 
nucleotide polymorphisms (SNPs) on the loci designated as the 46/1 haplotype, has been 
identified as strongly associated with JAK2 V617Fstatus in chromosome 9p (Jones et al., 
2009; Kilpivaara et al., 2009) (Olcaydu et al., 2009).  Three genome-wide studies have 
reported an association with this germ-line 46/1 haplotype in European population and 
JAK2 V617F MPNs (Jones et al., 2009; Kilpivaara et al., 2009; Olcaydu et al., 2009).  
The 46/1 haplotype is estimated to be present in approximately 50% of the population 
and, for those with the JAK2 V617F mutation, is associated with a three-fold increase in 
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risk of developing an JAK2 V617Fassociated MPN (Jones et al.,2009).  The 46/1 
haplotype is considered to be the only known risk factor for the JAK2 V617F mutation in 
PV patients (Andrikovics et al., 2010; Jones et al., 2009). 
 
MPNs and occupational and chemical exposures 
Starting with the discovery of the JAK2 V617F mutation and the 46/1 haplotype 
mutation, interest in environmental exposures and MPNs has emerged (Anderson et 
al.,2012).  There is evidence in the literature to suggest that some occupational chemical 
exposures may be associated with MPNs. 
 
Occupational exposures suggest petroleum products or benzene as a risk 
factor 
 
Occupational groups have been investigated for specific chemical exposures, but there is 
no consensus on what specific occupational exposures are associated with MPNs.  
Exposure to petroleum, of which benzene is a by-product, was associated with an 
increased risk of PV and myelofibrosis (demonstrated by Kaplan (1986)), although there 
were only seven cases.  Kaplan reported on a large cohort of petroleum refinery workers 
and found an elevated SMR in petroleum refiner workers (455, 95% CI: 120, 1164) 
(Kaplan, 1986).  The SMR for myelofibrosis was also elevated for these workers at 201 
(95% CI: 41, 588).  This data only included four deaths from PV and three deaths from 
myelofibrosis making SMR estimates imprecise.  Further investigation of PV or 
myelofibrosis was not recommended due to the small numbers of cases (Kaplan, 1986).  
All three of the above cohort studies suffered from a small numbers of cases.  Only six 
were PV out of a total of 14 MPN reported cases, and there were no ET or PMF cases. 
Two additional case-control studies done by Terreros et al. (1997) and Mele et al. (1997) 
on environmental and occupation exposures also suggest petroleum products or benzene 
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as a risk factor. Only Terreros, with nine cases of myeloproliferative syndrome, reported 
a statistically significant association (OR =47, 95% CI: 2, 2761) with self-reported 
exposure to benzene. 
A study in 1981 in Argentina reported an elevated risk of hemopoietic system neoplasms 
with exposure to petroleum (Quiroga et al., 1981).  Quiroga et al. (1981) conducted a 
case-control study from 16 medical centers in Argentina on 603 age matched cases and 
controls.  In this hospital-based study, cases were diagnosed with hemopoietic system 
neoplasms (HSN) between 1973 and 1980.  The analysis reported a relative risk (RR) of 
7.84 with no confidence intervals reported for myeloproliferative disorders with 
exposure to petroleum products.  The total MPNs were 51, although only ten PV cases 
and four myeloproliferative disorder cases were included (Quiroga et al., 1981).  This 
study was conducted a few decades ago without the advanced ability to detect a cancer 
and the pathways for their causes (let alone a bone marrow malignancy) does call into 
question the usefulness of such studies.  For instance, Quiroga et al. also focused on 
factors such as eye color and co-habitation with dogs (RR=1.30 for all HSNs). 
Risk of hematological malignancies and exposure to PAH was also observed in a case 
control study in Italy but not specifically for myeloproliferative syndromes.  Pasqualetti 
et al. (1991) reported an association for risk of hematological malignancies and exposure 
to aromatic hydrocarbons (OR=2.5, 95%CI: 1.39, 3.32).  This study consisted of 620 
cases of hematological malignancies and 1,240 age- and sex-matched controls.  The 
controls were from the same geographical area as the cases with other medical 
conditions, except for cancer or congenital disease.  Exposures were assessed by self-
report during an interview.  No association was found with myeloproliferative syndrome 
cases (n=44, ORs not reported) (Pasqualetti et al., 1991).   
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Schnatter et al. (1996) updated three nested case–control studies in 2012 specifically 
looking at occupational benzene exposure and lympho-hematopoetic (LH) (Schnatter, 
1996, Rushton, 1997, Glass, et al., 2003).  The three cohort studies that were used for the 
nested case-control study evaluated mortality in three different exposed populations.  
The first was mortality in Canadian petroleum workers from January 1964 to December 
1983.  The second was on Australian petroleum workers, looking at mortality and cancer 
incidence from January 1981 through December 1996.  The last cohort looked at 
mortality and cancer incidence in UK petroleum workers from January 1950 to 
December 1989.  In the 2012 Schnatter report, these nested case-control studies were 
updated and new cases of LH were added using mortality and cancer incidence registries 
from the respected countries of origin.  Each study included at least ten additional years 
of follow-up for cases (Canada: December 1994; Australia: December, 2006; and the UK: 
December, 2005).  The resulting data was pooled to look at the risk of five specific 
lymphatic–hematopoietic subtypes and benzene exposure.  The LH subtypes included 
were three types of leukemia-acute myeloid leukemia (AML), chronic myeloid leukemia 
(CML), and chronic lymphocytic leukemia (CLL) and two types of myeloid neoplasm, 
myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (now referred 
to as MPNs).  This pooled study population found an OR= 1.79 (95% CI: 0.68, 4.74) for 
30 cases of MPD with cumulative exposure assessed as the highest exposure to benzene 
(>=2.93 vs. <= 0.348 ppm-years) (Schnatter et al., 2012).     
All of these studies are of limited size and none of the studies mentioned above used the 
JAK2 V617F mutation molecular diagnostic tool, which is standard practice for diagnosis 
in 2013 (Seaman et al., 2009).  The lack of a molecular diagnostic tool affects their ability 
to assess error due to case misclassification, which has been documented to be upwards 
of 50% (Seaman et al., 2010).  As with many occupational studies, the lack of 
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information about lifestyle exposures is often not complete or non-existent in some 
cases, as in the Quiroga study of 1981.  Even the most recent of studies, the Schnatter 
study in 2012 investigating benzene exposures, did not use the latest WHO 2008 
diagnostic criteria. Schnatter only included lifestyle exposures such as smoking history 
for half of the studies cases, and no information on family history or diet was included. 
Two cohort studies looking at PV and/or myelofibrosis reported higher mortality rates 
among different occupational groups involving exposures other than petroleum or 
benzene exposure (Zoloth et al., 1986, Johnson et al., 2010, Kaplan, 1986).  In 1986, 
Zoloth reported higher than expected standardized mortality rates (SMRs) among 2,500 
commercial pressmen in three study locations in the US: New York City, Long Island, 
and New Jersey.  This cohort used incident cases from 1958 to 1981, with follow up for 
mortality until 1981.  They reported an annual incidence rate of 120 cases per 100,000, 
compared to a population incidence in the population of 2 per 100,000 with only three 
cases of reported of myelofibrosis in the study population (Zoloth, 1986). 
 
In a study of 2,639 local union members whom ever worked in poultry processing plant, 
Johnson et al., reported higher PV along with excess mortality of lymphoid leukemia and 
myelofibrosis mortality rates for a cohort of poultry workers.  A proportional mortality 
rate of 4.9 (95% CI: 1.4, 17.2) and 10.9 (95% CI: 1.4, 85.0) for non-white females 
(Johnson et al., 2010) was also reported.  However with only two cases of myelofibrosis, 
the precision of this study was impacted and should be noted.  Johnson et al. (2010) then 
updated their previous mortality study of poultry workers to consider exposure to 
oncogenic viruses. 
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Environmental exposures and blood cancer 
A large number of studies indicate exposure to many different chemicals may be 
associated with an increased risk of leukemia.  Leukemia, like MPNs, is a disease of the 
bone marrow.  However, the literature is inconsistent on providing evidence that 
exposure to individual agents (for instance, pesticides, metals, dioxins, and even PAHs) 
is associated with an increased risk of leukemia (Clapp et al., 2008).  In the Agricultural 
Health Study, risk doubled among a cohort of pesticide applicators with exposure to 
organochlorine pesticides like chlordane, aldrin, and toxaphene (Clapp et al., 2008; 
Purdue et al., 2007).  Studies looking at reactive chemicals are limited, but in one 
occupational study of synthetic rubber workers, strong associations between both high 
levels and intensity of butadiene exposure with leukemia were found (Alder et al., 2006).  
However, due to the many chemicals these workers are exposed to, it was not possible to 
relate the increased death meta-SMR of 1.2 specifically to exposure to butadiene (Alder 
et al., 2006; Clapp et al., 2008).  The potential role for benzene and its causal 
relationship to acute leukemia has been reviewed elsewhere by Smith, MT (2011), and 
Smith MT and Zang, (2011).  They indicate that benzene is associated with 
myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).  This supports 
the biological plausibility that mutagenic chemicals like benzene are toxic to 
hematopoietic stem cells (HSC) or progenitor cells, from which these bone-marrow 
disorders arise (Smith, 2010; Smith et al., 2011).  Acute and chronic exposures and 
observed hematologic effects have been well studied to show their direct association with 
hematologic changes in humans as well as animals (Galbraith et al., 2010; Smith, 2010).  
Investigating mutagenic exposures and their ability to make changes in our DNA is part 
of a growing body of literature.  Still much more research is needed, in particular, large 
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studies estimating the magnitude of effects estimates with more precision, as well as 
studies obtaining more accurate concentrations of exposures.  
PAHs and risk factors for leukemia 
Recent studies of exposure to PAHs and risk factors for childhood leukemia provide 
support that changes in bone marrow resulting from a chemical exposure may have a 
role in chronic leukemia diseases like MPNs (Rull et al., 2008).  In a recent sub-study of 
the Northern California Childhood Leukemia Study, PAH exposure was measured in the 
residential indoor dust in homes of 227 controls  and 210 cases with childhood leukemia 
(Rull et al., 2008).  In single-PAH risk models comparing highest to lowest quartiles, 
they observed elevated odds ratios for three PAHs: benzo[k]fluoranthene (1.8, 95% CI: 
1.0-3.5); benzo[b]fluoranthene (2.0, 95% CI: 1.0-3.9); indeno[1,2,3-cd]pyrene (1.7, 95% 
CI: 0.9-3.2) (Rull et al., 2008).  
A case-control study of acute myeloid leukemia (AML) in an eastern Indian population 
included 110 AML cases and 144 geographically and racially matched healthy controls.  It 
showed an increase in risk for developing AML with an odds ratio of 11.91 (CI: 4.04-
34.96, p<0.001) in subjects with both Glutathione S-transferase (GST) polymorphism 
GSTM1"null" and Polymorphic N-acetyltransferase (NAT2) (Majumdar et al., 2008). 
These findings suggest that benzo[a]pyrene exposure is associated with the elevated risk 
seen in both GSTM1 null and NAT2 genotypes.  
Although many studies group these hematological malignancies together with MPNs, 
they are not the same disease.  Specifically, one major difference is that in the classic 
MPNs (PV, ET, and PMF), patients do not carry the Philadelphia chromosome—they are 
(PH) negative.  The Philadelphia chromosome adversely impacts normal processes in the 
bone marrow cells and produces an abnormal protein, a different mechanism than found 
in MPNs.  This results in the proliferation of leukemic cells.  The Philadelphia 
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chromosome is also present in some cases of CML, AML, and ALL, which contributes to 
a more unfavorable prognosis with increasing age.   
Genetic susceptibility and PV, ET, PMF, and the JAK2 V617F mutation 
One family of genes that has been long studied and linked to increased cancer risk in 
general are the CYPs, GST, and NAT2 genes.  Genetic susceptibility might explain 
heterogeneity of environmental exposure effects on cancer risk.  It might also explain 
why some individuals have a disease risk at exposure levels that would not cause adverse 
effects for the majority of people.  However, there may also be other important categories 
of cancer susceptibility genes. 
 
The National Institute of Environmental Health Sciences Environmental Genome 
Project (NIEHS EGP) was developed in 1997 to explore and categorize environmentally 
responsive genes (ERG) in the human genome.  The NIEHS EGP finished gene list 
included 648 genes in the following eight categories: cell cycle; cell division; cell 
signalling; cell structure; DNA repair; gene expression; homeostasis and metabolism.  
Although these genes are being studied for a wide range of cancers, no studies have 
investigated any combination of these genotypes and the risk of MPNs.  Because JAK2 
V617Fis a de novo mutation of JAK2 V617Fand its role in MPNs, the gene-environment 
interaction mechanisms of most interest here relates to genes that modify susceptibility 
to mutagenic chemicals. 
 
Conclusion 
Environmental exposure and MPNs are not well enough studied to help us understand 
how these exposures may play a role in the etiology of the disease (Anderson et al., 
2012).  As described previously, there is evidence that chemicals can penetrate the cells 
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in the bone marrow and this is consistent with the biological pathways considers in this 
study (Smith, 2010; Smith et al., 2010).  In this investigation we focused on known 
mutagenic chemicals similar to benzene and PAHs, and the susceptible genotypes that 
modify these exposures, especially those previously implicated in blood cancer.   
  
Aims and Overview of the Dissertation 
Introduction 
In 2008, the Pennsylvania Department of Health (PADOH) and the Agency for Toxic 
Substances and Registry (ATSDR) of the Centers for Disease Control and Prevention 
(CDC) confirmed a PV cluster in a tri-county region of Northeast Pennsylvania.  The 
incidence of PV was 4.3 times higher within this cluster area than in a comparative tri-
county region.  The close proximity of this primary cluster zone—located at the 
intersection of Carbon, Luzerne, and Schuylkill Counties—to known hazardous waste 
sites and co-generation power plants raised the question as to whether they could have 
played a causal role in the disease cluster (Seaman et al., 2009).   
 
The aims of this dissertation are to evaluate the associations between lifestyle and 
environmental risk factors for the most common MPNs (PV, ET, and PMF), with and 
without JAK2 V617F.  We also explore an interaction between known susceptibility 
genotypes for a subset of cases and controls and potential mutagenic chemical 
exposures, including PAHs. 
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Aims 
Aim 1: Estimate the effect of exposure to PAHs on risk of MPNs in the tri-county area of 
Northeast Pennsylvania. 
 
Aim 1a: Estimate the effect of exposure to PAHs from residential sources, diet, and 
lifestyle/behavioral factors on the risk of PV-related outcomes. 
 
Aim 2: Explore the role of genotypes that may modify the potential of mutagenic 
chemicals to affect the risk for MPNsin the tri-county area. 
 
Aim 3: Estimate the joint effects of susceptible genotypes identified in Aim 2 and 
distance of residence from facilities with known hazardous emissions on risk of MPNs. 
 
The Drexel University School of Public Health, Department of Environmental and 
Occupational Health received funding from the CDC to investigate risk factors associated 
with PV in the tri-county area.  This Drexel University study was meant to be a 
population-based, case-referent study to evaluate possible lifestyle, environmental, and 
genetic risk factors for a family of myeloproliferative neoplasms (MPNs) believed to be 
related to PV, which include essential thrombocythemia (ET) and primary myelofibrosis 
(PMF).   
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Organization of this dissertation 
There are five chapters in this dissertation.  The overview and review of relevant 
literature of the dissertation was included in this chapter.  Chapter 2 addresses Aim 1 by 
describing a population-based, case-referent study that evaluated lifestyle and 
environmental risk factors for PV, ET, and PMF, as well as the risk factors for JAK2 
V617F.  In chapter 3, we use a subset of that study sample to investigate presence (in a 
qualitative sense) of gene-environment interactions, using gene-only analysis (Burstyn et 
al., 2009) for Aim 2.  We also investigate the association between the susceptible 
genotypes that can disrupt the metabolic breakdown of mutagenic chemicals with the 
risk of an MPN.  The genes we investigated were AHR, CYP1A1, CYP1A2, CYP1B1, 
CYP2B6, GSTP1, GSTM1, GSTM3, GSTT1, NAT2, and NQO1.  We hypothesized in Aims 1 
and 2 that there is increased risk of an MPN associated with aromatic and heterocyclic 
amines, as well as benzene.  In Chapter 4, we explore the possibility of gene-environment 
interaction by examining the identified genotypes in Aim 2 and chemical exposures 
assessed by using distance to hazardous facilities as a proxy for exposure.  The 
dissertation findings are summarized in chapter 5.    
 
This dissertation was designed to explore the environmental etiology of polycythemia 
vera, essential thrombocythemia, and primary myelofibrosis.  Results from this 
dissertation add to the very limited amount of epidemiological studies looking at 
environmental exposures as risk factors to MPNs. It will encourage further research for 
chemical exposures as well as susceptible genotypes for these diseases.  
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Chapter 2: The Risk of Myeloproliferative Neoplasms 
Due to Exposure to Polycyclic Aromatic Hydrocarbon
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Abstract 
 
Background 
The etiology of myeloproliferative neoplasms (MPN), rare bone marrow diseases with an 
excess of blood cells, is currently unknown.  A somatic point mutation—JAK2 V617F—is 
suspected to be an antecedent of the most common MPN, polycythemia vera (PV).  This 
mutation may also occur in excess in related MPNs (essential thrombocythemia (ET) and 
primary myelofibrosis (PMF)).  Consequently, environmental exposure to mutagens, 
such as polycyclic aromatic hydrocarbons (PAH) and heterocyclic amines, is suspected to 
contribute to PV.  An MPN cluster in northeastern Pennsylvania allowed investigation of 
residential and lifestyle risk factors, with particular focus on exposure to PAH. 
 
Objectives 
We evaluated exposure to PAH as a risk factor for PV, ET, and PMF.  We also studied the 
risk factors for having the JAK2 V617F mutation.  
 
Methods 
We conducted a population-based case-control study in northeastern Pennsylvania.  
People born from 1921-1968 and residing between 2000 and 2008 in three counties with 
a high incidence of MPN were eligible.  Cases (n=55) diagnosed between 2001 and 2010 
were identified from the Pennsylvania cancer registry and a previous MPN cluster 
investigation.  A panel of physicians verified all diagnoses.  Controls (n=473) were 
recruited through random digit dialling.  We collected lifetime, residential, smoking, and 
dietary histories during telephone interviews.  Blood samples for genotyping from 31 
cases and 292 controls were obtained. 
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Results 
Cases were older and more likely to be male compared to controls, but otherwise 
demographically similar.  Other lifestyle factors, including residential history and diet 
associated with exposure to PAH, were not associated with the outcomes.  The results 
were not altered by restricting cases to those with the JAK2 V617F mutation.  
 
Conclusions 
We found no evidence of relationships between risk of MPNs and residential history, 
diet, or lifestyle behaviors associated with exposure to aromatic and heterocyclic amines.  
However, we did not confirm PAH exposure using sources of information other than the 
interviews; therefore, exposure misclassification is a limitation of this analysis.  
Participation rates were poor, raising the possibility that results may be influenced by 
selections bias.  Our results do, in fact, provide evidence that PAHs are an unlikely 
etiologic agent for MPNs since no association was observed to cigarette smoke (rich in 
PAHs).   
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Introduction 
Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis 
(PMF) are a category of myeloproliferative neoplasms (MPN) that are characterized by 
an overproduction of erythrocytes and platelets (Campbell & Green, 2005).  They are 
diseases of the bone marrow, with myeloproliferative manifestation, meaning there is an 
excess of the otherwise healthy blood cells.   
 
In 2008, the joint efforts by the Pennsylvania Department of Health (PADOH) and the 
Agency for Toxic Substances and Registry (ATSDR) of the Centers for Disease Control 
and Prevention (CDC) confirmed a cancer cluster in a tri-county region of Northeast 
Pennsylvania.  These investigations found the incidence of PV to be 4.3 times higher 
within the cluster area than a comparative tri-county region.   
 
In 2001, PV, ET and PMF were required to be reported to the states cancer registries 
(Seaman, 2009). However, Seaman et.al found that for persons diagnosed in years 2001-
2005, there was still a high rate (59%) of unreported cases which suggests active case 
finding is still needed to complete cluster investigation (Seaman, 2009).  Only hospital 
cases were required to be reported to the registry, and treatment of MPNs typically does 
not require hospitalizion.  Symptoms that present in PV cases with increased red blood 
cell production could also be caused by chronic respiratory disease resulting from heavy 
smoking, renal disease, or chronic pulmonary disease (Stuart & Viera, 2004).  This has 
contributed to the presence of false positives found in cancer registries and even mis-
diagnosis of PV prior to the discovery of the JAK2 V617F mutation.   
 
Prior to the 2008 revised diagnostic criterion, in 2001-2004 the National Cancer 
Institute estimated incidence of PV at 2.8 per 100,000 persons per year (Kutti &Ridell, 
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2001).   For ET the incidence rate was estimated at 1.5 cases per 100,000 per year (Kutti 
&Ridell, 2001).  The rarest of the MPNs is PMF, with an incidence rate of only 0.4 cases 
per 100,000 persons per year (Kutti &Ridell, 2001).  PV patients may be asymptomatic.  
The diagnosis is now largely based on laboratory tests.  Most of the health concerns 
associated with PV are the result of thickening of the blood, such as clotting.  Itching is a 
classic symptom of PV and usually occurs after taking a bath, or other exposures to warm 
water (Steinman et al., 1987).  
 
The JAK2 V617F mutation and its role in MPN 
JAK2 is an on-and-off switch that regulates bone marrow activity (Baxter, 2005).  The 
JAK2 V617F mutation activates a tyrosine kinase complex in bone marrow normally 
responsible for regulating blood cell production through molecular signaling.  The 
mutation disrupts the normal inhibition of growth, thus increasing blood cell production 
(Spivak et al., 2010).  The JAK2-acquired point mutation occurs in nearly all PV patients 
(>95%) and about half of those with ET or PMF, but not in other cancers (Spivak et al., 
2010; Kralovics  et al., 2007; Tefferi et al., 2007).  Following recommendations by the 
World Health Organization (WHO) in 2008, physicians are recommended to test for the 
somatic point mutation, JAK2 617V>F (JAK2), to establish diagnosis of MPN (Seaman et 
al., 2010).  This has brought new interest into the etiology of the disease (Anderson et 
al.,2012).   
 
Polyaromatic hydrocarbons (PAHs) 
PAHs are formed from ringed structures of carbon atoms with attached hydrogen atoms, 
and other atoms as well.  PAHs are found in any combustion product, including tobacco 
smoke, vehicle exhaust, and waste incinerator emissions (Irigaray et al., 2007).  PAHs 
can adhere to fine particulate matter and are in the inhaled air (Irigaray et al., 2007).  
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This group of compounds is made of two or more fused aromatic rings.  PAHs – which 
are represented by over 100 distinct compounds that may mix together – include 
chemicals that are known carcinogens in humans (Hayes et al., 1990).  Primary 
environmental sources of PAHs include coal, oil and gas burning, and cigarette 
smoking.  Dietary sources include eating charbroiled or barbecued meats and 
grains or vegetables contaminated by ambient PAHs (Hayes et al., 1990; 
Rothman et al., 1993).  
 
PAHs can be a significant part of respirable particulate matter, and are a source of 
genotoxic activities (Singh et al., 2007; Irigaray et al., 2007).  A study of an occupational 
cohort in Italy reported high PAH exposure in some industries, including coal tar, coke 
production, and aluminium production, and found an increased risk of bladder and lung 
cancer in workers with PAH exposure (Bosetti et al., 2007).  A study of air-polluted cities 
found an 8% increase in death risk from lung cancer compared to less polluted cities, 
even after controlling for smoking (Irigaray et al., 2007).  From the literature on PAH 
exposure and other cancers, it is logical to study PAHs and PV, ET, PMF, and JAK2 
V617F.  
  
The suspected association of environmental PAHs with MPNs 
PAHs are ubiquitous by-products of organic matter combustion processes and are 
considered to be mutagens (Hung et al., 2003).  The Environmental Protection Agency 
has only identified sixteen of these PAHs as priority pollutants.  Of these, there are as 
least eight that could be considered as probable or possible human carcinogens, 
including benzo[a]pyrene, dibenzo[a,h]anthracene,  benzo[b]fluoranthene and  
indenol[1,2,3,c-d]pyrene, benzo[k]fluoranthene (Phillips, 1999).  Long-term exposure to 
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PAHs though air pollution has been associated with increases in morbidity and mortality 
(Galbraith et al., 2010; Stuart & Viera, 2004; Steinman et al., 1987; Irigaray et al., 2007).  
 
A recent sub-study of the Northern California Childhood Leukemia Study measured PAH 
exposure in the residential indoor dust in homes of 227 controls and 210 cases with 
childhood leukemia (Rull et al., 2008).  They observed, in single-PAH risk models 
comparing highest to lowest quartiles, elevated odds ratios for three PAHs: 
benzo[k]fluoranthene (1.8, 95%CI= 1.0-3.5), benzo[b]fluoranthene (2.0, 95% confidence 
interval (CI)= 1.0-3.9), and indeno[1,2,3-cd]pyrene (1.7, 95%CI= 0.9-3.2) (Rull et al., 
2008).  This provides support that changes in bone marrow resulting from a chemical 
exposure may have a role in chronic leukemia diseases like MPNs.  The study also 
highlighted a potential mechanism for the route of exposure to PAHs that cling to air 
particles of greater than 2.5u.m (Rull et al., 2008).  Respirable PAHs come from many 
sources, but most commonly from point sources, like power plants, residential heating, 
and mobile sources like motor vehicles (Phillips, 1999; Steinman et al., 1987). 
 
Pasqualetti, et al. (1991) reported an increased risk of 2.15 (95% CI=1.39, 3.32), with self-
reported exposure to aromatic hydrocarbons for all hematological malignances in a 
hospital-based, case-control study in Italy (Pasqualettiet al., 1991).  Among the 620 
cases, there were 44 with myeloproliferative syndromes, with 576 cases having one of the 
following malignancies (Pasqualetti et al., 1991): acute non-lymphoblastic leukemia; 
non-Hodgkin’s lymphoma; Hodgkin’s disease; myelodysplastic syndromes; malignant 
monoclonal gammopathies; multiple myeloma and chronic lymphocytic leukemia.  
 
However, the study did not include analysis for myeloproliferative syndromes separately 
in the published report (Pasqualetti et al., 1991).  
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The focus of this analysis is PAHs.  Since we could offer no strong a priori hypothesis 
about specific exposure sources, we consider a range of potential avenues of PAH 
exposure, especially those previously implicated in blood tumors, in our investigation.  
We expect that environmental PAHs from residential history, diet, lifestyle behaviors 
with presumed exposures might show associations with MPNs.  Although chemicals like 
PAHs are everywhere, they do represent a burdensome chemical exposure category for 
the PA geographic region containing the PV cluster given the extensive coal mining 
activities and the number of waste coal power plants in the tri-county area (Seaman et 
al., 2009). 
 
Methods 
The project used a case-control design.  The study area was comprised of a tri-county 
area in Northeast Pennsylvania (Carbon, Luzerne, and Schuylkill Counties).  Cases 
included individuals with diagnoses of PV, ET, and PMF, with and without the JAK2 
V617F mutation.  Study of prevalent cases is justified because mortality associated with 
these conditions is low (0.002 to 2.8 per 100,000 persons (Kutti & Ridell, 2001), so 
changes in prevalence will primarily reflect changes in incidence.  There is limited 
opportunity for incidence-prevalence bias, so prevalence odds ratios estimated in this 
design closely approximated prevalence rate ratios. 
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Control selection 
We selected a stratified random sample of controls from the study area.  The sample 
collected represents the population distribution based on the 2006-2008 American 
Community Survey Population Estimates for: age (60% 42-59, 40% 60-89); gender (50% 
male, 50% female); county of residence (15% Carbon, 55% Luzerne, and 30% Schuylkill 
County.  Control subjects were drawn from a purchased published residence lists for the 
tri-county area.  We contacted current residents at random by phone to seek eligible 
persons interested in receiving the study mailing and consent forms.  We asked subjects 
who consented to receive mailings to return signed consent forms.  Those sent, but not 
returned consents received a follow-up phone call where the research team sought their 
oral consent.  We continued to contact residents until the tri-county population was 
sufficiently sampled and the controls reflected the source population. 
 
Data collection 
The Geisinger Survey Research Unit interviewed all consenting participants.  The 
research unit’s staff administered the questionnaire in a standardized manner using a 
computer-assisted telephone interview.  Interviewers were initially blinded to case or 
control status of participants until the end of the interview, when they were asked about 
individual and familial history of blood diseases.  The questionnaire elicited detailed 
information about demographic characteristics, health behaviors, socioeconomic 
information, residential history, and past experience with conditions associated with 
exposure to hazardous materials (full questionnaire and IRB documents are in the 
Appendices A to E).   
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Consenting participants received a summary of the residential and occupational history 
questions in advance of the interview to help prepare them.  The interviews lasted 
between 45 minutes and about two hours.  We mailed a gift certificate incentive of $25 to 
participants after completion of the interview.  We also mailed and phoned eligible cases 
that had relocated since 2008 from the tri-county area.  We only conducted case 
interviews to surviving patients that consented to participate. 
 
Lifestyle exposures 
Lifestyle exposures were collected from multiple exposure sources.  This included 
questions on smoking history and diet.  The dietary questions used in our study were 
adapted from the Long Island Breast Cancer Study Questionnaire, available online 
through the National Cancer Institute website.  We collected consumption of grilled, 
barbequed, or smoked meat or fish by decade by five categorizations of different meats 
types per season, including; all year, summer, fall, winter and spring. 
 
Residential exposures 
Each subject was asked to list every primary residence they had lived in for six months or 
longer, beginning with current residence and working backwards, listing all residences 
back to age 21 with a maximum of nine.  We assessed distance to different industry types 
as well as hazardous waste sites and waste coal power plants.  
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Analytic method 
We conducted descriptive analysis on the characteristics of the study population.  
Logistic regression was used to estimate crude and adjusted odds ratios (OR) and 
associated 95% confidence intervals (CI) for each individual exposure measure with no 
or minimal exposure as the reference.  Adjusted models included age, sex, and county as 
covariates.  
 
Results 
 
Only 27% of cases consented for the telephone interview and only 56 % of those also 
consented to the optional blood draw.  Response rate among our controls was slightly 
better, at 41% (which is fair for a Radom Digit Dialling protocol to consent controls), 
with 61% of those also consenting for the blood draw.  
 
Demographics 
 
Cases were older (median age=71 vs. 61yrs) (OR=3.0, 95% CI=1.5, 5.8) and more likely to 
be male (49% vs. 39%) (OR=1.5, 95% CI=0.8, 2.8) compared to controls, but they were 
otherwise demographically similar (Table 2.3).  The study population was 
overwhelmingly Caucasian (98% of cases and 99% of controls). None of the cases and 
few (2%) controls were of Jewish ancestry and all participants except for one control 
were born in the US.  Two-thirds of the subjects were married at the time of the 
interview.  More cases than controls were retired (63% vs. 42%).  These findings were 
similar across all case categorizations (Table 2.4).   
 
Diet history 
Most of the cases (93%) and controls (97%) reported some exposure to grilled, 
barbequed, or smoked meat or fish (see Table 2.5).  In the analysis of the five 
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categorization per season of consumption of grilled, barbecued, or smoked meat or fish 
and seasonality, there were only three associations that reach statistical significance with 
having an MPN.  In the adjusted logistic regression models, we found that JAK2 V617F 
cases were more likely than controls to eat grilled or barbequed poultry in the winter 
(aOR =3.5,  95% CI=1.2,10.0) ( see Table 2.6).  However, there was no significant 
differences between our cases and controls for eating eat grilled or barbequed poultry in 
the fall or the summer.  All cases ate grilled or barbequed poultry or fish in the summer, 
and for the fall it was approximately 50% across all case categorizations.  In addition, 
cases were less likely to have ever eaten grilled or barbequed poultry or fish, significant 
across all case categorizations (aOR=0.3 -0.4, 95% CI=0.1, 0.9) and for JAK2 V617F 
cases (aOR=0.4, 95% CI=0.1, 0.9).  There were also no significant differences between 
cases and controls for eating fish from Still Creek or other local lakes or creeks (see 
Tables 2.9 and 2.10).  We also found no relationships between MPNs and residential 
history (Table 2.7 and 2.8). 
 
Smoking 
Half the controls ever smoked, as did 32%-45% of cases in Table 2.11. Out of the 49 % of 
cases who ever smoked, all (100%) smoked cigarettes and only eight confirmed JAK2 
V617F  cases ever smoked (32% , 95% CI:14,50).  Table 2.12 shows the results for the 
effect of smoking by pack years as well as smoked filtered vs. non-filtered cigarettes.  
Cases were less likely to be heavy smokers (>15 pack years) compared to non-smokers, 
with an adjusted OR of 0.2 (95% CI: <0.0, 0.8) for JAK2 V617F cases.  Results were 
similar although not statistically significant when heavy smokers were compared to light 
smoker s (<15 pack years), with an adjusted OR of 0.2 (95% CI= <0.0, 1.4) for JAK2 
V617F cases.   
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Discussion 
To our knowledge, this is the first study to look at PAH exposure from diet and smoking 
and risk of developing an MPN.  
 
We did not see any evidence of associations between PAH exposures and 
MPNs 
 
Significant lifestyle sources of PAH exposure are cigarette smoking and eating well-
barbequed meat and vegetables (Hayes, 1990; Rothman, 1993).  We saw a significant 
increased risk of MPNs in subjects who ate grilled or barbecued poultry or fish all year 
long (aOR 3.5, 95% CI: 1.2, 10.0), but a protective effect from ever eating grilled or 
barbecued poultry or fish (aOR 0.3, 95% CI: 0.2, 0.6).  All 38 other comparisons of 
significant exposure sources hovered around the null and were similar for all case 
categorizations, including JAK2- cases reporting no associations. 
 
Results for our analysis with smoking consistently suggested no association.  If PAHs 
were associated with an increased risk of developing an MPN, we would expect to see an 
association when examining smoking status, perhaps at least as strong (if not stronger), 
than that of eating grilled or barbequed poultry or fish all year long (high exposure to 
PAHs through diet) (Hayes et al., 1990; Rothman et al., 1993).  Our study had a detailed 
self-reported smoking history and since MPNs haven’t previously been thought to be 
associated with smoking, we do not expect differential misclassification of self-reported 
smoking status in cases or controls in this older population.  
 
Our findings do not support an association of PAHs and increased risk of getting an 
MPN.  However, this study was only had the power to detect very large effects (>4 ORs), 
so any small effects from PAHs would not be detected as statistically significant. 
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Limitations and strengths of the study 
This study has several limitations.  The first limitation of this study is the number of 
cases that were recruited from the area was only 55.  We did use state-of-the-art 
diagnostic criteria not used in past case-control studies and had cases reviewed by an 
independent expert panel.  However, the changing of the WHO diagnostic criteria 
(changed in both 2001 and 2008) was a challenge.  In 2001 PV, ET, and PMF became a 
reportable cancer under the ICD-O codes, and the WHO started reclassifying these 
disorders based on histological and molecular information (Vakil & Tefferi, 2011).  This 
included adding a molecular test (JAK2 V617F mutation) as diagnostic criteria in 2008 
and adding four other MPN–unclassifiable diseases into the MPN disease category (Vakil 
& Tefferi, 2011).  The ability to test cases for the JAK2 V617F mutation directly did 
attempt to minimize misclassification of our cases. 
 
Our study also suffered from a small response rate from our MPN cases.  The optional 
blood draw was a critical step in our study to help counter the drift in diagnostic criteria 
for this group on MPNs, especially PV.  Since each case must consent to participate, this 
was a moving target that determined the total number of cases in our study in a short 
period of time.  As with all retrospective studies, there was a potential for recall bias. 
 
A large limitation of this study is the potential for bias from misclassification of 
exposure.  We did not confirm PAH exposure with sources of information other than the 
interviews.  Participation rates were poor, particularly for cases, which raise concerns 
about selection bias; however, our use of random selection ensured the controls were 
representative of the tri county area population. 
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We were able to measure PAH exposures from multiple sources, including residence and 
lifestyle, and included a significant source to non-smokers (diet).  Taken together, the 
results do not support the role of PAH in etiology of MPNs. 
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Table 2.1 The demographics of the tri-county region (Carbon, Luzerne, and Schuylkill Counties) in Northeast 
Pennsylvania 
County Population 1 Percentage of Population Caucasian 
Median 
Age 1 
Carbon 62,937 96.1 41.4 
Luzerne 311,752 94.4 42.1 
Schuylkill 147,107 95.3 42.0 
Total Tri-County 521,796 94.9 42.0 
1. Data retrieved from U.S. Census American Community Survey, 2008. For 1921-1967 DOBs, we looked for 
ages 33-79 for the year 2000, ages 40-86 for 2007, and ages 43-89 for 2010. Census data age group numbers 
do not exactly match the 1921-1968 DOB cohort due to differences in intervals 
 
 
 
 
 
Table 2.2 Case Categories 
Consenting Case Subgroups 1 Total 
Interviewed With Genotype Data 
All cases  55 31 
Confirmed cases  41 27 
Confirmed PV cases  33 24 
Confirmed ET cases  7 2 
Confirmed PMF cases  1 0 
JAK2   V617F  mutation with 
PV, ET or PMF 
25 22 
1.All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed  
JAK2 V617F mutation with PV, ET or PMF by expert panel, confirmed by expert panel PV only 
 
 
 
 
 
 
 
   
 
 
   
 
Table 2.3 Study demographics 1 (cont’d) 
 All cases 2 
n= 55 
Confirmed  
cases 2 
n= 41 
Confirmed  
JAK2 V617Fcases 2 
n= 25 
Confirmed  
PV cases 2 
n= 33 
Controls 
n= 473 
County           
Carbon 7 (13%) 6  (15%) 4  (16%) 6  (18%) 77  (16%) 
Luzerne 27  (49%)  20  (49%)  13  (52%) 13  (39%)  267  (56%)  
Schuylkill 21  (38%)  15  (37%)  8  (32%)  14  (42%)  129  (27%)  
Age           
42-64 19  (35%) 14  (34%) 7  (28%) 10  (30%) 287  (61%) 
65+ 36  (65%) 27  (66%) 18  (72%) 23  (70%) 186  (39%) 
Sex           
Male 27  (49%)  20  (49%)  12  (48%)  18  (55%)  185  (39%)  
Female 28  (51%)  21  (51%)  13  (52%)  15  (45%)  288  (61%)  
Race/ethnicity           
Non-Hisp. White 54  (98%)  40  (98%)  25  (100%) 33  (100%) 468  (99%)  
Latino, Hispanic 0 0 0 0 5  (1%) 
Non-Hisp. Black 0 0 0 0 0 
Non-Hisp. Native 
American, Alaskan native 
0 0 0 0 0 
Non-Hisp. Asian or Pacific 
Islander 
1 ( 2%) 1  (2%) 0 0 0 
Non-Hisp. Other 0 0 0 0 0 
Non-Hisp., multiple race 0 0 0 0 0 
Country of origin           
USA 55  (100%) 41  (100%) 25  (100%) 33  (100%) 472  (100%)  
Other 0 0 0 0 1 (0%) 
2  
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Table 2.3 Study demographics 1 (cont’d) 
 All cases 2 
n= 55 
Confirmed  
cases 2 
n= 41 
Confirmed  
JAK2 V617Fcases 2 
n= 25 
Confirmed  
PV cases 2 
n= 33 
Controls 
n= 473 
State born in           
AK 0 0 0 0 1  (0%) 
CA 1  (2%)  1  (2%)  0 0 4  (1%)  
CT 1  (2%)  1  (2%)  1  (4%)  1  (3%) 0 
FL 0 0 0 0 1  (0%)  
IL 0 0 0 0 1  (0%)  
MA 1  (2%)  1  (2%)  1  (4%)  1  (3%)  1  (0%)  
MN 0 0 0 0 2  (0%)  
MS 0 0 0 0 1  (0%)  
NC 0 0 0 0 1  (0%)  
NH 0 0 0 0 1  (0%)  
NJ 2  (4%)  2  (5%)  2  (8%)  2  (6%)  14 (3%)  
NM 0 0 0 0 1  (0%)  
NY 0 0 0 0 16  (3%)  
OH 0 0 0 0 2  (0%) 
OK 1 (2%)  0 0 0 0 
PA 48 (87%) 35  (85%)  20  (80%)  28  (85%)  420 (89%)  
SC 0 0 0 0 1  (0%)  
SD 0 0 0 0 1  (0%)  
TN 0 0 0 0 1  (0%)  
TX 0 0 0 0 1  (0%)  
VA 0 0 0 0 2  (0%)  
WV 1  (2%)  1  (2%)  1  (4%)  1  (3%)  0 
non-US 0 0 0 0 1  (0%)  
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Table 2.3 Study demographics 1 (cont’d) 
 All cases 2 
n= 55 
Confirmed  
cases 2 
n= 41 
Confirmed  
JAK2 V617Fcases 2 
n= 25 
Confirmed  
PV cases 2 
n= 33 
Controls 
n= 473 
Jewish ancestry           
Yes 0 0 0 0 10  2%  
No 54  (100%) 40  (100%) 25  (100%) 33  (100%) 455  (98%)  
Don't know 0 0 0 0 5 
Missing 1 1 0 0 3 
Marital status           
Married 34  (62%)  27  (66%)  16  (64%)  21  (64%)  295  (62%)  
Widowed 13  (24%)  11  (27%) 7  (28%)  9  (27%) 76  (16%)  
Currently single 8  (15%)  3  (7%) 2  (8%)  3  (9%)  102  (22%)  
Education           
Less than high school 5  (9%)  3  (7%) 2  (8%) 2  (6%)  11  (2%)  
High school / GED 30  (55%)  22  (54%) 13  (52%)  20  (61%)  180  (38%)  
Some college 7  (13%)  7  (17%)  5  (20%) 5  (15%)  159  (34%)  
Bachelors degree 6  (11%  3  (7%)  2  (8%)  2  (6%)  58  (12%)  
More than bachelors 7  (13%)  6  (15%)  3  (12%) 4  (12%)  65  (14%)  
Household income           
Less than $20,000 8  (16%)  5  (14%)  3  (14%)  5  (17%)  67  (15%)  
$20,000 - $35,000 14  (28%) 10  (27%)  7  (32%)  10  (33%)  106  (24% ) 
$35,000 - $50,000 8  (16%)  5  (14%)  2  (9%)  4  (13%)  91  (20% ) 
$50,000 - $75,000 10  (20%)  9  (24%)  4  (18%)  8  (27%)  97  (22% ) 
More than $75,000 10  (20%) 8  (22%)  6  (27%)  3  (10%) 83  (19% ) 
Don't know 3 3 2 2 8 
Refused 2 1 1 1 21 
 
 
 39
 
 
 
 
 
   
 
 
   
Table 2.3 Study demographics 1 (cont’d) 
 All cases 2 
n= 55 
Confirmed  
cases 2 
n= 41 
Confirmed  
JAK2 V617Fcases 2 
n= 25 
Confirmed  
PV cases 2 
n= 33 
Controls 
n= 473 
Current employment           
Employed for wages 17  (31%  12  (29%) 7  (28%)  9  (27%) 184  (39%)  
Self-employed 1  (2%) 1  (2%)  1  (4%) 1  (3%)  16  (3%) 
Out of work for more than 
a year 
2  (4%) 1  (2%) 1  (4%)  0 15  (3%) 
Out of work for less than 
a year 
0 0 0 0 10  (2%) 
Homemaker 0 0 0 0 15  (3%)  
Student 0 0 0 0 1  (0%) 
Retired 32  (58%) 26  (63%)  16  (64%)  22  (67%) 200  (42%)  
Unable to work 3  (5%)  1  (2%)  0 1  (3%)  32  (7%)  
1. Self-reported socio economic factors, number and %  
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
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Table 2.4 Study demographic logistic regression models 1 (cont’d) 
 
 All cases 
OR 2 
(95% CI) 
n=55 
All cases 
aOR 3 
(95% CI) 
n=55 
Confirmed 
cases OR 2 
(95% CI) 
n=41 
Confirmed 
cases aOR 3 
(95% CI) 
n=41 
Confirmed 
JAK2 V617F OR 
2 
(95% CI) 
n=25 
Confirmed JAK2 
V617F aOR 3 
(95% CI) 
n=25 
Confirmed 
PV OR 2 
(95% CI) 
n=33 
Confirmed 
PV aOR 3 
(95% CI) 
n=33 
County                 
Carbon 0.9  
(0.4, 2.1) 
0.9  
(0.4, 2.1) 
1.0  
(0.4, 2.7) 
1.0  
(0.4, 2.6) 
1.1  
(0.3, 3.4) 
1.0  
(0.3, 3.3) 
1.6  
(0.6, 4.4) 
1.6  
(0.6, 4.3) 
Luzerne Referent Referent Referent Referent Referent Referent Referent Referent 
Schuylkill 1.6  
(0.9, 3.0) 
1.5  
(0.8, 2.8) 
1.6  
(0.8, 3.1) 
1.4  
(0.7, 2.9) 
1.3  
(0.5, 3.2) 
1.2  
(0.5, 2.9) 
2.2  
(1.0, 4.9) 
2.0  
(0.9, 4.4) 
Age                 
42-64   Referent   Referent   Referent   Referent 
65+   2.9  
(1.6, 5.2) 
  3.0  
(1.5, 5.8) 
  4.0  
(1.6, 9.7) 
  3.5  
(1.6, 7.5) 
Sex                 
Male   1.4  
(0.8, 2.5) 
  1.5  
(0.8, 2.8) 
  1.4  
(0.6, 3.2) 
  1.8  
(0.9, 3.7) 
Female   Referent   Referent   Referent   Referent 
Age                 
42-64 Referent Referent Referent Referent Referent Referent Referent Referent 
65+ 2.9  
(1.6, 5.3) 
2.9  
(1.6, 5.2) 
3.0  
(1.5, 5.8) 
3.0  
(1.5, 5.8) 
4.0  
(1.6, 9.7) 
4.0  
(1.6, 9.7) 
3.5  
(1.7, 7.6) 
3.5  
(1.6, 7.5) 
Sex                 
Male   1.4  
(0.8, 2.5) 
  1.5  
(0.8, 2.8) 
  1.4  
(0.6, 3.2) 
  1.8  
(0.9, 3.7) 
Female   Referent   Referent   Referent   Referent 
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Table 2.4 Study demographic logistic regression models 1 (cont’d) 
 
 All cases 
OR 2 
(95% CI) 
n=55 
All cases 
aOR 3 
(95% CI) 
n=55 
Confirmed 
cases OR 2 
(95% CI) 
n=41 
Confirmed 
cases aOR 3 
(95% CI) 
n=41 
Confirmed 
JAK2 V617F OR 
2 
(95% CI) 
n=25 
Confirmed JAK2 
V617F aOR 3 
(95% CI) 
n=25 
Confirmed 
PV OR 2 
(95% CI) 
n=33 
Confirmed 
PV aOR 3 
(95% CI) 
n=33 
County                 
Carbon   0.9  
(0.4, 2.1) 
  1.0  
(0.4, 2.6) 
  1.0  
(0.3, 3.3) 
  1.6  
(0.6, 4.3) 
Schuylkill   1.5  
(0.8, 2.8) 
  1.4  
(0.7, 2.9) 
  1.2  
(0.5, 2.9) 
  2.0  
(0.9, 4.4) 
Luzerne   Referent   Referent   Referent   Referent 
Sex                 
Male 1.5  
(0.9, 2.6) 
1.4  
(0.8, 2.5) 
1.5  
(0.8, 2.8) 
1.5  
(0.8, 2.8) 
1.4  
(0.6, 3.2) 
1.4  
(0.6, 3.2) 
1.9  
(0.9, 3.8) 
1.8  
(0.9, 3.7) 
Female Referent Referent Referent Referent Referent Referent Referent Referent 
Age                 
42-64   Referent   Referent   Referent   Referent 
65+   2.9  
(1.6, 5.2) 
  3.0  
(1.5, 5.8) 
  4.0  
(1.6, 9.7) 
  3.5  
(1.6, 7.5) 
County                 
Carbon   0.9  
(0.4, 2.1) 
  1.0  
(0.4, 2.6) 
  1.0  
(0.3, 3.3) 
  1.6  
(0.6, 4.3) 
Schuylkill   1.5  
(0.8, 2.8) 
  1.4  
(0.7, 2.9) 
  1.2  
(0.5, 2.9) 
  2.0  
(0.9, 4.4) 
Luzerne   Referent   Referent   Referent   Referent 
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Table 2.4 Study demographic logistic regression models 1 (cont’d) 
 
 All cases 
OR 2 
(95% CI) 
n=55 
All cases 
aOR 3 
(95% CI) 
n=55 
Confirmed 
cases OR 2 
(95% CI) 
n=41 
Confirmed 
cases aOR 3 
(95% CI) 
n=41 
Confirmed 
JAK2 V617F OR 
2 
(95% CI) 
n=25 
Confirmed JAK2 
V617F aOR 3 
(95% CI) 
n=25 
Confirmed 
PV OR 2 
(95% CI) 
n=33 
Confirmed 
PV aOR 3 
(95% CI) 
n=33 
Marital status                 
Married Referent Referent Referent Referent Referent Referent Referent Referent 
Widowed 1.5  
(0.7, 3.0) 
1.1  
(0.5, 2.2) 
1.6  
(0.8, 3.3) 
1.1  
(0.5, 2.6) 
1.7  
(0.7, 4.3) 
1.1  
(0.4, 3.0) 
1.7  
(0.7, 3.8) 
1.2  
(0.5, 3.1) 
Currently 
single 
0.7  
(0.3, 1.5) 
0.7  
(0.3, 1.6) 
0.3  
(0.1, 1.1) 
0.3  
(0.1, 1.1) 
0.4  
(0.1, 1.6) 
0.4  
(0.1, 1.7) 
0.4  
(0.1, 1.4) 
0.4  
(0.1, 1.6) 
Age                 
42-64   Referent   Referent   Referent   Referent 
65+   2.8  
(1.5, 5.2) 
  2.6  
(1.3, 5.4) 
  3.6  
(1.4, 9.2) 
  3.0  
(1.3, 6.9) 
Sex                 
Male   1.4  
(0.8, 2.6) 
  1.4  
(0.7, 2.8) 
  1.4  
(0.6, 3.3) 
  1.8  
(0.8, 3.8) 
Female   Referent   Referent   Referent   Referent 
County                 
Carbon   0.9  
(0.4, 2.1) 
  1.0  
(0.4, 2.6) 
  1.0  
(0.3, 3.2) 
  1.5  
(0.6, 4.2) 
Schuylkill   1.6  
(0.8, 2.9) 
  1.5  
(0.7, 3.2) 
  1.3  
(0.5, 3.2) 
  2.1  
(0.9, 4.8) 
Luzerne   Referent   Referent   Referent   Referent 
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Table 2.4 Study demographic logistic regression models 1 (cont’d) 
 
 All cases 
OR 2 
(95% CI) 
n=55 
All cases 
aOR 3 
(95% CI) 
n=55 
Confirmed 
cases OR 2 
(95% CI) 
n=41 
Confirmed 
cases aOR 3 
(95% CI) 
n=41 
Confirmed 
JAK2 V617F OR 
2 
(95% CI) 
n=25 
Confirmed JAK2 
V617F aOR 3 
(95% CI) 
n=25 
Confirmed 
PV OR 2 
(95% CI) 
n=33 
Confirmed 
PV aOR 3 
(95% CI) 
n=33 
Education                 
Less than 
high school 
4.2  
(1.1, 15.7) 
2.8  
(0.7, 10.9) 
3.0  
(0.6, 13.6) 
1.9  
(0.4, 9.3) 
3.9  
(0.6, 26.3) 
2.4  
(0.3, 17.4) 
3.0  
(0.5, 18.1) 
1.8  
(0.3, 12.1) 
High school / 
GED 
1.5  
(0.6, 3.7) 
1.2  
(0.5, 3.0) 
1.3  
(0.5, 3.4) 
1.0  
(0.4, 2.7) 
1.6  
(0.4, 5.7) 
1.2  
(0.3, 4.3) 
1.8  
(0.6, 5.5) 
1.4  
(0.4, 4.4) 
Some college 0.4  
(0.1, 1.2) 
0.4  
(0.1, 1.1) 
0.5  
(0.2, 1.5) 
0.4  
(0.1, 1.3) 
0.7  
(0.2, 2.9) 
0.6  
(0.1, 2.5) 
0.5  
(0.1, 2.0) 
0.4  
(0.1, 1.7) 
Bachelors 
degree 
1.0  
(0.3, 3.0) 
0.9  
(0.3, 2.9) 
0.6  
(0.1, 2.3) 
0.6  
(0.1, 2.4) 
0.7  
(0.1, 4.6) 
0.7  
(0.1, 4.7) 
0.6  
(0.1, 3.2) 
0.6  
(0.1, 3.3) 
More than 
bachelors 
Referent Referent Referent Referent Referent Referent Referent Referent 
Age                 
42-64   Referent   Referent   Referent   Referent 
65+   2.7  
(1.5, 4.9) 
  2.7  
(1.4, 5.5) 
  3.6  
(1.5, 9.1) 
  3.1  
(1.4, 6.9) 
Sex                 
Male   1.4  
(0.8, 2.5) 
  1.4  
(0.7, 2.7) 
  1.4  
(0.6, 3.2) 
  1.8  
(0.9, 3.7) 
Female   Referent   Referent   Referent   Referent 
 
 
 
        
    
 
 
   
Table 2.4 Study demographic logistic regression models 1 (cont’d) 
 
 All cases 
OR 2 
(95% CI) 
n=55 
All cases 
aOR 3 
(95% CI) 
n=55 
Confirmed 
cases OR 2 
(95% CI) 
n=41 
Confirmed 
cases aOR 3 
(95% CI) 
n=41 
Confirmed 
JAK2 V617F OR 
2 
(95% CI) 
n=25 
Confirmed JAK2 
V617F aOR 3 
(95% CI) 
n=25 
Confirmed 
PV OR 2 
(95% CI) 
n=33 
Confirmed 
PV aOR 3 
(95% CI) 
n=33 
County                 
Carbon   0.9  
(0.4, 2.2) 
  1.0  
(0.4, 2.6) 
  1.0  
(0.3, 3.4) 
  1.5  
(0.5, 4.2) 
Schuylkill   1.5  
(0.8, 2.8) 
  1.4  
(0.7, 2.9) 
  1.1  
(0.5, 2.9) 
  1.9  
(0.9, 4.3) 
Luzerne   Referent   Referent   Referent   Referent 
Household 
income 
                
Less than 
$20,000 
1.0  
(0.4, 2.7) 
0.5  
(0.2, 1.4) 
0.8  
(0.2, 2.5) 
0.3  
(0.1, 1.3) 
0.6  
(0.1, 2.6) 
0.2  
(0.1, 1.2) 
2.1  
(0.5, 9.0) 
1.0  
(0.2, 4.7) 
$20,000 - 
$35,000 
1.1  
(0.5, 2.6) 
0.6  
(0.2, 1.5) 
1.0  
(0.4, 2.6) 
0.5  
(0.2, 1.5) 
0.9  
(0.3, 2.8) 
0.4  
(0.1, 1.4) 
2.6  
(0.7, 9.8) 
1.3  
(0.3, 5.5) 
$35,000 - 
$50,000 
0.7  
(0.3, 1.9) 
0.4  
(0.2, 1.2) 
0.6  
(0.2, 1.8) 
0.3  
(0.1, 1.1) 
0.3  
(0.1, 1.5) 
0.1  
(0.0, 0.8) 
1.2  
(0.3, 5.6) 
0.7  
(0.1, 3.5) 
$50,000 - 
$75,000 
0.9  
(0.3, 2.2) 
0.7  
(0.3, 1.8) 
1.0  
(0.4, 2.6) 
0.8  
(0.3, 2.2) 
0.6  
(0.2, 2.1) 
0.4  
(0.1, 1.7) 
2.3  
(0.6, 8.9) 
1.7  
(0.4, 7.0) 
More than 
$75,000 
Referent Referent Referent Referent Referent Referent Referent Referent 
Age                 
42-64   Referent   Referent   Referent   Referent 
65+   3.6  
(1.8, 7.1) 
  3.7  
(1.7, 8.1) 
  5.3  
(1.9, 15.2) 
  3.5  
(1.5, 8.3) 
 
    
 
 
   
Table 2.4 Study demographic logistic regression models 1 (cont’d) 
 
 All cases 
OR 2 
(95% CI) 
n=55 
All cases 
aOR 3 
(95% CI) 
n=55 
Confirmed 
cases OR 2 
(95% CI) 
n=41 
Confirmed 
cases aOR 3 
(95% CI) 
n=41 
Confirmed 
JAK2 V617F OR 
2 
(95% CI) 
n=25 
Confirmed JAK2 
V617F aOR 3 
(95% CI) 
n=25 
Confirmed 
PV OR 2 
(95% CI) 
n=33 
Confirmed 
PV aOR 3 
(95% CI) 
n=33 
Sex                 
Male   1.5  
(0.8, 2.7) 
  1.4  
(0.7, 2.8) 
  1.4  
(0.6, 3.4) 
  1.7  
(0.8, 3.8) 
Female   Referent   Referent   Referent   Referent 
County                 
Carbon   1.1  
(0.4, 2.6) 
  1.2  
(0.5, 3.3) 
  1.3  
(0.4, 4.4) 
  1.8  
(0.6, 5.1) 
Schuylkill   1.8  
(0.9, 3.5) 
  1.7  
(0.8, 3.6) 
  1.4  
(0.5, 3.8) 
  2.1  
(0.9, 4.9) 
Luzerne   Referent   Referent   Referent   Referent 
1. Self-reported socio economic factors 
 2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only.  
 3. Adjusted (for age, sex and county) ORs (95% confidence intervals)
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Table 2.5. Cooked meat diet history 1 (cont’d) 
 All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed  
JAK2 V617Fcases2  
n=25 
Confirmed  
PV cases 2 
n=33 
Controls 
n=473 
Ever ate grilled, BBQ, or 
smoked meat or fish 
          
Yes 52  (95%)  38  (93%)  25  (100%) 31  (94%)  461  (97%)  
No 3  (5%)  3  (7%)  0 2  (6%)  12  (3%) 
Ate grilled, BBQ, or smoked 
meat or fish in the winter 
          
No 34  (65%)  25  (66%)  17  (68%)  22  (71%)  319  (69%)  
Yes 18  (35%)  13  (34%)  8  (32%)  9  (29%)  142  (31%)  
Missing 3 3 0 2 12 
Ate grilled, BBQ, smoked 
meat or fish in the spring 
          
No 32  (62%)  23  (61%)  14  (56%)  20  (65%)  250  (54%) 
Yes 20  (38%)  15  (39%)  11  (44%)  11  (35%)  211  (46%)  
Missing 3 3 0 2 12 
Ate grilled, BBQ, smoked 
meat or fish in the summer 
          
No 0 0 0 0 5  (1%)  
Yes 52  (100%) 38  (100%) 25  (100%) 31  (100%) 456  (99%)  
Missing 3 3 0 2 12 
Ate grilled, BBQ, smoked 
meat or fish in the fall 
          
No 33  (63%)  24  (63%)  15  (60%)  21  (68%)  269  (58%)  
Yes 19  (37%)  14  (37%)  10  (40%)  10  (32%)  192  (42%)  
Missing 3 3 0 2 12 
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Table 2.5. Cooked meat diet history 1 (cont’d) 
 All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed  
JAK2 V617Fcases2  
n=25 
Confirmed  
PV cases 2 
n=33 
Controls 
n=473 
Ate grilled, BBQ, smoked 
meat or fish all year 
          
No 35  (67%)  26  (68%)  17  (68%)  23  (74%)  323  (70%)  
Yes 17  (33%)  12  (32%)  8  (32%)  8  (26%)  138  (30%)  
Missing 3 3 0 2 12 
Ever ate grilled or BBQ beef, 
lamb, or pork 
          
Yes 45  (82%)   35  (85%)   23  (92%)   31  (94%) 421  (89%)   
No  10  (18%)   6  (15%) 2  (8%)   2  (6%)   52  (11%)  
Ate grilled or BBQ beef, 
lamb, or pork in the spring 
          
No 24  (53%) 20  (57%)   12  (52%)   18  (58%)   229  (54%)   
Yes 21  (47%)  15  (43 %)  11  (48%)   13  (42%)    192  (46%)   
Missing 10 6 2 2 52 
Ate grilled or BBQ beef, 
lamb, or pork in the summer 
          
No 0 0 0 0 2  (0%)  
Yes 45  (100%) 35  (100%) 23  (100%) 31  (100%) 419  (100%)  
Missing 10 6 2 2 52 
Ate grilled or BBQ beef, 
lamb, or pork in the fall 
          
No 26  (58%)  21  (60%)  13  (57%)  19  (61%)  243  (58%)  
Yes 19  (42%)  14  (40%)  10  (43%)  12  (39%)  178  (42%)  
Missing 10 6 2 2 52 
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Table 2.5. Cooked meat diet history 1 (cont’d) 
 All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed  
JAK2 V617Fcases2  
n=25 
Confirmed  
PV cases 2 
n=33 
Controls 
n=473 
Ate grilled or BBQ beef, 
lamb, or pork all year long 
          
No 29  (64%)  24  (69%)  15  (65%)  22  (71%)  304  (72%)  
Yes 16  (36%)  11  (31%) 8  (35%)  9  (29%)  117  (28%)  
Missing 10 6 2 2 52 
Ever ate grilled, or BBQ 
poultry or fish 
          
Yes 36  (65%)  26  (63%)  16  (64%)  21  (64%)  407  (86%)  
No 19  (35%)  15  (37%)  9  (36%)  12  (36%)  66  (14%)  
Ate grilled, or BBQ poultry or 
fish in the winter 
          
No 20  (56%)  15  (58%)  7  (44%)  12  (57%)  285  (70%)  
Yes 16  (44%)  11  (42%)  9  (56%)   9  (43%)  122  (30%)  
Missing 19 15 9 12 66 
Ate grilled, or BBQ poultry or 
fish in the spring 
          
No 19  (53%)  14  (54%)  7  (44%)  11  (52%)  215  (53%)  
Yes 17  (47%)  12  (46%)  9  (56%)  10  (48%) 192  (47%)  
Missing 19 15 9 12 66 
Ate grilled, or BBQ poultry or 
fish in the summer 
          
No 0 0 0 0 3  (1%)  
Yes 36  (100%) 26  (100%) 16  (100%) 21  (100%) 404  (99%)  
Missing 19 15 9 12 66 
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Table 2.5. Cooked meat diet history 1 (cont’d) 
 All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed  
JAK2 V617Fcases2  
n=25 
Confirmed  
PV cases 2 
n=33 
Controls 
n=473 
Ate grilled, or BBQ poultry or 
fish in the fall 
          
No 18  (50%) 13  (50%)  6  (38%) 10  (48%)  229  (56%)  
Yes 18  (50%)  13  (50%)  10  (63%)  11  (52%)  178  (44%)  
Missing 19 15 9 12 66 
Ate grilled, or BBQ poultry or 
fish all year long 
          
No 20  (56%)  15  (58%) 7  (44%)  12  (57%)  287  (71%)  
Yes 16  (44%)  11  (42%)  9  (56%)  9  (43%)  120  (29%)  
Missing 19 15 9 12 66 
Ever ate smoked beef, lamb, 
or pork 
          
Yes 42  (76%)  31  (76%)  19  (76%)  27  (82%)  436  (92%)  
No 13  (24%) 10  (24%)  6  (24%)  6  (18%)  37  (8%)  
Ate smoked beef, lamb, or 
pork in the winter 
          
No 1  (2%)  1  (3%) 0 1  (4%)  36  (8%)  
Yes 41  (98%)  30  (97%)  19  (100%) 26  (96%)  400  (92%)  
Missing 13 10 6 6 37 
Ate smoked beef, lamb, or 
pork in the spring 
          
No 3  (7%)  3  (10%) 1  (5%)  2  (7%)  39  (9%)  
Yes 39  (93%)  28  (90%)  18  (95%)  25  (93%)  397  (91%)  
Missing 13 10 6 6 37 
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Table 2.5. Cooked meat diet history 1 (cont’d) 
 All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed  
JAK2 V617Fcases2  
n=25 
Confirmed  
PV cases 2 
n=33 
Controls 
n=473 
Ate smoked beef, lamb, or 
pork in the summer 
          
No 5  (12%)  5  (16%)  2  (11%)  4  (15%)  31  (7%)  
Yes 37  (88%)  26  (84%)  17  (89%)  23  (85%) 405  (93%) 
Missing 13 10 6 6 37 
Ate smoked beef, lamb, or 
pork in the fall 
          
No 3  (7%)  3  (10%)  1  (5%)  2  (7%)  43  (10%)  
Yes 39  (93%)  28  (90%)  18  (95%)  25  (93%)  393  (90%)  
Missing 13 10 6 6 37 
Ate smoked beef, lamb, or 
pork all year long 
          
No 5  (12%)  5  (16%)  2  (11%)  4  (15%)  58  (13%)  
Yes 37  (88%)  26  (84%)  17  (89%)  23  (85%)  378  (87%)  
Missing 13 10 6 6 37 
Ever ate smoked poultry or 
fish 
          
Yes 15  (28%)  12  (30%)  8  (33%)  11  (34%)  140  (30%)  
No 39  (72%)  28  (70%) 16  (67%) 21  (66%)  332  (70%) 
Don't know 1 1 1 1 1 
Ate smoked poultry or fish in 
the winter 
          
No 1  (7%)  1  (8%)  0 1  (9%)  28  (20%)  
Yes 14  (93%)  11  (92%)  8  (100%) 10  (91%)  112  (80%)  
Missing 40 29 17 22 333 
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Table 2.5. Cooked meat diet history 1 (cont’d) 
 All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed  
JAK2 V617Fcases2  
n=25 
Confirmed  
PV cases 2 
n=33 
Controls 
n=473 
Ate smoked poultry or fish in 
the spring 
          
No 3  (20%) 3  (25%)  1  (13%) 2  (18%)  35  (25%)  
Yes 12  (80%)  9  (75%)  7  (88%)  9  (82%)  105  (75%) 
Missing 40 29 17 22 333 
Ate smoked poultry or fish in 
the summer 
          
No 3  (20%)  3  (25%)  1  (13%)  2  (18%)  29  (21%)  
Yes 12  (80%) 9  (75%)  7  (88%)  9  (82%)  111  (79%)  
Missing 40 29 17 22 333 
Ate smoked poultry or fish in 
the fall 
          
No 2  (13%)  2  (17%)  1  (13%)  1  (9%)  18  (13%)  
Yes 13  (87%)  10  (83%)  7  (88%)  10  (91%)  122  (87%)  
Missing 40 29 17 22 333 
Ate smoked poultry or fish 
all year 
          
No 3  (20%)  3  (25%)  1  (13%)  2  (18%)  40  (29%)  
Yes 12  (80%) 9  (75%) 7  (88%)  9  (82%)  100 (71%) 
Missing 40 29 17 22 333 
 
      
1. Assessed through questions estimating grilled and barbequed meat intake during different time periods, number and %  
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ever ate grilled, BBQ, or 
smoked meat or fish 
                
Yes 0.5  
(0.1, 1.7) 
0.5  
(0.1, 2.0) 
0.3  
(0.1, 1.2) 
0.4  
(0.1, 1.5) 
-- -- 0.4  
(0.1, 1.9) 
0.5  
(0.1, 2.6) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ate grilled, BBQ, or 
smoked meat or fish in 
the winter 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.2  
(0.6, 2.2) 
1.4  
(0.7, 2.6) 
1.2  
(0.6, 2.3) 
1.3  
(0.6, 2.6) 
1.1  
(0.4, 2.5) 
1.2  
(0.5, 3.0) 
0.9  
(0.4, 2.0) 
0.9  
(0.4, 2.2) 
Ate grilled, BBQ, 
smoked meat or fish in 
the spring 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.7  
(0.4, 1.3) 
0.9  
(0.5, 1.6) 
0.8  
(0.4, 1.5) 
0.9  
(0.4, 1.8) 
0.9  
(0.4, 2.1) 
1.2  
(0.5, 2.7) 
0.7  
(0.3, 1.4) 
0.7  
(0.3, 1.6) 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ate grilled, BBQ, 
smoked meat or fish in 
the fall 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.8  
(0.4, 1.5) 
0.9  
(0.5, 1.8) 
0.8  
(0.4, 1.6) 
0.9  
(0.4, 1.9) 
0.9  
(0.4, 2.1) 
1.2  
(0.5, 2.7) 
0.7  
(0.3, 1.4) 
0.7  
(0.3, 1.6) 
Ate grilled, BBQ, 
smoked meat or fish all 
year 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.1  
(0.6, 2.1) 
1.3  
(0.7, 2.4) 
1.1  
(0.5, 2.2) 
1.2  
(0.6, 2.4) 
1.1  
(0.5, 2.6) 
1.3  
(0.5, 3.1) 
0.8  
(0.4, 1.9) 
0.8  
(0.3, 1.9) 
Ever ate grilled or BBQ 
beef, lamb, or pork 
                
Yes 0.6  
(0.3, 1.2) 
0.7  
(0.3, 1.5) 
0.7  
(0.3, 1.8) 
0.9  
(0.4, 2.3) 
1.4  
(0.3, 6.2) 
1.9  
(0.4, 8.3) 
1.9  
(0.4, 8.2) 
2.6  
(0.6, 11.7) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ate grilled or BBQ beef, 
lamb, or pork in the 
winter 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.4  
(0.7, 2.6) 
1.4  
(0.7, 2.7) 
1.1  
(0.5, 2.4) 
1.1  
(0.5, 2.4) 
1.3  
(0.5, 3.2) 
1.4  
(0.5, 3.6) 
1.0  
(0.5, 2.3) 
0.9  
(0.4, 2.1) 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ate grilled or BBQ beef, 
lamb, or pork in the 
spring 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.6, 1.9) 
1.1  
(0.6, 2.2) 
0.9  
(0.4, 1.8) 
0.9  
(0.4, 1.9) 
1.1  
(0.5, 2.5) 
1.3  
(0.5, 3.3) 
0.9  
(0.4, 1.8) 
0.8  
(0.4, 1.8) 
Ate grilled or BBQ beef, 
lamb, or pork in the 
summer 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes -- -- -- -- -- -- -- -- 
Ate grilled or BBQ beef, 
lamb, or pork in the fall 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.5, 1.9) 
1.0  
(0.5, 2.0) 
0.9  
(0.5, 1.8) 
0.9  
(0.4, 1.9) 
1.1  
(0.5, 2.4) 
1.2  
(0.5, 3.0) 
0.9  
(0.4, 1.8) 
0.8  
(0.4, 1.8) 
Ate grilled or BBQ beef, 
lamb, or pork all year 
long 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.4  
(0.8, 2.7) 
1.4  
(0.7, 2.9) 
1.2  
(0.6, 2.5) 
1.1  
(0.5, 2.5) 
1.4  
(0.6, 3.4) 
1.5  
(0.6, 3.9) 
1.1  
(0.5, 2.4) 
0.9  
(0.4, 2.2) 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ever ate grilled, or BBQ 
poultry or fish 
                
Yes 0.3  
(0.2, 0.6) 
0.4  
(0.2, 0.7) 
0.3  
(0.1, 0.6) 
0.3  
(0.2, 0.7) 
0.3  
(0.1, 0.7) 
0.4  
(0.1, 0.9) 
0.3  
(0.1, 0.6) 
0.4  
(0.2, 0.8) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ate grilled, or BBQ 
poultry or fish in the 
winter 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.9  
(0.9, 3.7) 
2.0  
(1.0, 4.1) 
1.7  
(0.8, 3.8) 
1.7  
(0.7, 4.0) 
3.0  
(1.1, 8.2) 
3.5  
(1.2, 10.0) 
1.8  
(0.7, 4.3) 
1.6  
(0.6, 4.1) 
Ate grilled, or BBQ 
poultry or fish in the 
spring 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.5, 2.0) 
1.1  
(0.5, 2.3) 
1.0  
(0.4, 2.1) 
1.0  
(0.4, 2.3) 
1.4  
(0.5, 3.9) 
1.8  
(0.6, 5.2) 
1.0  
(0.4, 2.4) 
1.0  
(0.4, 2.5) 
Ate grilled, or BBQ 
poultry or fish in the 
summer 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes -- -- -- -- -- -- -- -- 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ate grilled, or BBQ 
poultry or fish in the fall 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.3  
(0.7, 2.5) 
1.4  
(0.7, 2.9) 
1.3  
(0.6, 2.8) 
1.3  
(0.6, 3.1) 
2.1  
(0.8, 6.0) 
2.6  
(0.9, 7.6) 
1.4  
(0.6, 3.4) 
1.4  
(0.6, 3.5) 
Ate grilled, or BBQ 
poultry or fish all year 
long 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.9  
(1.0, 3.8) 
2.1  
(1.0, 4.2) 
1.8  
(0.8, 3.9) 
1.8  
(0.8, 4.1) 
3.1  
(1.1, 8.4) 
3.6  
(1.2, 10.4) 
1.8  
(0.7, 4.4) 
1.7  
(0.7, 4.3) 
Ever ate smoked beef, 
lamb, or pork 
                
Yes 0.3  
(0.1, 0.6) 
0.3  
(0.1, 0.5) 
0.3  
(0.1, 0.6) 
0.2  
(0.1, 0.6) 
0.3  
(0.1, 0.7) 
0.2  
(0.1, 0.7) 
0.4  
(0.1, 1.0) 
0.4  
(0.1, 1.0) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ate smoked beef, lamb, 
or pork in the winter 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 3.7  
(0.5, 27.6) 
4.2  
(0.6, 32.1) 
2.7  
(0.4, 20.4) 
3.1  
(0.4, 24.2) 
-- -- 2.3  
(0.3, 17.7) 
2.7  
(0.3, 20.9) 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ate smoked beef, lamb, 
or pork in the spring 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.3  
(0.4, 4.3) 
1.4  
(0.4, 5.0) 
0.9  
(0.3, 3.2) 
1.0  
(0.3, 3.6) 
1.8  
(0.2, 13.6) 
2.2  
(0.3, 17.6) 
1.2  
(0.3, 5.4) 
1.4  
(0.3, 6.1) 
Ate smoked beef, lamb, 
or pork in the summer 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.6  
(0.2, 1.5) 
0.6  
(0.2, 1.8) 
0.4  
(0.1, 1.1) 
0.4  
(0.2, 1.3) 
0.7  
(0.1, 2.9) 
0.9  
(0.2, 4.0) 
0.4  
(0.1, 1.4) 
0.5  
(0.1, 1.5) 
Ate smoked beef, lamb, 
or pork in the fall 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.4  
(0.4, 4.8) 
1.4  
(0.4, 4.8) 
1.0  
(0.3, 3.5) 
1.0  
(0.3, 3.5) 
2.0  
(0.3, 15.1) 
2.1  
(0.3, 16.4) 
1.4  
(0.3, 6.0) 
1.2  
(0.3, 5.6) 
Ate smoked beef, lamb, 
or pork all year long 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.1  
(0.4, 3.0) 
1.2  
(0.5, 3.3) 
0.8  
(0.3, 2.2) 
0.9  
(0.3, 2.4) 
1.3  
(0.3, 5.8) 
1.6  
(0.3, 7.2) 
0.9  
(0.3, 2.6) 
0.9  
(0.3, 2.8) 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ever ate smoked 
poultry or fish 
                
Yes 0.9  
(0.5, 1.7) 
1.0  
(0.5, 1.9) 
1.0  
(0.5, 2.1) 
1.1  
(0.5, 2.3) 
1.2  
(0.5, 2.8) 
1.3  
(0.5, 3.3) 
1.2  
(0.6, 2.6) 
1.4  
(0.6, 3.0) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ate smoked poultry or 
fish in the winter 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 3.5  
(0.4, 27.8) 
3.3  
(0.4, 28.7) 
2.7  
(0.3, 22.2) 
2.5  
(0.3, 22.3) 
-- -- 2.5  
(0.3, 20.3) 
2.5  
(0.3, 22.2) 
Ate smoked poultry or 
fish in the spring 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.3  
(0.4, 5.0) 
1.2  
(0.3, 4.8) 
1.0  
(0.3, 3.9) 
0.9  
(0.2, 3.7) 
2.3  
(0.3, 19.6) 
2.1  
(0.2, 19.7) 
1.5  
(0.3, 7.3) 
1.3  
(0.3, 7.1) 
Ate smoked poultry or 
fish in the summer 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.3, 3.9) 
0.8  
(0.2, 3.3) 
0.8  
(0.2, 3.1) 
0.6  
(0.1, 2.6) 
1.8  
(0.2, 15.5) 
1.4  
(0.2, 13.2) 
1.2  
(0.2, 5.7) 
0.9  
(0.2, 4.9) 
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Table 2.6 Cooked meat diet history logistic regression models 1  (cont’d) 
 
All cases 
OR 2 
n=55 
All cases 
aOR 3 
n=55 
Confirmed 
cases OR 2 
n=41 
Confirmed 
cases aOR 3 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
n=25 
Confirmed 
PV OR 2 
n=33 
Confirmed 
PV aOR 3 
n=33 
Ate smoked poultry or 
fish in the fall 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.2, 4.6) 
0.9  
(0.2, 5.2) 
0.7  
(0.1, 3.6) 
0.7  
(0.1, 4.1) 
1.0  
(0.1, 8.9) 
1.0  
(0.1, 9.9) 
1.5  
(0.2, 12.2) 
1.4  
(0.2, 13.5) 
Ate smoked poultry or 
fish all year 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.6  
(0.4, 6.0) 
1.3  
(0.3, 5.3) 
1.2  
(0.3, 4.7) 
1.0  
(0.2, 4.1) 
2.8  
(0.3, 23.5) 
2.3  
(0.3, 21.3) 
1.8  
(0.4, 8.7) 
1.5  
(0.3, 8.0) 
1. Assessed through questions estimating grilled and barbequed meat intake during different time periods, 
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only  
3. Adjusted (for age, sex and county) ORs (95% confidence intervals) 
  
 60
 
 
 
 
Table 2.7  Residential history 1 (cont’d) 
 
All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed 
JAK2 V617Fcases 2 
n=25 
Confirmed PV 
cases 2 
n=33 
Controls 
n=473 
Lived within 0.5 mile of a 
dump/landfill 
          
No 47  (85%)  37  (90%)  23  (92%  29  (88%)  377  (80%)  
Yes 8  (15%)  4  (10%)  2  (8%)  4  (12%)  96  (20%)  
Lived within 0.5 mile of a 
hazardous waste site 
          
No 51  (93%)  40  (98%)  25  (100%) 32  (97%)  436  (92%)  
Yes 4  (7%)  1  (2%)  0 1  (3%)  37  (8%) 
Lived within 0.5 mile of an airport           
No 48  (87%)  37  (90%) 24  (96%)  30  (91%)  396  (84%)  
Yes 7  (13%)  4  (10%) 1  (4%)  3  (9%)  77  (16%)  
Lived within 0.5 mile of a farm           
No 30  (55%)  20  (49%)  13  (52%)  16  (48%)  262  (55%) 
Yes 25  (45%)  21  (51%) 12  (48%)  17  (52%)  211  (45%) 
Lived within 0.5 mile of a 
nursery/greenhouse 
          
No 42  (76%)  33  (80%) 20  (80%)  26  (79%)  343  (73%)  
Yes 13  (24%)  8  (20%) 5  (20%)  7  (21%) 130  (27%)  
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Table 2.7  Residential history 1 (cont’d) 
 
All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed 
JAK2 V617Fcases 2 
n=25 
Confirmed PV 
cases 2 
n=33 
Controls 
n=473 
Lived within 0.5 mile of a golf 
course 
          
No 49  (89%)  
 
36  (88%)  
 
22  (88%)  
 
28  (85%)  
 
390  (82%)  
 
Yes 6  (11%)  
 
5  (12%)  
 
3  (12%)  
 
5  (15%)  
 
83  (18%)  
 
Lived within 0.5 mile of a railroad 
track 
          
No 24  (44%)  19  (46%)  11  (44%)  15  (45%)  163  (34%)  
Yes 31  (56%) 22  (54%) 14  (56%)  18  (55%)  310  (66%)  
Lived within 0.5 mile of a gas 
station 
          
No 18  (33%)  16  (39%) 9  (36%)  13  (39%)  84  (18%)  
Yes 37  (67%) 25  (61%)  16  (64%)  20  (61%) 389  (82%)  
Lived within 0.5 mile of a high 
voltage tower 
          
No 43  (78%)  34  (83%)  22  (88%)  26  (79%) 369  (78%) 
Yes 12  (22%) 7  (17%)  3  (12%)  7  (21%)  104  (22%)  
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Table 2.7  Residential history 1 (cont’d) 
 
All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed 
JAK2 V617Fcases 2 
n=25 
Confirmed PV 
cases 2 
n=33 
Controls 
n=473 
Lived within 0.5 mile of a 
incinerator 
          
No 55  (100%) 41  (100%) 25  (100%) 33  (100%) 450  (95%)  
Yes 0 0 0 0 23  (5%)  
Lived within 0.5 mile of a 
factory/industrial plant 
          
No 33  (60%)  26  (63%)  14  (56%)  18  (55%)  219  (46%)  
Yes 22  (40%)  15  (37%)  11  (44%) 15  (45%)  254  (54%)  
Lived within 0.5 mile of a quarry 
or mine 
          
No 31  (56%)  23  (56%)  13  (52%)  17  (52%)  293  (62%)  
Yes 24  (44%)  18  (44%)  12  (48%)  16  (48%) 180  (38%) 
Lived within 0.5 mile of a coal 
power plant 
          
No 54  (98%)  40  (98%)  24  (96%)  32  (97%)  452  (96%)  
Yes 1  (2%)  1  (2%) 1  (4%) 1  (3%)  21  (4%)  
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Table 2.7  Residential history 1 (cont’d) 
 
All cases 2 
n=55 
Confirmed  
cases 2 
n=41 
Confirmed 
JAK2 V617Fcases 2 
n=25 
Confirmed PV 
cases 2 
n=33 
Controls 
n=473 
Lived within 0.5 mile of a nuclear 
power plant 
          
No 55  (100%) 41  (100%) 25  (100%) 33  (100%) 469  (99%)  
Yes 0 0 0 0 4  (1%) 
1 Every primary residence that they have lived in for 6 months or longer beginning with current residence and work backwards, listing all residences back to age 21, 
number and %  
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
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Table 2.8 Residential history logistic regression models 1 (cont’d) 
 
All cases 
OR 2 
(95%CI) 
n=55 
All cases 
aOR 3 
(95%CI) 
n=55 
Confirmed 
cases OR 2 
(95%CI) 
n=41 
Confirmed 
cases aOR 3 
(95%CI) 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
(95%CI) 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
(95%CI) 
n=25 
Confirmed 
PV OR 2 
(95%CI) 
n=33 
Confirmed 
PV aOR 3 
(95%CI) 
n=33 
Lived within 0.5 mile of 
a dump/landfill 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.7  
(0.3, 1.5) 
0.6  
(0.3, 1.4) 
0.4  
(0.1, 1.2) 
0.4  
(0.1, 1.1) 
0.3  
(0.1, 1.5) 
0.3  
(0.1, 1.4) 
0.5  
(0.2, 1.6) 
0.5  
(0.2, 1.5) 
Lived within 0.5 mile of 
a hazardous waste site 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.9  
(0.3, 2.7) 
1.0  
(0.3, 3.0) 
0.3  
(0.0, 2.2) 
0.3  
(0.0, 2.4) 
-- -- 0.4  
(0.0, 2.8) 
0.4  
(0.0, 2.8) 
Lived within 0.5 mile of 
an airport 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.8  
(0.3, 1.7) 
0.8  
(0.4, 2.0) 
0.6  
(0.2, 1.6) 
0.6  
(0.2, 1.8) 
0.2  
(0.0, 1.6) 
0.2  
(0.0, 1.8) 
0.5  
(0.2, 1.7) 
0.6  
(0.2, 2.1) 
Lived within 0.5 mile of 
a farm 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.6, 1.8) 
1.0  
(0.6, 1.9) 
1.3  
(0.7, 2.5) 
1.3  
(0.7, 2.5) 
1.1  
(0.5, 2.6) 
1.2  
(0.5, 2.8) 
1.3  
(0.7, 2.7) 
1.3  
(0.6, 2.6) 
Lived within 0.5 mile of 
a nursery/greenhouse 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.8  
(0.4, 1.6) 
0.9  
(0.5, 1.7) 
0.6  
(0.3, 1.4) 
0.7  
(0.3, 1.6) 
0.7  
(0.2, 1.8) 
0.7  
(0.3, 2.0) 
0.7  
(0.3, 1.7) 
0.8  
(0.3, 1.9) 
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Table 2.8 Residential history logistic regression models 1 (cont’d) 
 
All cases 
OR 2 
(95%CI) 
n=55 
All cases 
aOR 3 
(95%CI) 
n=55 
Confirmed 
cases OR 2 
(95%CI) 
n=41 
Confirmed 
cases aOR 3 
(95%CI) 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
(95%CI) 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
(95%CI) 
n=25 
Confirmed 
PV OR 2 
(95%CI) 
n=33 
Confirmed 
PV aOR 3 
(95%CI) 
n=33 
Lived within 0.5 mile of 
a golf course 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.6  
(0.2, 1.4) 
0.6  
(0.3, 1.5) 
0.7  
(0.2, 1.7) 
0.7  
(0.3, 1.9) 
0.6  
(0.2, 2.2) 
0.7  
(0.2, 2.4) 
0.8  
(0.3, 2.2) 
1.0  
(0.4, 2.7) 
Lived within 0.5 mile of 
a railroad track 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.7  
(0.4, 1.2) 
0.7  
(0.4, 1.2) 
0.6  
(0.3, 1.2) 
0.6  
(0.3, 1.1) 
0.7  
(0.3, 1.5) 
0.6  
(0.3, 1.5) 
0.6  
(0.3, 1.3) 
0.6  
(0.3, 1.3) 
Lived within 0.5 mile of 
a gas station 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.4  
(0.2, 0.8) 
0.5  
(0.2, 0.8) 
0.3  
(0.2, 0.7) 
0.3  
(0.2, 0.7) 
0.4  
(0.2, 0.9) 
0.4  
(0.2, 1.0) 
0.3  
(0.2, 0.7) 
0.3  
(0.2, 0.7) 
Lived within 0.5 mile of 
a high voltage tower 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.0  
(0.5, 1.9) 
1.0  
(0.5, 2.1) 
0.7  
(0.3, 1.7) 
0.8  
(0.3, 1.8) 
0.5  
(0.1, 1.6) 
0.5  
(0.1, 1.8) 
1.0  
(0.4, 2.3) 
1.0  
(0.4, 2.4) 
Lived within 0.5 mile of 
a incinerator 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes -- -- -- -- -- -- -- --  66
 
 
 
Table 2.8 Residential history logistic regression models 1 (cont’d) 
 
All cases 
OR 2 
(95%CI) 
n=55 
All cases 
aOR 3 
(95%CI) 
n=55 
Confirmed 
cases OR 2 
(95%CI) 
n=41 
Confirmed 
cases aOR 3 
(95%CI) 
n=41 
Confirmed 
JAK2 V617F 
OR 2 
(95%CI) 
n=25 
Confirmed 
JAK2 V617F 
aOR 3 
(95%CI) 
n=25 
Confirmed 
PV OR 2 
(95%CI) 
n=33 
Confirmed 
PV aOR 3 
(95%CI) 
n=33 
Lived within 0.5 mile of 
a factory/industrial 
plant 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.6  
(0.3, 1.0) 
0.6  
(0.3, 1.0) 
0.5  
(0.3, 1.0) 
0.5  
(0.3, 1.0) 
0.7  
(0.3, 1.5) 
0.7  
(0.3, 1.6) 
0.7  
(0.4, 1.5) 
0.7  
(0.3, 1.5) 
Lived within 0.5 mile of 
a quarry or mine 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 1.3  
(0.7, 2.2) 
1.3  
(0.7, 2.4) 
1.3  
(0.7, 2.4) 
1.3  
(0.7, 2.6) 
1.5  
(0.7, 3.4) 
1.5  
(0.7, 3.5) 
1.5  
(0.8, 3.1) 
1.7  
(0.8, 3.4) 
Lived within 0.5 mile of 
a coal power plant 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.4  
(0.1, 3.0) 
0.3  
(0.0, 2.2) 
0.5  
(0.1, 4.1) 
0.4  
(0.0, 3.1) 
0.9  
(0.1, 7.0) 
0.7  
(0.1, 5.3) 
0.7  
(0.1, 5.2) 
0.4  
(0.1, 3.3) 
 
 
 
1. Every primary residence that they have lived in for 6 months or longer beginning with current residence and work backwards, listing all residences back to age 21 
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
3. Adjusted (for age, sex and county) Odds Ratio (95% confidence intervals) 
  
 67
 
 
 
 
Table 2.9. Other lifestyle behaviors 1 (cont’d) 
 All cases 2 
n=55 
Confirmed 
cases 2 
n=41 
Confirmed JAK2 
V617Fcases 2 
n=25 
Confirmed PV cases 2 
n=33 
Controls 
n=473 
Ever use hair color           
Yes 26  (47%)  20  (49%)  14  (56%)  15  (45%)  267  (56%) 
No 29  (53%)  21  (51%)  11  (44%)  18  (55%) 206  (44%) 
Hair coloring frequency           
Weekly (or more) 1  (4%)  1  (5%)  0 1  (7%) 3  (1%)  
Monthly 11  (42%)  8  (40%)  5  (36%)  6  (40%)  128  (48%)  
Yearly (A few times a year or less) 14  (54%)  11  (55%)  9  (64%) 8  (53%)  134  (51%)  
Don't know 0 0 0 0 2 
Ever visited the Still Creek Reservoir           
Yes 4  (7%)  2  (5%)  1  (4%)  2  (6%)  30  (6%) 
No 51  (93%)  39  (95%)  24  (96%)  31  (94%)  438  (94%)  
Don't know 0 0 0 0 5 
Ever take soil from Still Creek Reservoir           
Yes 0 0 0 0 1 ( 3%)  
No 4  (100%) 2  (100%) 1  (100%) 2  (100%) 29  (97%)  
Ever eaten fish from other local creeks or 
lakes 
          
Yes 16  (29%) 13  (32%)  7  (28%)  10  (30%)  181  (39%)  
No 39  (71%)  28  (68%) 18  (72%)  23  (70%)  286  (61%)  
Don't know 0 0 0 0 6 
 
1. Other behaviors, including hair coloring, visiting Still Creek Reservoir, and eating fish from other local lakes or creeks, number and % with 95% confidence 
intervals 
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
 
 68
 
 
 
Table  2.10  Other lifestyle behavior logistic regression models 1 (cont’d) 
 
All cases  
OR 2 
(95%CI) 
All cases 
 aOR 3 
(95%CI) 
Confirmed 
cases  
OR 2 
(95%CI) 
Confirmed 
cases 
 aOR 3 
(95%CI) 
Confirmed JAK2 
V617F  
OR 2 
(95%CI) 
Confirmed 
 JAK2 V617F  
aOR 3 
(95%CI) 
Confirmed 
 PV  
OR 2 
(95%CI) 
Confirmed  
PV  
aOR 3 
(95%CI) 
Ever use hair color                 
Yes 0.7  
(0.4, 1.2) 
1.0  
(0.5, 2.2) 
0.7  
(0.4, 1.4) 
1.1  
(0.5, 2.8) 
1.0  
(0.4, 2.2) 
1.9  
(0.6, 6.0) 
0.6  
(0.3, 1.3) 
1.3  
(0.5, 3.5) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ever visited the Still 
Creek Reservoir 
                
Yes 1.1  
(0.4, 3.4) 
1.0  
(0.3, 3.2) 
0.7  
(0.2, 3.3) 
0.6  
(0.1, 2.9) 
0.6  
(0.1, 4.7) 
0.5  
(0.1, 4.5) 
0.9  
(0.2, 4.1) 
0.7  
(0.1, 3.1) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Ever eaten fish from 
other local creeks or 
lakes 
                
Yes 0.6  
(0.4, 1.2) 
0.7  
(0.4, 1.3) 
0.7  
(0.4, 1.5) 
0.8  
(0.4, 1.5) 
0.6  
(0.3, 1.5) 
0.7  
(0.3, 1.7) 
0.7  
(0.3, 1.5) 
0.7  
(0.3, 1.6) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Lived within 0.5 mile of 
a coal power plant 
                
No Referent Referent Referent Referent Referent Referent Referent Referent 
Yes 0.4  
(0.1, 3.0) 
0.3  
(0.0, 2.2) 
0.5  
(0.1, 4.1) 
0.4  
(0.0, 3.1) 
0.9  
(0.1, 7.0) 
0.7  
(0.1, 5.3) 
0.7  
(0.1, 5.2) 
0.4  
(0.1, 3.3) 
                 
                    
1. Other behaviors, including hair coloring, visiting Still Creek Reservoir, and eating fish from other local lakes or creeks  
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only  
3.  Adjusted (for age, sex and county) Odds Ratio (95% confidence intervals) 
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Table 2.11 Smoking history 1    (cont’d) 
 
Smoking history All cases 
2 
n=55 
Confirmed cases 2 
n=41 
Confirmed JAK2 
V617Fcases 2 
n=25 
Confirmed PV 
cases 2 
n=33 
Controls 
n=473 
Ever smoked           
Yes 27  (49%)  18  (44%)  8  (32%) 15  (45%)  237  (50%) 
No 28  (51%) 23  (56%)  17  (68%)  18  (55%)  236  (50%)  
Ever smoked cigarettes           
Yes 27  (100%) 18  (100%) 8  (100%) 15  (100%) 234  (99%)  
No 0 0 0 0 3  (1%)  
Cigarette pack-years           
Non smoker 28  (51%)  23  (56%)  17  (68%)  18  (55%) 239  (51%)  
Light smoker (<15 py) 13  (24%)  10  (24%)  6  (24%)  8  (24%)  115  (24%) 
Heavy smoker (>=15 py) 14  (25%)  8  (20%)  2  (8%)  7  (21%)  119  (25%)  
Cigarette pack-years (among smokers)           
Light smoker (<15 py) 13  (48%)  10  (56%)  6  (75%)  8  (53%)  115  (49%)  
Heavy smoker (>=15 py) 14  (52%)  8  (44%)  2  (25%)  7  (47%)  119  (51%)  
Smoked filtered or nonfiltered cigarettes           
Filtered 21  (78%) 13  (72%) 6  (75%)  10  (67%)  203  (87%)  
Non-filtered 6  (22%) 5  (28%) 2  (25%)  5  (33%)  30  (13%)  
Both 0 0 0 0 1  (0%)  
Smoked manufactured or hand rolled 
cigarettes 
          
Manufactured (store bought) 22  (81%)  16  (89%) 7  (88%)  13  (87%)  215  (92%)  
Hand rolled 1  (4%)  0 0 0 2  (1%)  
Both 4  (15%)  2  (11%)  1  (13%)  2  (13%)  17  (7%)  
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Table 2.11 Smoking history 1    (cont’d) 
 
Smoking history All cases 
2 
n=55 
Confirmed cases 2 
n=41 
Confirmed JAK2 
V617Fcases 2 
n=25 
Confirmed PV 
cases 2 
n=33 
Controls 
n=473 
Number of smoking episodes           
1 27  (100%) 18  (100%) 8  (100%) 15  (100%) 202  (86%)  
2 0 0 0 0 24  (10%)  
3 0 0 0 0 7  (3%)  
4 0 0 0 0 1  (0%)  
5 0 0 0 0 0 
Number of cessation attempts           
0 6  (22%)  4  (22%)  1  (13%) 3  (20%)  51  (22%)  
1 21  (78%)  14  (78%)  7  (88%)  12  (80%)  161  (69%)  
 
1 .Detailed self-reported smoking history, number and %   
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only  
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Table 2.12 Smoking history logistic regression models 1 (cont’d) 
 
All cases 
OR 2 
(95%CI) 
n=55 
All cases 
aOR 3 
(95%CI) 
n=55 
Confirmed 
cases 
 OR 2 
(95%CI) 
n=41 
Confirmed 
cases  
aOR 3 
(95%CI) 
n=41 
Confirmed 
JAK2 V617F  
OR 2 
(95%CI) 
n=25 
Confirmed 
JAK2 V617F  
aOR 3 
(95%CI) 
n=25 
Confirmed 
PV 
 OR 2 
(95%CI) 
n=33 
Confirmed 
PV  
aOR 3 
(95%CI) 
n=33 
Ever smoked                 
Yes 1.0  
(0.5, 1.7) 
0.8  
(0.5, 1.5) 
0.8  
(0.4, 1.5) 
0.7  
(0.3, 1.3) 
0.5  
(0.2, 1.1) 
0.4  
(0.2, 1.0) 
0.8  
(0.4, 1.7) 
0.7  
(0.3, 1.5) 
No Referent Referent Referent Referent Referent Referent Referent Referent 
Cigarette pack-years                 
Non smoker Referent Referent Referent Referent Referent Referent Referent Referent 
Light smoker  
(<15 py) 
1.0  
(0.5, 1.9) 
0.9  
(0.5, 1.9) 
0.9  
(0.4, 2.0) 
0.9  
(0.4, 2.0) 
0.7  
(0.3, 1.9) 
0.7  
(0.3, 2.0) 
0.9  
(0.4, 2.2) 
0.9  
(0.4, 2.3) 
Heavy smoker  
(>=15 py) 
1.0  
(0.5, 2.0) 
0.8  
(0.4, 1.7) 
0.7  
(0.3, 1.6) 
0.6  
(0.2, 1.3) 
0.2  
(0.1, 1.0) 
0.2  
(0.0, 0.8) 
0.8  
(0.3, 1.9) 
0.6  
(0.2, 1.5) 
Cigarette pack-years  
(among smokers) 
                
Light smoker  
(<15 py) 
Referent Referent Referent Referent Referent Referent Referent Referent 
Heavy smoker  
(>=15 py) 
1.0  
(0.5, 2.3) 
0.8  
(0.4, 2.0) 
0.8  
(0.3, 2.0) 
0.6  
(0.2, 1.6) 
0.3  
(0.1, 1.6) 
0.2  
(0.0, 1.4) 
0.8  
(0.3, 2.4) 
0.6  
(0.2, 1.8) 
Smoked filtered or 
nonfiltered cigarettes 
                
Filtered Referent Referent Referent Referent Referent Referent Referent Referent 
Non-filtered 1.9  
(0.7, 5.2) 
1.1  
(0.4, 3.1) 
2.6  
(0.9, 7.8) 
1.5  
(0.5, 4.9) 
2.3  
(0.4, 11.7) 
1.1  
(0.2, 6.4) 
3.4  
(1.1, 10.6) 
2.0  
(0.6, 6.9) 
Both -- -- -- -- -- -- -- -- 
1.Detailed self-reported smoking history  
2.All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F mutation with PV, ET or PMF by 
expert , confirmed by expert panel PV only 3. Adjusted (for age, sex and county) Odds Ratio (95% confidence intervals)
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Chapter 3: The Role of Genotypes that Modify the Toxicity of Chemical 
Mutagens in the Risk for Myeloproliferative Neoplasms 
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Abstract 
Introduction 
The etiology of a rare category of myeloproliferative neoplasms (MPN)—bone marrow 
diseases with an excess of blood cells—is currently unknown.  These MPNs 
(polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis 
(PMF))  differ phenotypically but commonly share the same JAK2 V617F point mutation 
(JAK2 V617F), which is thought to be at least partly responsible for disease initiation or 
progression.  Thus, the presence of JAK2 V617F mutation suspected to be 
pathognomonic of MPNs is included in this study as an outcome of interest.  
Objectives 
To investigate the potential for gene-environment interactions in aetiology of MPNs and 
JAK2 V617F using a biological pathway candidate gene approach. 
Methods 
We conducted a population-based case-control study among residents of three 
Pennsylvania counties where a cluster of PV was previously described.  Subjects were 
included if they were born between 1921 and 1968 and resided in the three counties 
between 2000 and 2008 in 2011.  Cases were identified from the Pennsylvania Cancer 
Registry and a previously completed cluster investigation we used multiple case 
categorizations, including all MPNs combined, JAK2 V617F cases, and PV cases only.  
Controls were selected based on eligibility screening following random digit dialling with 
the aim of obtaining an age and sex distribution that reflected that of the sources 
counties.  A DNA sample was obtained from participants consenting to blood collection 
and genotyped for a panel of a prior selected environmentally sensitive genes. Blood 
samples were collected from 31 cases and 292 controls.  Data were analyzed using 
logistic regression models that controlled for the design variables (age, sex, county) and 
evaluated one genetic variant at a time. 
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Results 
Cases and controls were demographically similar.  In analysis that examined the main 
effects of 14 environmentally sensitive genes, the presence of NAT2 slow acetylator 
genotype, CYP1A2 and GSTA1, and GSTM3 variants were associated with an increased 
risk for all MPNs combined (point estimates of adjusted (aORs) 2.7 to 4.6, with 95% C.I.s 
that excluded 1.0).  Results were similar for analysis restricted to JAK2 V617F cases. 
Conclusions 
 Our findings suggest that genotypes that modify the toxicity of aromatic and 
heterocyclic amines play a role in MPNs.  Sources and types of exposures important to 
the pathway whereby NAT2 or other genotypes modify risk of MPNs in this population 
remain unclear.  
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Introduction 
Myeloproliferative neoplasms are rare cancers characterized by an overproduction of red 
blood cells and platelets.  These includes polycythemia vera (PV), essential 
thrombocythemia (ET), and primary myelofibrosis (PMF) (Campbell & Green, 2005).  
PV patients expense an excess of red blood cells, >25% above predicted red cell mass 
(Campbell &Green, 2005).  The overproduction of platelets in the bone marrow is seen in 
ET cases, and scarring of the bone occurs in PMF cases (the most severe of the three) 
(Tefferi et al., 2007 ).  The World Health Organization classified MPNs and reporting on 
MPNs began in 2001.  Before the WHO’s revised diagnostic criterion in 2008, the 
National Cancer Institute estimated the incidence of PV at 2.8 per 100,000 persons per 
year for 2001-2004 (Kutti &Ridell, 2001).  For ET the incidence rate was estimated at 1.5 
cases per 100,000 per year (Kutti &Ridell, 2001).  For PMF, only 0.4 cases per 100,000 
persons per year were estimated (Kutti &Ridell, 2001).  There are no known causes of 
MPNs (Anderson et al.,2012). 
 
The JAK2 V617F mutation and its role in MPNs 
The presence of the JAK2 V617F somatic point mutation is suspected to be 
pathognomonic of PV with clinical diagnosis of PV.  JAK2 is a protein that acts as an on-
and-off switch regulating bone marrow activity (Baxter, 2005).  The acquired mutation is 
a single-base substitute that results in a valine to phenylalanine amino acid at position 
617 on the JAK2 gene (Langabeer et al., 2007) and is seen in nearly all PV patients 
(>95%) and about half of those with ET or PMF, and less frequently in other hematologic 
diseases but not in any other cancers (Spivak et al., 2010; Kralovics  et al., 2007; Tefferi 
et al., 2007). The JAK2 V617F mutation activates a tyrosine kinase complex in bone 
marrow normally responsible for regulating blood cell production through molecular 
signalling; the mutation disrupts the normal inhibition of growth, thus increasing blood 
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cell production (Spivak et al., 2010). The causes of the JAK2 V617F mutation are 
currently unknown (Kralovics  et al., 2007). 
 
Familial clustering of PV, ET, and PMF 
There is strong evidence for an increased risk of developing an MPN in people who have 
a family member with an MPN (Anderson et al., 2012, Landgren et al., 2008).  Familial 
clustering has been documented in a 24,577 first degree relatives of 11,039 MPN patients 
diagnosed from 1958 to 2005 in Sweden, which showed a 5 to 7-fold increase in risk of 
developing an MPN for first-degree relatives of MPN patients (Landgren et al., 2008).  
The role of inherited genetics has been suspected to influence both MPN phenotype and 
susceptibility, including potential germ-line mutations yet to be identified (Andrikovics 
et al., 2010).  
Recently a germ-line haplotype, a sequence of single nucleotide polymorphisms (SNPs) 
on the loci designated as the 46/1 haplotype, has been identified as strongly associated 
with JAK2 V617F status (Jones et al., 2009; Kilpivaara et al., 2009) (Olcaydu et al., 
2009). Three genome-wide studies have identified this germ-line 46/1 haplotype in 
European populations in the range of 5%-41% associated with positivity MPNs (Jones et 
al., 2009; Olcaydu et al., 2009; Kilpivaara et al., 2009).  The 46/1 haplotype is 
considered to be the only known risk factor for the JAK2 V617F mutation in PV patients 
(Jones et al., 2009; Andrikovics et al., 2010). 
Environmental exposures and MPNs 
Since the discovery of the acquired and germ-line mutations in MPN patients, the notion 
that environmental exposures that can produce such mutations may play a role in the 
increased risk of developing an MPN became plausible.  The evidence that exists in the 
literature to date suggests that some occupational exposures to may be associated with 
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MPNs. There were three cohort studies looking at PV or myelofibrosis that reported 
higher mortality rates.  Zoloth reported in 1986 higher than expected standardized 
mortality rates (SMRs) among commercial pressmen n=2,500 in US, 120 cases per 
100,000 compared to incidence in population of 2 per 100,000 with four deaths from PV 
(Zoloth et al., 1986).  In a study of poultry workers in Baltimore, a proportional mortality 
rate of 4.9 (95%CI: 1.4,o17.2) with myelofibrosis was reported for only two cases out of a 
cohort of 28,900 poultry workers from 1954 to 1979 with follow up until 2003 (Johnson 
et al., 2010).  Kaplan et al., reported an elevated SMR of petroleum refiner workers of 
455 (95%CI: 1.20, 11.64) (Kaplan et al., 1986).  Although in these studies that detected 
statistically significant results, there were only 14 cases of MPNs, of which only six were 
PV, and none were ET or PMF.     
Different occupational groups have been investigated but there is little agreement as to 
specific occupational exposures that may be implicated.  Cohort studies done by Kaplan 
et al. (1986), Terreros et al. (1997) and a case control study reported by Mele et al. (1997) 
suggest benzene as a risk factor.  Terreros et al. (1997), with only nine cases of 
myeloproliferative syndrome, reported an association with benzene exposure obtained 
from hospital case interview  yielding on the basis of 9 cases an odds ratio (OR) of 46.6 
(95% CI: 2.02,2761).  Exposure to petroleum, of which benzene is a by-product, was 
associated with an increased risk of PV, ET (Kaplan, et.al., 1986).  Quiroga (1981) 
reported a statistical association with exposure to petroleum. However, Pasqualetti et al. 
(1991) reported an elevated risk of haematological malignancies related to exposure to 
aromatic hydrocarbons, assessed as  self-reported exposures to groups of chemicals 
(OR)=2.5 (95%1.39,3,32). This case control study assessed exposures via direct interview 
(59% of cases, 85% of controls) and the remaining questions obtained from relatives. 
From the list of occupational toxic substances gained from the interview, the researchers 
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then grouped these exposures into 21 at risk categories (Pasqualetti et al., 1991).  No 
associations were found with myeloproliferative syndrome (MPS), (n=44, ORs not 
reported) (Pasqualetti et al., 1991).  All of these studies were of limited size and did not 
use the molecular markers such as the JAK2 V617F mutation or the 46/1 haplotype that 
have significantly improved the identifying of true cases of MPNs (Seaman et al., 2009).  
Additonally, more advanced methods for occupational expsoure assesment are currently 
avaible, such as Job exposure matrix etc., that were not developed at the time of these 
studies.  No association between MPNs and residential behaviors and presumed to be 
associated with exposure to aromatic and heterocyclic amines have been reported.  
Genetic susceptibility to environmental exposures and PV, ET, PMF, and 
JAK2 V617F 
 
Although functional genes that may modify the biological dose of a chemical mutagen 
have been studied for a wide range of cancers, no studies have investigated associations 
of these genotypes with MPNs. Susceptibility genotypes examined in these studies 
include, but are not limited to Cytochrome P450 superfamily (CYP genes), polymorphic 
N-acetyltransferase (NAT2), and glutathione S-transferase (GST) polymorphisms.  These 
are all functional genes that encode enzymes on the pathway for biotransformation of 
genotoxic chemicals such as PAHs and benzene (Their, 2003).  Because of the JAK2 
V617F mutation and its role in MPNs, gene-environment interaction between genes that 
modify susceptibility to mutagenic chemicals and level of exposure to such chemicals is 
of particular interest. 
 
Candidate gene and Single Nucleotide Polymorphisms (SNPs) selection 
overview  
 
The families of genes that has been long studied and linked to increased cancer risk 
continue to be the CYP, GST, and NAT2 genes.  One of the methods to estimate gene-
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environment interactions is a candidate-gene approach using a biological pathway 
hypothesis as its framework (Hunter, 2005).  The National Institute of Environmental 
Health Sciences Environmental Genome Project (NIEHS EGP) has already categorized 
environmentally sensitive genes (ESG) in the human genome.  A total of 647 genes are 
included in the NIEHS EGP list in the following categories: cell structure, metabolism, 
DNA repair, cell cycle, cell division, cell signalling, gene expression, and homeostasis.  
This was the starting for our search for candidate genes, and specific polymorphisms to 
be used as a toxicological marker for susceptibility, including Cytochrome P450 
superfamily (CYP genes), Polymorphic N-acetyltransferase (NAT2), and Glutathione S-
transferase (GST) polymorphisms. The benefits of using Mendelian randomization are 
apparent when the genetic variants are functional SNPs and the biological function of the 
variant is known.   
  
 
Garcia-Closas et al. (2011) reported on the use and utility of a novel tag SNP NAT2 
(rs1495741) for the slow acetylator phenotype.  In the past, a 7-SNP inferred phenotype 
had been used to assign individuals to the slow category, which was not always possible.  
Garcia-Closas reported a strong agreement between the rs1495741 tag SNP and 
established 7-SNP inferred NAT2 slow phenotype.  They reported a sensitivity and 
specificity of 99 and 95% respectively for the tag SNP for slow (compared to 
intermediate/rapid) from 154 individuals with European background (Garcia-Closas, 
et.al, 2011).  
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Methods 
Study design 
The project used an unmatched case-control design.  The study area was comprised of a 
tri-county area in Northeast Pennsylvania (Carbon, Luzern, and Schuylkill Counties). 
Cases included individuals with diagnoses of all MPNs combined, JAK2 V617F cases, and 
PV cases only.  Controls were selected using random digit dialing sample stratified by age 
and county to obtain distributions that reflected that of the source counties.  Cases and 
controls were evaluated for presence of the JAK2 V617F mutation (JAK2 V617F) and 
select genotypes susceptible to increases to genotoxic environmental toxins. 
 
Participants 
In 2007, an estimated 500,000 people resided in the tri-county region. People were 
eligible if they were born between 1921 and 1968 (42 and 89 years old).  The restricted 
age group in the three counties was estimated to include 244,870 people. The study 
population was restricted by age to eliminate younger individuals not at risk for the 
MPNs.  Since this study focuses on environmental exposures in the tri-county area, all 
subjects were required to reside in the tri-county area between 2000 and 2008.  
 
Cases must have met the clinical criteria for a MPN and received a diagnosis between the 
years 2001 and 2010 to be eligible for inclusion in this study. The following case 
categorizations were used in this study for analysis: all MPNs, and confirmed MPN 
cases; JAK2 V617F mutation and confirmed JAK2 V617F mutation; PV only cases and 
confirmed PV only cases.  Table 2.2 describes the case categorizations used in this study. 
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Cases were identified from the Pennsylvania Cancer Registry (PCR) using the 
International Classification of Diseases codes (ICD-O) for MPNs (codes M-9950/3, M-
9962/3, M-9961/3; M-9931/3) as well as a cluster investigation published in 2009 for PV 
conducted by ATSDR.    The second source was from a PV cluster investigation that 
included cases diagnosed between 2001 and 2006 in the three county area.  We included 
cases diagnosed up to December 31, 2010.  
 
All cases not previously confirmed by the ATSDR cluster investigation (Seaman et al., 
2009) were evaluated by one of the two expert panels.  Either hematologist’s panel 
created by the Pennsylvania Department of Health or panel used in case ascertainment 
for a related study done by the University of Pittsburgh. Both panels used similar 
summary sheets, and a two thirds majority decision rule for case determination.  The 
medial records of cases were summarized and both patients’ and physicians’ names were 
removed to facilitate impartial evaluation of the medical records.  Full-case interviews 
only included surviving patients that consented to participate in the study.  We also tried 
to contact eligible cases that had relocated from the tri-county area.  
 
Controls were selected using random digit dialing.  Individuals born from 1921-1968 and 
residing in these three counties were eligible.  We selected a stratified random sample of 
controls on age and gender from the study area.  The sample collected was similar to the 
population distribution documented by the from U.S. Census American Community 
Survey, 2008. 
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To participate in this genetic study subjects enrolled in the main study also had to 
consent to a blood draw.  Genotype data were available for 57% of the cases and 62% of 
controls.  The candidate gene-environment analysis was therefore based on information 
from approximately 31 MPNs (all MPNs combined) cases and 292 controls agreeing to 
the blood draw. 
 
Data collection 
Consent to compete the phone survey phase of the study was required to be eligible with 
an additional incentive $25 gift card to consent for a blood sample.  A description of 
what consent entails was included at the bottom of the consent form, along with a yes/no 
box. As well, we offered a second incentive (a $25 gift card) for this phase, to encourage 
blood draw recruitment.  
 
Blood draw was a one-time peripheral venipuncture of 25-30ml of blood. The maximum 
volume taken for samples was: (1)10ml for JAK2 V617F mutation testing, (2)10ml for 
gene susceptibility testing, (3)10ml for storage and possible future testing for biomarkers 
linked to MPN by other studies ongoing in the tri-county area (PV Partners studies). The 
blood samples were sent to at Columbia University Laboratory to perform genotyping. 
Mt. Sinai and Geisinger conducted the JAK2 V617F testing. 
 
Genotyping procedure 
Columbia University used the following steps to conduct genotyping: DNA was extracted 
from white blood cells by a standard salting-out protocol.  DNA quality was assessed by 
absorption at 260 and 280 nm.  Samples were aliquoted into 96 well plates for analysis.  
Genotyping for all selected SNPs, except rs#1048943 and rs#4646903, was carried out 
using the Illumina Bead Express platform that employs VeraCode technology (Illumina 
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San Diego CA). Rs#1048943 and rs#4646903 were genotyped by TaqMan™ assays 
(LifeTechnologies/Applied Biosystems, Carlsbad CA) in a 384 well plate format using an 
Applied Biosystems 7900 PCR system.  About 7% of samples were run in duplicate for 
both SNP genotyping assays. Deletions in GSTM1 and GSTT1 were determined using 
TaqMan Copy Number Assays™ and RNase P as the control gene.  Samples were run in 
triplicate and CopyCaller™ Software was used for determination of copy number. 
 
Selection of environmentally sensitive genes 
Because of the JAK2 V617F mutation and its role in PV-related outcomes, our interest in 
the mechanism of gene-environment interaction relates to genes that modify 
susceptibility to mutagenic chemicals. We considered only NIEHS genes and that were 
non-synonymous single nucleotide polymorphisms (nsSNPs), with a >5% minor allele 
frequency (MAF).  From the full list of the 648 environmentally sensitive genes, 114 
NIEHS metabolism genes were given initial consideration, predominantly, the Phase I 
and Phase II detoxifying enzyme classes. The functional gene groups of interest were 
genes that regulate enzymes of two categories: metabolism or detoxification. Although 
other functional categories may be associated with the chemicals of interest (e.g. PAHs), 
they are out of the scope of this research. 
 
To facilitate the nsSNP selection, we needed an online database with genotyping 
information for each gene.  The Genome Variation Server (GVS) includes detailed SNP 
information for nearly all EGP genes and is sponsored by Seattle SNPs Program for 
Genomic Applications (PGA), through the National Heart Lung and Blood Institute 
(NHLBI) (GVS,2011).  Only 82 of the 114 had coding SNP data in the GVS database.  We 
reviewed the 82 genes with nsSNP data for relevance to chemicals, and a mutagenic 
pathway of interest in the literature.  We ultimately included 14 genes for this project, in 
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addition to the three genes without coding data, as shown in Table 3.1. Table 3.1 lists the 
mutagenic chemicals of interest. Based on this list, all but three chemicals (those being 
metals), are captured by the list of susceptibility genes.  
 
In general the variants included in this analysis modify enzyme function, usually 
weakening the resultant gene product and thereby magnifying the effect of the xenobiotic 
substrate and are associated with a mutagenic chemical of interest (Dong et al., 2008).  
The genes we selected that may be associated with a mutagenic chemical (based on this 
biological pathway hypothesis) are AHR, CYP1A1, CYP1A2, CYP1B1, CYP2B6, GSTP1, 
GSTM1, GSTM3, GSTT1, NAT2, and NQO1 (see Table 3.1) (Genome Variation Server 
(GVS), 2010,2011) (Hung et al., 2003).   One, SNP consistently did not perform well and 
was recommended by the Columbia University Laboratory to be omitted from our 
analysis.   
 
The benefits of using Mendelian randomization are apparent when the genetic variants 
are functional SNPs and the biological function of the variant is known.  Exploiting the 
assumptions of Mendelian randomizations that genotype and environmental exposures 
are independent and that risk of disease cannot vary with genotype without some 
environmental exposure.  Gustasfon and Burstyn (2011) present this method as a 
practical approach to investigate gene-environment interaction.  
  
Data analysis 
Descriptive analysis was conducted on the characteristics of the study population. 
Logistic regression using SAS version 9.2 was used to estimate adjusted odds ratios 
(aOR) and associated 95% confidence intervals (CI).  For genotypes with more than one 
functional SNP, we created and used dummy variables.  A gene-only analysis (Burstyn et 
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al., 2009) used logistic regression to estimate unadjusted and adjusted odds ratios and 
95% confidence intervals. The only covariates used were forced into the model.  We 
controlled only for designed variables (sex, age, county) and conducted analysis of 
genotypes in the control population to demonstrate Hardy-Weinberg equilibrium in the 
genetic variants.  We used the highest frequency of the homozygous genotype as the 
reference unless the literature indicated a different referent group.  The reference groups 
used for each genotype are shown in Table 3.3.  In addition, analysis of the number of 
deleterious SNPs was done, using logistic regression to estimate crude and adjusted ORs 
(aOR) with 95% confidence intervals. 
 
Results 
Demographics 
Most (90%) of the cases were PV, 2 (7%) were diagnosed with ET, and 1 (>3%) was 
diagnosed with PMF.  A greater proportion of cases were > age 65 (71 yrs. vs. 63 yrs.) and 
more likely to be male (55% vs. 45%) compared to controls but otherwise 
demographically similar (Table 3.5).  The study population was overwhelmingly 
Caucasian (100% of cases and 99% of controls).  None of the cases and few (2%) controls 
were of Jewish ancestry and all participants were born in the US.  Two-thirds of the 
sample was currently married.  More cases than controls were retired (65% versus 47%).  
These findings were similar across all case categories (Tables 3.4 and 3.5). 
 
Susceptible genotypes associated with MPNs 
Table 3.7 shows the main effects of the genetic polymorphisms. The crude estimates were 
very similar to the effect estimates that were adjusted for the design variables.  The 
prevalence of CYP1A2, GSTA1, GSTM3, and NAT2 risk genotype in controls were 7%, 
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18%, 9% and 57%, respectfully, which was in agreement with the reported frequency in 
the literature (see Tables 3.1 and 3.6).   
 
All consenting cases as a group were more likely to have the 46/1 haplotype 
(rs12340895), with an aOR of 5.3 (95% CI: 1.8, 15.7). For analysis restricted to JAK2 
V617F and confirmed PV JAK2 V617F cases, respectfully, the effect estimates increased 
to aOR 10.2 (95% CI: 2.8, 37.9) and 10.8 (95% CI: 3.0, 38.2).  All cases were also more 
likely to have the second 46/1 haplotype (rs12343867) (aOR of 4.3, 95% CI: 1.3, 14.7).  
Again, the effect estimates increased when the analysis was restricted to confirmed JAK2 
V617F cases (aOR 7.9, 95% CI: 1.8, 34.9) or confirmed PV JAK2 V617F cases (aOR=9.6, 
95% CI: 2.3, 39.8). 
 
Having the CYP1A2 genotype increased the odds of MPNs by about four fold (aOR= 3.5, 
95% CI: 1.1, 110).  When case genotypes in the analysis were restricted to confirmed 
JAK2 V617F  cases or PV JAK2 V617F  cases, the effects estimates were similar (aOR 3.9, 
95% CI: 1.1, 13.8 and aOR 3.7, 95% CI: 1.0, 13.3, respectively).   
 
The GSTA1 genotype was associated with a 3 fold increase in effect estimates for all 
MPNs, with an aOR of 2.7 (95% CI: 1.0, 7.0) for confirmed JAK2 V617F cases only. The 
GSTM3 genotype increased the risk of MPNs: the aOR was 4.5 (95% CI: 1.2, 16.0) for all 
confirmed JAK2 V617F cases and was similar across all case categorizations.   
 
The GSTM1 null genotype followed a similar trend of increasing ORs as the case 
categorizations were restricted to confirmed cases only, and JAK2 V617F only, although 
not all of these associations were statistically significant.  We found a doubling of risk, 
aOR of 2.0 (95% CI: 0.9, 4.6), for risk of all MPNs, and an aOR of 2.2 (95% CI: 0.8, 6.0) 
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for all confirmed JAK2 V617F cases. When restricted to only confirmed PV JAK2 V617F 
cases, the aOR was 2.5 (95% CI: 0.9, 6.5). 
 
We found that the adjusted OR of the NAT2 novel tag SNP (rs1495741) slow acetylator 
genotype compared to the wild type was three times greater among cases for all MPNs, 
(aOR=3.0, 95% CI:1.2,7.6).  These associations were about the same magnitude yet 
understandably less precise when the analysis was limited to PV JAK2 V617F confirmed 
and JAK2 V617F case categorizations, (aOR=3.5, 95% CI:1.1,10.8) and (aOR=4.6, 95% 
CI:1.3,16.1) respectively.  We were not able to test for all seven of the other NAT2 SNPs 
shown in the literature to determine slow acetylator phenotype, but we were able to test 
for four of them (shown in Table 3.7) that are consistent with slow phenotype.  All but 
one (96.7%) case harbored at least two of the SNPs; AHR, CYP1E2, GSTM1, Tp53, 
GSTT1, GSTM3, CYP1A2, NAT2, and GSTA1 30/31 compared to 63.3 % in the control 
population (Table 3.8).  
 
Discussion 
After studying the main effects of 14 environmentally sensitive genes, we found that the 
NAT2, CYP1A2, GSTA1, and GSTM3 variants were significantly associated with MPNs in 
this study sample ORs averaging between 3- to 5-fold.  The prevalence of GSTA1, 
GSTM3, and NAT2 slow acetylator genotype in our controls was consistent with the 
reported frequency in the literature. While these results do not confirm a gene-
environment interaction effect for any one specific chemical the findings encourage 
further explanation of the interaction hypothesis with respect to NAT2, GST, and CYP 
gene biological pathway and chemical exposures. These same genes appear to be 
implicated in presence of JAK2 V617F mutation also known to be implicated in aetiology 
of MPNs, especially PV. 
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To detect the potential for existence of gene-environment interaction, the main effects of 
genes were used in this analysis. By design we did not have a measure of exposures of 
interest and therefore could not estimate interactions or stratified effects directly. If we 
assume that genes alone do not cause MPNs, but can only act by modifying the toxicity of 
an environmental exposure, then testing the main effect of genes is an efficient way to 
generate evidence supporting qualitative gene-environment interaction (Burstyn et al., 
2009, Gustafson & Burstyn, 2011).  Based on this reasoning, we are essentially assuming 
there was a qualitative interaction and that there was no gene effect without exposure. A 
main gene effect without exposure is unlikely, based on the biological knowledge about 
the pathway for this disease.  Therefore we have no reason to believe that MPNs (or any 
other disease for that matter) are caused exclusively by the genotypes under 
investigation. 
 
In our study sample, we did not find consistent marginal effects from smoking and diet 
(data not shown) with risk of developing an MPN (Gross-Davis, Chapter 3, 2013).  
However, perhaps paradoxically, our findings suggest that specific genotypes that modify 
the toxicity of these exposures may play a role in MPNs.  Because no relationship was 
seen in our previous work with cigarette smoking and MPNs, even though we had a 
detailed self-reported smoking history for all cases and controls and consequently are 
not concerned about exposure measurement error, despite the diminishing support for 
compounds present in tobacco smoke playing a role in MPNs.  Lack of association of 
smoking with MPNs is consistent with all of the prior literature (Anderson et al., 2012).  
However, the literature on occupational exposures and chemical exposures are extremely 
vague with regard to details of what lifestyle exposure data was actually collected in these 
occupational cohorts as well as case control Kaplan, et.al.,(1986),  Terreros et al. (1997), 
Zoloth et al., (1986), Johnson et al., (2010) and Pasqualetti et al. (1991).   
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Moore et al. (2011) reported an association of bladder cancer with NAT2 slow acetylator 
genotype and smoking intensity.  They found that the NAT2 slow acetylator genotype 
and bladder cancer interaction differed with intensity of tobacco smoking but not ever, 
former or current smokers alone.  Only slow acetylator types who smoked at least 40 
cigarettes a day among ever smoked (aORs=1.82; CI: 95% 1.14, 2.91) and current 
smokers (aORs=3.16; CI: 95% 1.22, 8.19) compared to rapid acetylator showed 
significant risk.  Since aromatic amines are detoxified by NAT2, interaction is 
biologically plausible.  Thus, if carcinogens in tobacco smoke where implicated in MPNs, 
as they are in bladder cancer, then we should have detected the main effect of NAT2 in 
our study.  However, absence of effect of smoking per se suggests that compounds not 
important to toxicity of tobacco smoke but affected by NAT2 should be scrutinized.  The 
body of literature on chemical constituents of tobacco smoke is reported elsewhere and 
was not the focus on this study (Hecht,2003).  Our analysis of smoking consistently 
refuted existence of positive association with very small numbers for cases for who were 
heavy smokers.  
 
Other functional SNPs associated with benzene exposure were also explored in this 
analysis.  These genotypes, CYP2E1, GSTM1, AHR, and GSTT1 also modify the biological 
dose of benzene and showed some interesting results worth reporting that support our 
MPN hypothesis.  We observed a 2-fold increase for CYP2E1 across all case 
categorizations.  A similar doubling of risk was found for individuals with the GSTM1 
null genotype as well.  These genotypes have been consistently reported in the literature 
in the pathway for the transformation of benzene (Lan, 2009).  Looking at gene only 
effect the AHR and GSTT1 genotypes centered on the null with an aOR of 1.0-1.3 (95% 
CI: 0.4-3.8) for AHR and aOR=0.6-0.9 (95%CI: 0.2-2.6).  In addition, the tumor 
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suppressor SNP, TP53 showed upwards of an 8-fold effect with an aOR=4.7-8.0 (95%CI: 
1.2, 33) and has been reported to be involved with benzene hematopoietic stem-cell 
toxicity in mice (Hirabayashi, 2005). 
   
Schnatter et al, updated three nested case–control studies in 2012 (Schnatter et al., 1996, 
Rushton et al., 1997, Glass et al., 2003).  The resulting data was pooled to look at the risk 
of five specific lymphatic–hematopoietic subtypes and benzene exposure.  The LH 
subtypes included were three types of leukemia -acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML), and chronic lymphocytic leukemia (CLL) and – two types of 
myeloid neoplasm - myelodysplastic syndrome (MDS) and myeloproliferative disorders 
(MPD) (now referred to as MPNs).  These nested studies were reviewed in 2010 by 
Miller, et al., and they concluded that these studies were similar in study design, and 
methods used to estimated benzene exposure.  Any differences found were thought to be 
a result of how (cases) were studied and what data could be gathered for them, rather 
than any exposure assessments methods (Miller et al., 2010).  This pooled study 
population consisted of 227 out of the original 370 cases and 1587 controls (Schnatter, et 
al., 2012).  For the 29 cases of MDS, this pooled analysis showed a monotonic-dose 
response relationship with cumulative exposure to benzene (OR= 4.33 95% CI: 1.31, 
14.3) but not for other subtypes including 30 MPD cases (OR=1.79, 95% CI: 0.68, 4.74) 
(Schnatter, et al., 2012).    
 
Limitations  
Our study suffered from a small number of cases.  These MPNs are rare hematological 
malignancies with only a limited number of cases available for recruitment under ideal 
conditions.  There were thirty one cases available for this study.  Using the PCR as a 
source of cases, we did attempt to pull cases into our study that arose from this sample 
92 
 
 
population.  However not optimal, our case categorizations allow us to look across all 
MPN outcomes and not be limited to only the number of incident cases of  PV, ET, or 
PMF.  By expanding the case definition to include individuals with the JAK2 V617F  
mutation, we increased our number of cases as much as possible, a for total of 31 MPN 
cases, which is reasonable with respect to other studies of MPN etiology, PV n=10 
(Quiroga et al, 1981), ET= 133 (Mele et al., 1997, Falcetta et al., 2003) and 
myeloproliferative disorders n=53 (Pasqualetti, 1991, Terreros, 1997) and MPDs n=30 
(Schnatter et al., 2012).    
 
Although MPNs are now reported to the National Cancer Registry, MPNs only became a 
reportable disease in 2001 and in Pennsylvania only hospitals were required to report, so 
there is possible under reporting of these MPNs to the cancer registry. There were also 
changes in the diagnostic criteria by the World Health Organization (WHO) in 2001 and 
again in 2008 (Vakil&Tefferi, 2011).  The 2008 diagnostic criteria included molecular as 
well as histological information for diagnosis, including the JAK2 V617F mutation (Vakil 
& Tefferi, 2011).  Our ability to test for this JAK2 V617F mutation directly helped 
minimize case misclassification. 
 
The University of Pittsburgh reported finding from a 2011 case ascertainment study in 
the tri county area both false reporting and underreporting in the tri-county area for PV 
and ET.  They reported that 44% were true cases, 23% were false cases, 19% could not be 
determined due to a lack of information, and that 87% of the true cases were from the 
original PCR dataset.  The reporting of the incidence and prevalence of these MPNs are 
not necessarily improving, and further monitoring of these diseases was recommended 
in this case ascertainment study (Buchanich & Mertz 2013).  Since these MPNs often do 
not require hospitalization, reporting should be required and enforced at the 
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hematologist’s office directly as this is not currently the case.  The CDC has an ongoing 
effort to improve reporting of MPNs to cancer registries all over the country.  
Our randomized selection of controls for the tri-county area attempted to minimize any 
concern over selection bias.  Our response rate from MPN cases was small. We had a 1 to 
9 ratio of cases and controls with no significant demographic differences observed 
between subjects who consented to genotyping and those who did not. 
 
The latency period between possible exposures related to the development of an MPN is 
currently unknown, which complicates identification of potential risk factors when the 
timeframe of effective exposure is not clearly defined.  However given this and other 
measurement challenges for exposures, assuming universal exposures and using a gene 
only analysis to detect gene-environmental interaction can be more reliable than 
assigning exposure groups to individuals.  
Our study is vulnerable to false positive discovery do to “multiple comparisons” (Hunter 
et al., 2005).  However, unlike GWAS studies, we started with 648 genes of interest and 
only examined 14 genes that met our a priori “plausible candidate”.  Our selective 
genotypes were functional SNPs, and did directly affect the enzymatic activity of the 
gene, influences biological pathways that affect metabolic activation/detoxification 
processes of metabolism for mutagenic chemicals.  We did not correct for elevated type 
II error associations in applying a correction factor in the analysis. 
   
Strengths 
This study capitalized on the initial blood sample needed for JAK2 V617F mutation 
molecular testing to include additional genotyping for 14 genes using our biological 
pathway candidate gene approach.  This study was not at risk from misclassification of 
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genotypes in our subjects as is often the case when testing for gene-environmental 
interaction directly using cross product of genetic marker and estimate of exposure in a 
statistical model or in stratified analysis (Hunter et al., 2005).  As the misclassification 
error for DNA extraction are dependent on the genotype call rates, misclassification of 
genotypes was not a concern in this study because our call rate was high (>95%), and we 
only had one SNP that consistently did not perform well (Smith et al., 2011, Deitz et al., 
2004).  
 
Mendelian randomization is a strength here because we went to great lengths to identify 
functional SNPs that produced an effect that would modify the exposure of interest. 
While the exposure data is important, testing for known genotypes that are susceptible to 
environmental exposures allowed us to use the genotype as an instrument or proxy for 
the exposure.  Another benefit of using the concept of Mendelian randomization 
minimizes the potential bias in exposure measurement (McKeigue et al., 2010; Lawlor, 
2008; Verduijn et al., 2010).    
 
Our analysis was done working under two main assumptions.  First, that genotype and 
environmental exposures in this study population are independent. And second, that 
disease risk will not vary with genotype for subjects without environmental exposure.  
From this, we exploit the most generic form of Mendelian randomization that individuals 
receive a random allocation of alleles from their parents.  Gustasfon and Burstyn (2011) 
present this method and concluded that when both of these assumptions are met, using 
data on genotype and disease jointly, with only knowledge of the prevalence of exposure 
without individual level data on exposure can be a practical approach to investigate 
gene-environment interaction.  Through this gene-environment interaction approach, a 
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signal of increased risk will only result, if there is truly gene environment interaction 
(Smith et al., 2011).  
 
None of the studied proxies of PAH exposure revealed associations, including smoking 
(Gross-Davis, Chapter 3, 2013).  In addition, we did not see an association with the 
CYP1A1 SNP that would reveal a gene-environment interaction with PAHs.  Our data 
does not support PAHs as a suspected exposure associated with development of an MPN. 
 
In this application we use known biological pathways and candidate gene 
polymorphisms such as the GSTM3, CYP1A2 and NAT2 gene that modify environmental 
exposures due to increased ability to metabolize or decreased ability to detoxify the 
chemical.  Since this if the first study to explore genetic polymorphisms and MPNs, this 
can help target future studies where only ecological environmental exposure data is 
available, with disease and genotype data.   
 
Exposures other than smoking that are important to the pathways influenced by NAT2, 
GST, CYPs are of interest and for future investigations into the etiology of MPNs.  
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Table 3.1 Genes associated with a mutagenic chemical and Minor Allele Frequency in the study population 
  
 
Genes 
 Functions (GVS) 
Minor Allele 
Frequency (%) Chemical Exposure 
AHR This gene encodes a ligand-activated transcription factor involved in the 
regulation of biological responses to planar aromatic hydrocarbons. 
10 1 2,3,7,8-TCDD, benzo[a]pyrene 2,4'-
DDT, Benzene 
CYP1A1 
 
CYP1A1 is also known as AHH (aryl hydrocarbon hydroxylase). It is involved in 
the metabolic activation of aromatic hydrocarbons (polycyclic aromatic 
hydrocarbons, PAH). 
10 1 
 
2,3,7,8-TCDD, sodium arsenite 
(NaAsO2), 2,4'-DDT, Aroclor-
1260(weak), benzo[a]pyrene, 
benzo[k]fluoranthene , cadmium 
chloride 
CYP1A2 This protein encoded by this gene localizes to the endoplasmic reticulum and its 
expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of 
which are found in cigarette smoke. The enzyme's endogenous substrate is 
unknown; however, it is able to metabolize some PAHs to carcinogenic 
intermediates. Other xenobiotic substrates for this enzyme include caffeine, 
aflatoxin B1, and acetaminophen. 
24 2,3,7,8-TCDD, benzo[a]pyrene 
CYP1B1 metabolizes procarcinogens such as polycyclic aromatic hydrocarbons and 17beta-
estradiol. 
 
441 2,3,7,8-TCDD, benzo[a]pyrene 
CYP2B6 This enzyme is known to metabolize some xenobiotics, such as the anti-cancer 
drugs cyclophosphamide and ifosphamide. 
21 1 2,4'-DDT 
CYP2E1 Inactivates a number of  drugs and  Xenobiotics and also bioactivates many 
xenobiotic substrates to their hepatotoxic or carcinogenic forms 
6 Benzene, methylene chloride, Styrene, 
1,1,1-trichloroethane, Trichloroethylene 
GSTM1 This GST family member is a polymorphic gene encoding active, functionally 
different GSTP1 variant proteins that are thought to function in xenobiotic 
metabolism and play a role in susceptibility to cancer, and other diseases. 
49 1 Styrene, Benzene 
GSTM3 This GST family member is a polymorphic gene encoding active, functionally 
different GSTP1 variant proteins that are thought to function in xenobiotic 
metabolism and play a role in susceptibility to cancer, and other diseases. 
32 1  
GSTT1 This GST family member is a polymorphic gene encoding active, functionally 
different GSTP1 variant proteins that are thought to function in xenobiotic 
metabolism and play a role in susceptibility to cancer, and other diseases. 
20 1 benzo[a]pyrene ,methylene chloride, 
Styrene, Benzene 
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Genes 
 Functions (GVS) 
Minor Allele 
Frequency (%) Chemical Exposure 
NAT2 Polymorphisms in this gene are responsible for the N-acetylation polymorphism 
in which human populations segregate into rapid, intermediate, and slow 
acetylator phenotypes. Polymorphisms in this gene are also associated with 
higher incidences of cancer and drug toxicity. 
- benzo[a]pyrene 
NQO1 Mutations in this gene have been associated with tardive dyskinesia (TD), an 
increased risk of hematotoxicity after exposure to benzene, and susceptibility to 
various forms of cancer. 
221 2,3,7,8-TCDD, benzo[a]pyrene 
 
Table 3.1 Genes associated with a mutagenic chemical  and Minor Allele Frequency in the study population 
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Table 3.2 Case categorizations 
Case definition1  Cases JAK2 V617F mutation cases controls 
 Total interviewed Cases with 
genotype data 
Total interviewed cases with 
genotype data 
Total interviewed Controls with 
genotype data 
All cases  55 31 25 22 473 292 
Confirmed cases  41 27 25 22 473  
Confirmed PV cases  33 24 21 20 473  
Confirmed ET cases  7  3  473  
Confirmed PMF 
cases  
1  1  473  
1. Cases confirmed by one of two expert panels, Pa Department of Health  or University of Pittsburgh by reviewing medical records. 
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Table 3.3 Single Nucleotide polymorphisms (SNPs)  of select genes with reference groups (cont’d) 
Gene SNP Reference group(s) 
AHR rs2066853 GG 
ARNT rs12410394 GG or AG 
CYP17A1  rs743572 AA 
CYP19A1  rs700519 GG 
CYP1A1 
rs1048943 TT 
rs4646903 TT 
CYP1A2 rs762551 
AC or CC 
AC or AA 
AA 
CYP1B1  rs1056836 GG 
CYP2B6  rs3745274 AA 
CYP2C9 
rs1057910 AA 
rs1799853 GG 
CYP2E1 
rs2031920 GG 
rs2070673 TT 
rs6413432 AA 
CYP3A4 rs2740574 AA 
CYP3A5 rs776746 GG 
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Table 3.3 Single Nucleotide polymorphisms (SNPs)  of select genes with reference groups (cont’d) 
Gene SNP Reference group(s) 
CYP4B1 rs2297810 GG 
GSTA1 rs3957356 
AG or GG 
AG or AA 
AA 
GSTM1  >0 
GSTM3 
rs7483 GG 
rs1332018 AA 
rs1799735 GG 
GSTP1 
rs1695 AA 
rs1138272 GG 
GSTT1  >0 
GSTZ1 
rs7972 GG 
rs1046428 GG 
JAK2 V617F 
rs12340895 GG 
rs12343867 AA 
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Table 3.3 Single Nucleotide polymorphisms (SNPs)  of select genes with reference groups (cont’d) 
Gene SNP Reference group(s) 
NAT2 
rs1041983 
AG or GG 
AG or AA 
AA 
rs1495741 
AG  or GG 
AG or AA 
AA 
rs1799929 
AG or GG 
AG or AA 
AA 
rs1799930 
AG or GG 
AG or AA 
AA 
rs1801279 
AG or GG 
AG or AA 
AA 
rs1801280 
AG or GG 
AG or AA 
AA 
NQO1 
rs1131341 GG 
rs1800566 GG 
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Table 3.4  Study participants demographics in gene environment interaction analysis 1  (cont’d) 
 
 
All cases 2 and % 
frequencies 
n=31 
Confirmed cases 2 
and % frequencies 
n=27 
Confirmed JAK2 
V617F cases 2 and  % 
frequencies 
n=22 
Confirmed PV 
cases 2 and  % 
frequencies 
n=24 
Controls and  % 
frequencies 
n=292 
County      
Carbon 5  (16%) 4  (15%) 4  (18%) 4  (17%) 31  (11%) 
Luzerne 15  (48%) 12  (44%) 10  (45%) 10  (42%) 177  (61%) 
Schuylkill 11  (35%) 11  (41%) 8  (36%) 10  (42%) 84  (29%) 
Age      
42-64 8  (26%) 7  (26%) 6  (27%) 5  (21%) 167  (57%) 
65+ 23  (74%) 20  (74%) 16  (73%) 19  (79%) 125  (43%) 
Sex      
Male 17  (55%) 15  (56%) 12  (55%) 13  (54%) 118  (40%) 
Female 14  (45%) 12  (44%) 10  (45%) 11  (46%) 174  (60%) 
Race/ethnicity      
Non-Hisp. White 31  (100%) 27  (100%) 22  (100%) 24  (100%) 290  (99%) 
Latino, Hispanic 0 0 0 0 2  (1%) 
Non-Hisp. Black 0 0 0 0 0 
Non-Hisp. Native American, Alaskan native 0 0 0 0 0 
Non-Hisp. Asian or Pacific Islander 0 0 0 0 0 
Non-Hisp. Other 0 0 0 0 0 
Non-Hisp., multiple race 0 0 0 0 0 
Country of origin      
USA 31  (100%) 27  (100%) 22  (100%) 24  (100%) 292  (100%) 
Other 0 0 0 0 0 
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Table 3.4  Study participants demographics in gene environment interaction analysis 1  (cont’d) 
 
 
All cases 2 and % 
frequencies 
n=31 
Confirmed cases 2 
and % frequencies 
n=27 
Confirmed JAK2 
V617F cases 2 and  % 
frequencies 
n=22 
Confirmed PV 
cases 2 and  % 
frequencies 
n=24 
Controls and  % 
frequencies 
n=292 
State born in      
AK 0 0 0 0 1  (0%) 
CA 1  (2%) 1  (2%) 0 0 1  (1%) 
CT 1  (2%) 1  (2%) 1  (4%) 1  (3%) 0 
FL 0 0 0 0 0 
IL 0 0 0 0 1  (0%) 
MA 1  (2%) 1  (2%) 1  (4%) 1  (3%) 0 
MN 0 0 0 0 2 ( 0%) 
MS 0 0 0 0 1  (0%) 
NC 0 0 0 0 0 
NH 0 0 0 0 1  (0%) 
NJ 2  (4%) 2  (5%) 2  (8%) 2  (6%) 8  (3%) 
NM 0 0 0 0 1  (0%) 
NY 0 0 0 0 10  (3%) 
OH 0 0 0 0 1  (0%) 
OK 1 (2%) 0 0 0 0 
PA 26  (87%) 22 (85%) 17  (80%) 19 ( 85%) 262  (89%) 
SC 0 0 0 0 0 
SD 0 0 0 0 1  (0%) 
TN 0 0 0 0 0 
TX 0 0 0 0 1  (0%) 
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Table 3.4  Study participants demographics in gene environment interaction analysis 1  (cont’d) 
 
 
All cases 2 and % 
frequencies 
n=31 
Confirmed cases 2 
and % frequencies 
n=27 
Confirmed JAK2 
V617F cases 2 and  % 
frequencies 
n=22 
Confirmed PV 
cases 2 and  % 
frequencies 
n=24 
Controls and  % 
frequencies 
n=292 
VA 0 0 0 0 1  (0%) 
WV 1  (2%) 1  (2%) 1  (4%) 1  (3%) 0 
non-US 0 0 0 0 0 
Jewish ancestry      
Yes 0 0 0 0 6  (2%) 
No 31  (100%) 27  (100%) 22  (100%) 24  (100%) 282 (98%) 
Don't know 0 0 0 0 3 
Missing 0 0 0 0 1 
Marital status      
Married 22  (71%) 18  (67%) 15  (68%) 15  (63%) 183  (63%) 
Widowed 7  (23%) 7  (26%) 5  (23%) 7  (29%) 47  (16%) 
Currently single 2  (6%) 2  (7%) 2  (9%) 2  (8%) 62  (21%) 
Education      
Less than high school 2  (6%) 2  (7%) 2  (9%) 2  (8%) 5  (2%) 
High school / GED 16  (52%) 13  (48%) 11  (50%) 13  (54%) 106  (36%) 
Some college 7  (23%) 7  (26%) 5  (23%) 5  (21%) 104  (36%) 
Bachelors degree 3  (10%) 2  (7%) 2  (9%) 2  (8%) 36  (12%) 
More than bachelors 3  (10%) 3  (11%) 2  ( 9%) 2  (8%) 41  (14%) 
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Table 3.4  Study participants demographics in gene environment interaction analysis 1  (cont’d) 
 
 
All cases 2 and % 
frequencies 
n=31 
Confirmed cases 2 
and % frequencies 
n=27 
Confirmed JAK2 
V617F cases 2 and  % 
frequencies 
n=22 
Confirmed PV 
cases 2 and  % 
frequencies 
n=24 
Controls and  % 
frequencies 
n=292 
Household income      
Less than $20,000 3  (11%) 3  (12%) 3  (15%) 3  (14%) 38  (14%) 
$20,000 - $35,000 10  (36%) 9  (36%) 7  (35%) 9  (41%) 67  (24%) 
$35,000 - $50,000 3  (11%) 2  (8%) 2  (10%) 2  (9%) 54  (20%) 
$50,000 - $75,000 6  (21%) 6  (24%) 4  (20%) 6  (27%) 67  (24%) 
More than $75,000 6  (21%) 5  (20%) 4  (20%) 2  (9%) 48  (18%) 
Don't know 1 1 1 1 4 
Refused 2 1 1 1 14 
Current employment      
Employed for wages 9  (29%) 7  (26%) 6  (27%) 6  (25%) 101  (35%) 
Self-employed 1  (3%) 1  (4%) 1  (5%) 1  (4%) 9  (3%) 
Out of work for more than a year 1  (3%) 1  (4%) 1  (5%) 0 11  (4%) 
Out of work for less than a year 0 0 0 0 6  (2%) 
Homemaker 0 0 0 0 9  (3%) 
Student 0 0 0 0 0 
Retired 20  (65%) 18  (67%) 14  (64%) 17  (71%) 137  (47%) 
Unable to work 0 0 0 0 19  (7%) 
1. Self-reported socio economic factors, number and % 
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F  mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only
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Table 3.5 Study demographic in gene environment interaction logistic regression models 1 (cont’d) 
 
 
All cases 
OR 2 
n=31 
All cases 
aOR 3 
n=31 
Confirmed 
cases OR 2 
n=27 
Confirmed 
cases aOR 3 
n=27 
Confirmed 
JAK2 V617F 
OR 2 
n=22 
Confirmed 
JAK2 V617F 
aOR 3 
n=22 
Confirmed 
PV OR 2 
n=24 
Confirmed 
PV aOR 3 
n=24 
Marital status                 
Married Referent Referent Referent Referent Referent Referent Referent Referent 
Widowed 1.5 (0.7, 3.0) 1.1 (0.5, 2.2) 1.6 (0.8, 3.3) 1.1 (0.5, 2.6) 1.7 (0.7, 4.3) 1.1 (0.4, 3.0) 1.7 (0.7, 3.8) 1.2 (0.5, 3.1) 
Currently single 0.7 (0.3, 1.5) 0.7 (0.3, 1.6) 0.3 (0.1, 1.1) 0.3 (0.1, 1.1) 0.4 (0.1, 1.6) 0.4 (0.1, 1.7) 0.4 (0.1, 1.4) 0.4 (0.1, 1.6) 
Education         
Less than high school 4.2 (1.1, 15.7) 2.8 (0.7, 10.9) 3.0 (0.6, 13.6) 1.9 (0.4, 9.3) 3.9 (0.6, 26.3) 2.4 (0.3, 17.4) 3.0 (0.5, 18.1) 1.8 (0.3, 12.1) 
High school / GED 1.5 (0.6, 3.7) 1.2 (0.5, 3.0) 1.3 (0.5, 3.4) 1.0 (0.4, 2.7) 1.6 (0.4, 5.7) 1.2 (0.3, 4.3) 1.8 (0.6, 5.5) 1.4 (0.4, 4.4) 
Some college 0.4 (0.1, 1.2) 0.4 (0.1, 1.1) 0.5 (0.2, 1.5) 0.4 (0.1, 1.3) 0.7 (0.2, 2.9) 0.6 (0.1, 2.5) 0.5 (0.1, 2.0) 0.4 (0.1, 1.7) 
Bachelors degree 1.0 (0.3, 3.0) 0.9 (0.3, 2.9) 0.6 (0.1, 2.3) 0.6 (0.1, 2.4) 0.7 (0.1, 4.6) 0.7 (0.1, 4.7) 0.6 (0.1, 3.2) 0.6 (0.1, 3.3) 
More than bachelors Referent Referent Referent Referent Referent Referent Referent Referent 
Household income         
Less than $20,000 1.0 (0.4, 2.7) 0.5 (0.2, 1.4) 0.8 (0.2, 2.5) 0.3 (0.1, 1.3) 0.6 (0.1, 2.6) 0.2 (0.1, 1.2) 2.1 (0.5, 9.0) 1.0 (0.2, 4.7) 
$20,000 - $35,000 1.1 (0.5, 2.6) 0.6 (0.2, 1.5) 1.0 (0.4, 2.6) 0.5 (0.2, 1.5) 0.9 (0.3, 2.8) 0.4 (0.1, 1.4) 2.6 (0.7, 9.8) 1.3 (0.3, 5.5) 
$35,000 - $50,000 0.7 (0.3, 1.9) 0.4 (0.2, 1.2) 0.6 (0.2, 1.8) 0.3 (0.1, 1.1) 0.3 (0.1, 1.5) 0.1 (0.0, 0.8) 1.2 (0.3, 5.6) 0.7 (0.1, 3.5) 
$50,000 - $75,000 0.9 (0.3, 2.2) 0.7 (0.3, 1.8) 1.0 (0.4, 2.6) 0.8 (0.3, 2.2) 0.6 (0.2, 2.1) 0.4 (0.1, 1.7) 2.3 (0.6, 8.9) 1.7 (0.4, 7.0) 
More than $75,000 Referent Referent Referent Referent Referent Referent Referent Referent 
1. Self-reported socio economic factors  
2 All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F  mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
3. Adjusted (for age, sex and county) Odds Ratios (95% confidence intervals) 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
AHR 
rs2066853 
     
AG 6  (19%) 5  (19%) 5  (23%) 5  (21%) 59  (20%) 
AA 0 0 0 0 1  (0 %) 
GG 25  (81%) 22  (81%) 17  (77%) 19  (79%) 230  (79%) 
Missing 0 0 0 0 2 
ARNT 
rs12410394 
     
GG 8  (26%) 7  (26%) 7  (32%) 6  (25%) 122  (42%) 
AA 2  (6%) 1  (4%) 0 1  (4%) 33  (11%) 
AG 21  (68%) 19  (70%) 15  (68%) 17  (71%) 135  (47%) 
Missing 0 0 0 0 2 
ARNT 
rs12410394 
     
AA 2  (6%) 1  (4%) 0 1  (4%) 33  (11%) 
AG 21  (68%) 19  (70%) 15  (68%) 17  (71%) 135  (47%) 
GG 8  (26%) 7  (26%) 7  (32%) 6  (25%) 122  (42%) 
Missing 0 0 0 0 2 
CYP17A1 
rs743572 
     
AG 13  (42%) 12  (44%) 11  (50%) 11  (46%) 140  (48%) 
GG 5  (16%) 4  (15%) 3  (14%) 4  (17%) 44  (15%) 
AA 13  (42%) 11  (41%) 8  (36%) 9  (38%) 106  (37%) 
Missing 0 0 0 0 2 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
CYP19A1 
rs700519 
     
AG 2  (6%) 2  (7%) 1  (5%) 1  (4%) 21  (7%) 
GG 29  (94%) 25  (93%) 21  (95%) 23  (96%) 267  (93%) 
Missing 0 0 0 0 4 
CYP1A2 
rs762551 
     
AA 12  (39%) 11  (41%) 9  (41%) 10  (42%) 145  (50%) 
AC 14  (45%) 11  (41%) 9  (41%) 10  (42%) 128  (44%) 
CC 5  (16%) 5  (19%) 4  (18%) 4  (17%) 19  (7%) 
CYP1A2 
rs762551 
     
CC 5  (16%) 5  (19%) 4  (18%) 4  (17%) 19  (7%) 
AC 14  (45%) 11  (41%) 9  (41%) 10  (42%) 128  (44%) 
AA 12  (39%) 11  (41%) 9  (41%) 10  (42%) 145  (50%) 
CYP1A2 
rs762551 
     
AC or CC 19  (61%) 16  (59%) 13  (59%) 14  (58%) 147  (50%) 
AA 12  (39%) 11  (41%) 9  (41%) 10  (42%) 145  (50%) 
CYP1B1 
rs1056836 
     
CC 10  (32%) 9  (33%) 7  (32%) 7  (29%) 52  (18%) 
CG 12  (39%) 9  (33%) 6  (27%) 8  (33%) 148  (51%) 
GG 9  (29%) 9  (33%) 9  (41%) 9  (38%) 91  (31%) 
Missing 0 0 0 0 1 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
CYP2B6 
rs3745274 
     
AC 21  (68%) 17  (63%) 14  (64%) 16  (67%) 164  (56%) 
AA 10  (32%) 10  (37%) 8  (36%) 8  (33%) 128  (44%) 
CYP2C9 
rs1057910 
     
AC 5  (16%) 4  (15%) 3  (14%) 4  (17%) 32  (11%) 
AA 26  (84%) 23  (85%) 19  (86%) 20  (83%) 257  (89%) 
Missing 0 0 0 0 3 
rs1799853      
AG 6  (19%) 6  (22%) 5  (23%) 4  (17%) 64  (22%) 
GG 25  (81%) 21  (78%) 17  (77%) 20  (83%) 225  (78%) 
Missing 0 0 0 0 3 
CYP2E1 
rs2031920 
     
AG 2  (6%) 2  (7%) 2  (9%) 2  (8%) 12  (4%) 
GG 29  (94%) 25  (93%) 20  (91%) 22  (92%) 275  (96%) 
Missing 0 0 0 0 5 
rs2070673      
AT 6  (19%) 5  (19%) 4  (18%) 4  (17%) 74  (26%) 
AA 0 0 0 0 9  (3%) 
TT 25  (81%) 22  (81%) 18  (82%) 20  (83%) 206  (71%) 
Missing 0 0 0 0 3 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
rs6413432      
AT 7  (23%) 6  (22%) 6  (27%) 6  (25%) 48  (17%) 
TT 0 0 0 0 2  (1%) 
AA 24  (77%) 21  (78%) 16  (73%) 18  (75%) 240  (83%) 
Missing 0 0 0 0 2 
CYP3A4 
rs2740574 
     
AG 0 0 0 0 14  (5%) 
AA 30  (100%) 26  (100%) 22  (100%) 23  (100%) 277  (95%) 
Missing 1 1 0 1 1 
CYP3A5 
rs776746 
     
AA 1  (3%) 1  (4%) 1  (5%) 1  (4%) 1  (0%) 
AG 3  (10%) 3  (11%) 2  (9%) 3  (13%) 38  (13%) 
GG 27  (87%) 23  (85%) 19  (86%) 20  (83%) 252  (87%) 
Missing 0 0 0 0 1 
CYP4B1 
rs2297810 
     
AG 10  (32%) 9  (33%) 7  (32%) 9  (38%) 74  (26%) 
AA 0 0 0 0 3  (1%) 
GG 21  (68%) 18  (67%) 15  (68%) 15  (63%) 212  (73%) 
Missing 0 0 0 0 3 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
GSTA1 
rs3957356 
     
AA 10  (32%) 9  (33%) 9  (41%) 9  (38%) 53  (18%) 
AG 14  (45%) 11  (41%) 7  (32%) 9  (38%) 148  (51%) 
GG 7  (23%) 7  26% 6  (27% 6  (25%) 91  (31%) 
GSTA1 
rs3957356 
     
GG 7  (23%) 7  (26%) 6  (27%) 6  (25%) 91  (31%) 
AG 14  (45%) 11  (41%) 7  (32%) 9  (38%) 148  (51%) 
AA 10  (32%) 9  (33%) 9  (41%) 9  (38%) 53  (18%) 
GSTA1      
rs3957356      
AG or GG 21  (68%) 18  (67%) 13  (59%) 15  (63%) 239  (82%) 
AA 10  (32%) 9  (33%) 9  (41%) 9  (38%) 53  (18%) 
GSTM1      
Undetermined 0 0 0 0 1  (0%) 
0 22  (71%) 20  (74%) 16  (73%) 18  (75%) 155  (53%) 
1 9  (29%) 7  (26%) 6  (27%) 6  (25%) 116  (40%) 
2 0 0 0 0 20  (7%) 
GSTM3      
rs7483      
AA 6  (19%) 6  (22%) 5  (23%) 5  (21%) 26  (9%) 
AG 12  (39%) 11  (41%) 10  (45%) 9  (38%) 124  (43%) 
GG 13  (42%) 10  (37%) 7  (32%) 10  (42%) 137  (48%) 
Missing 0 0 0 0 5 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
rs1332018      
CC 8  (26%) 7  (26%) 5  (23%) 7  (29%) 45  (16%) 
AC 9  (29%) 7  (26%) 6  (27%) 7  (29%) 156  (54%) 
AA 14  (45%) 13  (48%) 11  (50%) 10  (42%) 89  (31%) 
Missing 0 0 0 0 2 
rs1799735      
TG 5  (16%) 4  (15%) 3  (14%) 4  (17%) 81  (28%) 
TT 0 0 0 0 8  (3%) 
GG 26  (84%) 23  (85%) 19  (86%) 20  (83%) 200  (69%) 
Missing 0 0 0 0 3 
 
GSTM3 
     
rs7483      
AA 6  (19%) 6  (22%) 5  (23%) 5  (21%) 26  (9%) 
AG 12  (39%) 11  (41%) 10  (45%) 9  (38%) 124  (43%) 
GG 13  (42%) 10  (37%) 7  (32%) 10  (42%) 137  (48%) 
Missing 0 0 0 0 5 
GSTP1      
rs1695      
AG 15  (48%) 13  (48%) 10  (45%) 11  (46%) 135  (47%) 
GG 0 0 0 0 33  (11%) 
AA 16  (52%) 14  (52%) 12  (55%) 13  (54%) 122  (42%) 
Missing 0 0 0 0 2 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
rs1138272      
AA 4  (13%) 4  (15%) 3  (14%) 3  (13% (35  12%) 
AG 1  (3%) 1  (4%) 0 1  (4% ) 30  (10%) 
GG 26  (84%) 22  (81%) 19  (86%) 20  (83%) 227  78% 
GSTT1      
3 0 0 0 0 1  (0%) 
Undetermined 0 0 0 0 1  (0%) 
0 5  (16%) 4  (15%) 2  (9%) 3  (13%) 46  (16%) 
1 25  (81%) 22  (81%) 20  (91%) 21  (88%) 197  (67%) 
2 1  (3%) 1  (4%) 0 0 47  (16%) 
 GSTZ1      
rs7972      
AA 1  (3%) 1  (4%) 1  (5%) 1  (4%) 6  (2%) 
AG 5  (16%) 5  (19%) 5  (23%) 5  (21%) 44  (15%) 
GG 25  (81%) 21  (78%) 16  (73%) 18  (75%) 242  (83%) 
rs1046428      
AG 8  (27%) 6  (23%) 4  (19%) 5  (22%) 98  (34%) 
AA 0 0 0 0 9  (3%) 
GG 22  (73%) 20  (77%) 17  (81%) 18  (78%) 184  (63%) 
Missing 1 1 1 1 1 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
NAT2      
rs1041983      
AA 2  (6%) 2  (7%) 2  (9%) 1  (4%) 35  (12%) 
AG 15  (48%) 12  (44%) 8  (36%) 11  (46%) 116  (40%) 
GG 14  (45%) 13  (48%) 12  (55%) 12  (50%) 140  (48% ) 
Missing 0 0 0 0 1 
rs1495741      
AA 25  (81%) 22  (81%) 19  (86%) 20  (83%) 164  (57%) 
AG 5  (16%) 4  (15%) 2  (9%) 3  (13%) 104  (36%) 
GG 1  (3%) 1  (4%) 1  (5%) 1  (4%) 22  (8%) 
Missing 0 0 0 0 2 
rs1799929      
AA 11  (35%) 10  (37%) 10  (45%) 9  (38%) 56  (19%) 
AG 10  (32%) 8  (30%) 5  (23%) 8  (33%) 124  (42%) 
GG 10  (32%) 9  (33%) 7  (32%) 7  (29%) 112  (38%) 
rs1799930      
AA 1  (3%) 1  (4%) 1  (5%) 0 29  (10%) 
AG 14  (47%) 12  (44%) 8  (36%) 11  (46%) 114  (39%) 
GG 15  (50%) 14  (52%) 13  (59%) 13  (54%) 148  (51%) 
Missing 1 0 0 0 1 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
rs1801279      
AA      
AG      
GG 31  (100%) 27  (100%) 22  (100%) 24  (100%) 291  (100%) 
Missing 0 0 0 0 1 
rs1801280      
AA 8  (26%) 7  (26%) 5  (23%) 5  (21%) 106  (36%) 
AG 11  (35%) 9  (33%) 6  (27%) 9  (38%) 127  (44%) 
GG 12  (39%) 11  (41%) 11  (50%) 10  (42%) 58  (20%) 
Missing 0 0 0 0 1 
NAT2 
rs1041983 
     
GG 14  (45%) 13  (48%) 12  (55%) 12  (50%) 140  (48%) 
AG 15  (48%) 12  (44%) 8  (36%) 11  (46%) 116  (40%) 
AA 2  (6%) 2  (7%) 2  (9%) 1  (4%) 35  (12%) 
Missing 0 0 0 0 1 
rs1495741      
GG 1  (3%) 1  (4%) 1  (5%) 1  (4%) 22  (8%) 
AG 5  (16%) 4  (15%) 2  (9%) 3  (13%) 104  (36%) 
AA 25  (81%) 22  (81%) 19  (86%) 20  (83%) 164  (57%) 
Missing 0 0 0 0 2 
rs1799929      
GG 10  (32%) 9  (33%) 7  (32%) 7  (29%) 112  (38%) 
AG 10  (32%) 8  (30%) 5  (23%) 8  (33%) 124  (42%) 
AA 11  (35%) 10  (37%) 10  (45%) 9  (38%) 56  (19%)  121
  
Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
rs1799930      
GG 15  (50%) 14  (52%) 13  (59%) 13  (54%) 148  (51%) 
AG 14  (47%) 12  (44%) 8  (36%) 11  (46%) 114  (39%) 
AA 1  (3%) 1  (4%) 1  (5%) 0 29  (10%) 
Missing 1 0 0 0 1 
rs1801279      
GG 31  (100%) 27  (100%) 22  (100%) 24  (100%) 291  (100%) 
AG      
AA      
Missing 0 0 0 0 1 
rs1801280      
GG 12  (39%) 11  (41%) 11  (50%) 10  (42%) 58  (20%) 
AG 11  (35%) 9  (33%) 6  (27%) 9  (38%) 127  (44%) 
AA 8  (26%) 7  (26%) 5  (23%) 5  (21%) 106  (36%) 
Missing 0 0 0 0 1 
NAT2 
rs1041983 
     
AG or GG 29  (94%) 25  (93%) 20  (91%) 23  (96%) 256  (88%) 
AA 2  (6%) 2  (7%) 2  (9%) 1  (4%) 35  (12%) 
Missing 0 0 0 0 1 
rs1495741      
AG or GG 6  (19%) 5  (19%) 3  (14%) 4  (17%) 126  (43%) 
AA 25  (81%) 22  (81%) 19  (86%) 20  (83%) 164  (57%) 
Missing 0 0 0 0 2  122
  
Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
rs1799929      
AG or GG 20  (65%) 17  (63%) 12  (55%) 15  (63%) 236  (81%) 
AA 11  (35%) 10  (37%) 10  (45%) 9  (38%) 56  (19%) 
rs1799930      
AG or GG 29  (97%) 26  (96%) 21  (95%) 24  (100%) 262  (90%) 
AA 1  3% 1  (4%) 1  (5%) 0 29  (10%) 
Missing 1 0 0 0 1 
rs1801279      
AG or GG 31  (100%) 27  (100%) 22  (100%) 24  (100%) 291  (100%) 
AA      
Missing 0 0 0 0 1 
rs1801280      
AG or GG 23  (74%) 20  (74%) 17  (77%) 19  (79%) 185  (64%) 
AA 8  (26%) 7  (26%) 5  (23%) 5  (21%) 106  (36%) 
Missing 0 0 0 0 1 
Gene = NQO1      
rs1131341      
AG 3  (10%) 3  (11%) 3  (14%) 2  (8%) 17  (6%) 
GG 28  (90%) 24  (89%) 19  (86%) 22  (92%) 275  (94%) 
rs1800566      
AA 1  (3%) 1  (4%) 0 1  (4%) 12  (4%) 
AG 13  (42%) 12  (44%) 10  (45%) 10  (42%) 87  (30%) 
GG 17  (55%) 14  (52%) 12  (55%) 13  (54%) 193  (66%) 
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Table 3.6. Select genotype frequencies in the study population for cases and controls  (cont’d) 
 
Susceptible genotype 
SNP and rs number1 
All cases 2 
% frequencies 
n=31 
Confirmed 
cases 2 
% frequencies 
n=27 
Confirmed 
JAK2 V617F cases 2 
% frequencies 
n=22 
Confirmed 
PV cases 2 
% frequencies 
n=24 
Controls 3 
% frequencies 
n=292 
CYP1A1 
rs1048943 
     
CT 3  (10%) 3  (12%) 3  (14%) 2  (9%) 18  (6%) 
TT 27  (90%) 23  (88%) 19  (86%) 21  (91%) 269  (94%) 
Missing 1 1 0 1 5 
rs4646903      
CC 1  (3%) 1  (4%) 0 1  (4%) 3  (1%) 
CT 8  (27%) 6  (23%) 5  (24%) 5  (22%) 46  (16%) 
TT 21  (70%) 19  (73%) 16  (76%) 17  (74%) 239  (83%) 
Missing 1 1 1 1 4 
Tp53 
rs1042522 
GG 
 
 
- 
 
 
4  (15%) 
 
 
 
4 (18%) 
 
 
 
 
4  (17%) 
 
 
12 (4%) 
 
CG - 10 (37%) 9 (41%) 9 (38%) 117 (40%) 
CC - 13 (48%) 9 (41%) 11 (46%) 160 (55%) 
      
      
      
 
1. Susceptible genes to mutagenic chemicals and Single Nucleotide Polymorphisms (SNPs) with rs number 
2. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F  mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
3. Controls who also consented to provide a blood sample for genotyping 
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Table 3.7  Select environmentally sensitive genotype logistic regression models  (cont’d) 
 
 All cases 
OR 1 
n=31 
All cases aOR 2 
n=31 
Confirmed 
cases OR 1 
n=27 
Confirmed 
cases aOR 2 
n=27 
Confirmed 
JAK2 
V617F OR 1 
n=22 
Confirmed 
JAK2 V617F 
aOR 2 
n=22 
Confirmed 
PV OR 1 
n=24 
Confirmed 
PV aOR 2 
n=24 
AHR 
rs2066853 
        
AG 0.9  
(0.4, 2.4) 
1.0  
(0.4, 2.7) 
0.9  
(0.3, 2.4) 
1.0  
(0.4, 2.9) 
1.1  
(0.4, 3.2) 
1.3  
(0.4, 3.8) 
1.0  
(0.4, 2.9) 
1.2  
(0.4, 3.5) 
AA -- -- -- -- -- -- -- -- 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
ARNT 
rs12410394 
        
GG 0.4  
(0.2, 1.0) 
0.4  
(0.2, 1.0) 
0.4  
(0.2, 1.0) 
0.4  
(0.2, 1.0) 
0.5  
(0.2, 1.3) 
0.5  
(0.2, 1.3) 
0.4  
(0.1, 1.0) 
0.4  
(0.1, 1.0) 
AA 0.4  
(0.1, 1.7) 
0.4  
(0.1, 1.9) 
0.2  
(0.0, 1.7) 
0.2  
(0.0, 1.8) 
-- -- 0.2  
(0.0, 1.9) 
0.2  
(0.0, 2.0) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing 
 
        
ARNT 
rs12410394 
        
AA 0.5  
(0.1, 2.4) 
0.6  
(0.1, 2.7) 
0.3  
(0.0, 2.3) 
0.3  
(0.0, 2.4) 
-- -- 0.3  
(0.0, 2.6) 
0.3  
(0.0, 2.8) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
 125
 
  
Missing         
ARNT 
rs12410394 
        
GG 0.5  
(0.2, 1.1) 
0.5  
(0.2, 1.1) 
0.5  
(0.2, 1.2) 
0.5  
(0.2, 1.2) 
0.6  
(0.3, 1.6) 
0.6  
(0.2, 1.6) 
0.5  
(0.2, 1.2) 
0.4  
(0.2, 1.2) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
ARNT 
rs12410394 
        
AG or GG 1.9  
(0.4, 8.2) 
1.7  
(0.4, 7.9) 
3.3  
(0.4, 25.4) 
3.2  
(0.4, 25.6) 
-- -- 3.0  
(0.4, 22.6) 
2.9  
(0.4, 23.3) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP17A1 
rs743572 
        
AG 0.8  
(0.3, 1.7) 
0.8  
(0.4, 1.9) 
0.8  
(0.4, 1.9) 
0.9  
(0.4, 2.2) 
1.0  
(0.4, 2.7) 
1.1  
(0.4, 2.9) 
0.9  
(0.4, 2.3) 
1.0  
(0.4, 2.7) 
GG 0.9  
(0.3, 2.8) 
0.8  
(0.2, 2.4) 
0.9  
(0.3, 2.9) 
0.7  
(0.2, 2.5) 
0.9  
(0.2, 3.6) 
0.7  
(0.2, 3.0) 
1.1  
(0.3, 3.7) 
0.8  
(0.2, 3.1) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP19A1 
rs700519 
        
AG 0.9  
(0.2, 3.9) 
1.0  
(0.2, 4.9) 
1.0  
(0.2, 4.6) 
1.2  
(0.3, 5.8) 
0.6  
(0.1, 4.7) 
0.7  
(0.1, 5.5) 
0.6  
(0.1, 4.3) 
0.7  
(0.1, 5.6)  126
  
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP1A2 
rs762551 
        
AA 0.6  
(0.3, 1.4) 
0.7  
(0.3, 1.5) 
0.7  
(0.3, 1.6) 
0.8  
(0.3, 1.7) 
0.7  
(0.3, 1.7) 
0.8  
(0.3, 1.9) 
0.7  
(0.3, 1.7) 
0.8  
(0.3, 1.9) 
AC Referent Referent Referent Referent Referent Referent Referent Referent 
CC Referent Referent Referent Referent Referent Referent Referent Referent 
 CYP1A2 
rs762551 
        
CC 2.8  
(1.0, 8.0) 
3.5  
(1.1, 11.0) 
3.3  
(1.1, 9.6) 
4.1  
(1.3, 13.2) 
3.2  
(1.0, 10.4) 
3.9  
(1.1, 13.8) 
2.9  
(0.9, 9.3) 
3.7  
(1.0, 13.3) 
AC Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
CYP1A2 
rs762551 
        
AC or CC 1.6  
(0.7, 3.3) 
1.4  
(0.7, 3.2) 
1.4  
(0.6, 3.2) 
1.3  
(0.6, 3.0) 
1.4  
(0.6, 3.4) 
1.3  
(0.5, 3.2) 
1.4  
(0.6, 3.2) 
1.2  
(0.5, 3.0) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
CYP1B1 
rs1056836 
        
CC 1.9  
(0.7, 5.1) 
2.1  
(0.8, 5.7) 
1.8  
(0.7, 4.7) 
1.9  
(0.7, 5.4) 
1.4  
(0.5, 3.9) 
1.5  
(0.5, 4.4) 
1.4  
(0.5, 3.9) 
1.5  
(0.5, 4.5) 
CG 0.8  
(0.3, 2.0) 
0.9  
(0.3, 2.2) 
0.6  
(0.2, 1.6) 
0.7  
(0.2, 1.8) 
0.4  
(0.1, 1.2) 
0.4  
(0.1, 1.3) 
0.5  
(0.2, 1.5) 
0.6  
(0.2, 1.6) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
 127
  
CYP2B6 
rs3745274 
        
AC 1.6  
(0.7, 3.6) 
1.4  
(0.6, 3.1) 
1.3  
(0.6, 3.0) 
1.1  
(0.5, 2.6) 
1.4  
(0.6, 3.4) 
1.2  
(0.5, 3.0) 
1.6  
(0.6, 3.8) 
1.3  
(0.5, 3.2) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
CYP2C9 
rs1057910 
        
AC 1.5  
(0.6, 4.3) 
1.4  
(0.5, 4.2) 
1.4  
(0.5, 4.3) 
1.4  
(0.4, 4.5) 
1.3  
(0.4, 4.5) 
1.2  
(0.3, 4.5) 
1.6  
(0.5, 5.0) 
1.6  
(0.5, 5.3) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1799853         
AG 0.8  
(0.3, 2.1) 
0.7  
(0.3, 2.0) 
1.0  
(0.4, 2.6) 
0.9  
(0.3, 2.5) 
1.0  
(0.4, 2.9) 
0.9  
(0.3, 2.6) 
0.7  
(0.2, 2.1) 
0.6  
(0.2, 1.9) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP2E1 
rs2031920 
        
AG 1.6  
(0.3, 7.4) 
1.7  
(0.3, 8.2) 
1.8  
(0.4, 8.7) 
2.0  
(0.4, 9.8) 
2.3  
(0.5, 11.0) 
2.4  
(0.5, 12.3) 
2.1  
(0.4, 9.9) 
2.3  
(0.4, 11.7) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs2070673         
AT 0.7  
(0.3, 1.7) 
0.7  
(0.3, 1.9) 
0.6  
(0.2, 1.7) 
0.7  
(0.2, 2.0) 
0.6  
(0.2, 1.9) 
0.7  
(0.2, 2.1) 
0.6  
(0.2, 1.7) 
0.6  
(0.2, 1.9) 
AA -- -- -- -- -- -- -- -- 
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TT Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs6413432         
AT 1.5  
(0.6, 3.6) 
1.5  
(0.6, 3.9) 
1.4  
(0.5, 3.7) 
1.5  
(0.6, 4.2) 
1.9  
(0.7, 5.0) 
2.0  
(0.7, 5.6) 
1.7  
(0.6, 4.4) 
1.8  
(0.6, 5.0) 
TT -- -- -- -- -- -- -- -- 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP3A4 
rs2740574 
        
AG -- -- -- -- -- -- -- -- 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP3A5 
rs776746 
        
AA 9.3  
(0.6, 153.5) 
7.0  
(0.4, 122.6) 
11.0  
(0.7, 181.0) 
9.1  
(0.5, 162.6) 
13.3  
(0.8, 220.5) 
11.0  
(0.6, 200.1) 
12.6  
(0.8, 209.1) 
10.7  
(0.6, 192.5) 
AG 0.7  
(0.2, 2.5) 
0.8  
(0.2, 2.8) 
0.9  
(0.2, 3.0) 
0.9  
(0.3, 3.4) 
0.7  
(0.2, 3.1) 
0.7  
(0.2, 3.4) 
1.0  
(0.3, 3.5) 
1.1  
(0.3, 4.2) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
CYP4B1 
rs2297810 
        
AG 1.4  
(0.6, 3.0) 
1.2  
(0.5, 2.8) 
1.4  
(0.6, 3.3) 
1.3  
(0.5, 3.0) 
1.3  
(0.5, 3.4) 
1.2  
(0.5, 3.1) 
1.7  
(0.7, 4.1) 
1.5  
(0.6, 3.7) 
AA -- -- -- -- -- -- -- -- 
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GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
GSTA1 
rs3957356 
        
AA 2.1  
(1.0, 4.8) 
1.7  
(0.7, 4.1) 
2.3  
(1.0, 5.3) 
1.9  
(0.8, 4.7) 
3.1  
(1.3, 7.7) 
2.7  
(1.0, 7.0) 
2.7  
(1.1, 6.5) 
2.3  
(0.9, 5.9) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
GSTA1 
rs3957356 
        
GG 0.6  
(0.3, 1.5) 
0.6  
(0.3, 1.6) 
0.8  
(0.3, 1.9) 
0.8  
(0.3, 2.0) 
0.8  
(0.3, 2.2) 
0.8  
(0.3, 2.2) 
0.7  
(0.3, 1.9) 
0.7  
(0.3, 1.9) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
GSTA1 
rs3957356 
        
AG or GG 0.5  
(0.2, 1.0) 
0.6  
(0.2, 1.4) 
0.4  
(0.2, 1.0) 
0.5  
(0.2, 1.3) 
0.3  
(0.1, 0.8) 
0.4  
(0.1, 1.0) 
0.4  
(0.2, 0.9) 
0.4  
(0.2, 1.1) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
GSTM1 
Undetermined 
        
0 2.2  
(1.0, 4.9) 
2.0  
(0.9, 4.6) 
2.5  
(1.0, 6.2) 
2.4  
(1.0, 5.9) 
2.4  
(0.9, 6.2) 
2.2  
(0.8, 6.0) 
2.7  
(1.0, 6.9) 
2.5  
(0.9, 6.5) 
1 Referent Referent Referent Referent Referent Referent Referent Referent 
2 Referent Referent Referent Referent Referent Referent Referent Referent 
GSTM3 
rs7483 
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AA 2.4  
(0.8, 7.0) 
2.8  
(0.9, 8.6) 
3.2  
(1.1, 9.5) 
3.9  
(1.2, 12.3) 
3.8  
(1.1, 12.8) 
4.5  
(1.2, 16.0) 
2.6  
(0.8, 8.3) 
3.3  
(1.0, 11.2) 
AG 1.0  
(0.4, 2.3) 
1.0  
(0.4, 2.4) 
1.2  
(0.5, 3.0) 
1.2  
(0.5, 3.1) 
1.6  
(0.6, 4.3) 
1.6  
(0.6, 4.5) 
1.0  
(0.4, 2.5) 
1.0  
(0.4, 2.6) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1332018         
CC 1.1  
(0.4, 2.9) 
0.8  
(0.3, 2.3) 
1.1  
(0.4, 2.9) 
0.8  
(0.3, 2.2) 
0.9  
(0.3, 2.7) 
0.6  
(0.2, 2.1) 
1.4  
(0.5, 3.9) 
1.0  
(0.3, 3.0) 
AC 0.4  
(0.2, 0.9) 
0.3  
(0.1, 0.7) 
0.3  
(0.1, 0.8) 
0.2  
(0.1, 0.7) 
0.3  
(0.1, 0.9) 
0.3  
(0.1, 0.7) 
0.4  
(0.1, 1.1) 
0.3  
(0.1, 0.9) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1799735         
TG 0.5  
(0.2, 1.3) 
0.5  
(0.2, 1.4) 
0.4  
(0.1, 1.3) 
0.5  
(0.2, 1.4) 
0.4  
(0.1, 1.4) 
0.4  
(0.1, 1.6) 
0.5  
(0.2, 1.5) 
0.6  
(0.2, 1.7) 
TT -- -- -- -- -- -- -- -- 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
GSTM3 
rs7483 
        
AA 2.4  
(0.9, 6.4) 
2.8  
(1.0, 7.9) 
2.9  
(1.1, 7.7) 
3.5  
(1.2, 10.0) 
3.0  
(1.0, 8.7) 
3.5  
(1.1, 10.7) 
2.6  
(0.9, 7.7) 
3.3  
(1.1, 10.3) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
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GSTP1 
rs1695 
        
AG 0.8  
(0.4, 1.8) 
0.8  
(0.4, 1.8) 
0.8  
(0.4, 1.9) 
0.8  
(0.4, 1.9) 
0.8  
(0.3, 1.8) 
0.7  
(0.3, 1.8) 
0.8  
(0.3, 1.8) 
0.7  
(0.3, 1.8) 
GG -- -- -- -- -- -- -- -- 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1138272         
AA 1.0  
(0.3, 3.0) 
1.0  
(0.3, 3.3) 
1.2  
(0.4, 3.6) 
1.2  
(0.4, 4.0) 
1.0  
(0.3, 3.6) 
1.1  
(0.3, 4.0) 
1.0  
(0.3, 3.4) 
1.0  
(0.3, 3.8) 
AG 0.3  
(0.0, 2.2) 
0.3  
(0.0, 2.3) 
0.3  
(0.0, 2.6) 
0.4  
(0.0, 2.9) 
-- -- 0.4  
(0.0, 2.9) 
0.4  
(0.0, 3.2) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
GSTT1 
Undetermined 
        
0 1.0  
(0.4, 2.8) 
0.9  
(0.3, 2.6) 
0.9  
(0.3, 2.8) 
0.8  
(0.3, 2.5) 
0.5  
(0.1, 2.4) 
0.5  
(0.1, 2.1) 
0.8  
(0.2, 2.7) 
0.6  
(0.2, 2.4) 
1 Referent Referent Referent Referent Referent Referent Referent Referent 
2 Referent Referent Referent Referent Referent Referent Referent Referent 
GSTZ1 
rs7972 
        
AA 1.6  
(0.2, 13.9) 
2.6  
(0.3, 25.4) 
1.9  
(0.2, 16.7) 
2.8  
(0.3, 28.7) 
2.5  
(0.3, 22.2) 
4.0  
(0.4, 41.2) 
2.2  
(0.3, 19.6) 
3.4  
(0.3, 37.3) 
AG 1.1  
(0.4, 3.0) 
1.1  
(0.4, 3.2) 
1.3  
(0.5, 3.7) 
1.4  
(0.5, 3.9) 
1.7  
(0.6, 4.9) 
1.8  
(0.6, 5.3) 
1.5  
(0.5, 4.3) 
1.6  
(0.5, 4.8) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
rs1046428         
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AG 0.7  
(0.3, 1.6) 
0.5  
(0.2, 1.3) 
0.6  
(0.2, 1.4) 
0.4  
(0.2, 1.1) 
0.4  
(0.1, 1.3) 
0.3  
(0.1, 1.0) 
0.5  
(0.2, 1.4) 
0.4  
(0.1, 1.1) 
AA -- -- -- -- -- -- -- -- 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
JAK2 V617F 
rs12340895 
        
CC 4.7  
(1.7, 12.9) 
5.3  
(1.8, 15.7) 
7.4  
(2.5, 22.2) 
8.7  
(2.6, 28.9) 
9.0  
(2.7, 30.8) 
10.2  
(2.8, 37.9) 
8.6  
(2.7, 27.0) 
10.8  
(3.0, 38.2) 
CG 1.4  
(0.6, 3.3) 
1.5  
(0.6, 3.6) 
2.2  
(0.8, 5.8) 
2.5  
(0.9, 6.8) 
2.5  
(0.8, 7.7) 
2.6  
(0.8, 8.3) 
2.1  
(0.7, 6.1) 
2.4  
(0.8, 7.1) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
          
rs12343867         
GG 3.1  
(1.0, 9.6) 
4.3  
(1.3, 14.7) 
4.8  
(1.4, 16.4) 
7.2  
(1.9, 27.5) 
5.4  
(1.3, 21.6) 
7.9  
(1.8, 34.9) 
5.6  
(1.6, 19.9) 
9.6  
(2.3, 39.8) 
AG 1.3  
(0.5, 3.1) 
1.3  
(0.5, 3.3) 
2.0  
(0.7, 5.4) 
2.2  
(0.8, 6.2) 
2.2  
(0.7, 6.9) 
2.3  
(0.7, 7.5) 
1.8  
(0.6, 5.5) 
2.1  
(0.7, 6.5) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
NAT2 
rs1041983 
        
AA 0.5  
(0.1, 2.2) 
0.5  
(0.1, 2.1) 
0.6  
(0.1, 2.6) 
0.6  
(0.1, 2.5) 
0.7  
(0.2, 3.3) 
0.7  
(0.1, 3.1) 
0.3  
(0.0, 2.4) 
0.3  
(0.0, 2.2) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
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GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1495741         
AA 3.2  
(1.3, 8.0) 
3.0  
(1.2, 7.6) 
3.4  
(1.2, 9.2) 
3.1  
(1.1, 8.7) 
4.9  
(1.4, 16.8) 
4.6  
(1.3, 16.1) 
3.8  
(1.3, 11.5) 
3.5  
(1.1, 10.8) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1799929         
AA 2.3  
(1.1, 5.1) 
2.3  
(1.0, 5.2) 
2.5  
(1.1, 5.7) 
2.4  
(1.0, 5.7) 
3.5  
(1.4, 8.5) 
3.4  
(1.3, 8.4) 
2.5  
(1.1, 6.1) 
2.4  
(1.0, 6.1) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
rs1799930         
AA 0.3  
(0.0, 2.4) 
0.3  
(0.0, 2.2) 
0.3  
(0.0, 2.7) 
0.3  
(0.0, 2.6) 
0.4  
(0.1, 3.3) 
0.4  
(0.0, 3.1) 
-- -- 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1801279         
AA 1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
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Missing         
rs1801280         
AA 0.6  
(0.3, 1.4) 
0.6  
(0.2, 1.4) 
0.6  
(0.3, 1.5) 
0.6  
(0.2, 1.5) 
0.5  
(0.2, 1.4) 
0.5  
(0.2, 1.4) 
0.5  
(0.2, 1.3) 
0.4  
(0.2, 1.2) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
NAT2         
rs1041983         
GG 0.9  
(0.4, 1.9) 
1.0  
(0.5, 2.1) 
1.0  
(0.5, 2.2) 
1.1  
(0.5, 2.4) 
1.3  
(0.5, 3.1) 
1.4  
(0.6, 3.3) 
1.1  
(0.5, 2.5) 
1.2  
(0.5, 2.8) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1495741         
GG 0.4  
(0.1, 3.1) 
0.4  
(0.0, 3.0) 
0.5  
(0.1, 3.6) 
0.5  
(0.1, 3.7) 
0.6  
(0.1, 4.5) 
0.6  
(0.1, 4.6) 
0.5  
(0.1, 4.1) 
0.5  
(0.1, 4.3) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1799929         
GG 0.8  
(0.3, 1.7) 
0.8  
(0.3, 1.7) 
0.8  
(0.3, 1.9) 
0.8  
(0.3, 1.9) 
0.8  
(0.3, 1.9) 
0.8  
(0.3, 2.0) 
0.7  
(0.3, 1.6) 
0.7  
(0.3, 1.7) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
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AA Referent Referent Referent Referent Referent Referent Referent Referent 
rs1799930         
GG 1.0  
(0.5, 2.0) 
1.1  
(0.5, 2.3) 
1.0  
(0.5, 2.3) 
1.1  
(0.5, 2.6) 
1.4  
(0.6, 3.4) 
1.5  
(0.6, 3.7) 
1.1  
(0.5, 2.6) 
1.3  
(0.5, 3.0) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1801279         
GG 1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1801280         
GG 2.5  
(1.2, 5.5) 
2.6  
(1.2, 5.8) 
2.8  
(1.2, 6.3) 
2.8  
(1.2, 6.5) 
4.0  
(1.7, 9.7) 
4.0  
(1.6, 9.9) 
2.9  
(1.2, 6.8) 
2.9  
(1.2, 7.1) 
AG Referent Referent Referent Referent Referent Referent Referent Referent 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
NAT2 
rs1041983 
        
AG or GG 2.0  
(0.5, 8.7) 
2.1  
(0.5, 9.4) 
1.7  
(0.4, 7.5) 
1.8  
(0.4, 8.2) 
1.4  
(0.3, 6.1) 
1.5  
(0.3, 6.8) 
3.1  
(0.4, 24.0) 
3.5  
(0.5, 27.9) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
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rs1495741         
AG or GG 0.3  
(0.1, 0.8) 
0.3  
(0.1, 0.9) 
0.3  
(0.1, 0.8) 
0.3  
(0.1, 0.9) 
0.2  
(0.1, 0.7) 
0.2  
(0.1, 0.8) 
0.3  
(0.1, 0.8) 
0.3  
(0.1, 0.9) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1799929         
AG or GG 0.4  
(0.2, 1.0) 
0.4  
(0.2, 1.0) 
0.4  
(0.2, 0.9) 
0.4  
(0.2, 1.0) 
0.3  
(0.1, 0.7) 
0.3  
(0.1, 0.7) 
0.4  
(0.2, 0.9) 
0.4  
(0.2, 1.0) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
rs1799930         
AG or GG 3.2  
(0.4, 24.4) 
3.5  
(0.4, 27.1) 
2.9  
(0.4, 22.0) 
3.0  
(0.4, 23.8) 
2.3  
(0.3, 17.9) 
2.5  
(0.3, 20.1) 
-- -- 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1801279         
AG or GG 1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
1.0  
(., .) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs1801280         
AG or GG 1.6  
(0.7, 3.8) 
1.7  
(0.7, 4.1) 
1.6  
(0.7, 4.0) 
1.7  
(0.7, 4.2) 
1.9  
(0.7, 5.4) 
2.0  
(0.7, 5.7) 
2.2  
(0.8, 6.0) 
2.3  
(0.8, 6.5) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
rs854560          137
  
AT 0.9  
(0.4, 1.8) 
0.9  
(0.4, 1.9) 
0.7  
(0.3, 1.6) 
0.7  
(0.3, 1.7) 
0.8  
(0.3, 1.9) 
0.8  
(0.3, 2.0) 
0.7  
(0.3, 1.6) 
0.7  
(0.3, 1.6) 
TT 0.2  
(0.0, 1.7) 
0.2  
(0.0, 1.6) 
0.2  
(0.0, 1.8) 
0.2  
(0.0, 1.7) 
0.3  
(0.0, 2.3) 
0.3  
(0.0, 2.1) 
0.2  
(0.0, 1.9) 
0.2  
(0.0, 1.8) 
AA Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
NQO1 
rs1131341 
        
AG 1.7  
(0.5, 6.3) 
1.5  
(0.4, 5.7) 
2.0  
(0.6, 7.4) 
1.7  
(0.4, 6.6) 
2.6  
(0.7, 9.5) 
2.3  
(0.6, 8.8) 
1.5  
(0.3, 6.8) 
1.2  
(0.2, 5.6) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
rs1800566         
AA 0.9  
(0.1, 7.7) 
1.3  
(0.1, 11.2) 
1.1  
(0.1, 9.5) 
1.6  
(0.2, 14.4) 
-- -- 1.2  
(0.1, 10.3) 
2.0  
(0.2, 17.9) 
AG 1.7  
(0.8, 3.6) 
1.7  
(0.8, 3.7) 
1.9  
(0.8, 4.3) 
1.9  
(0.8, 4.3) 
1.8  
(0.8, 4.4) 
1.8  
(0.7, 4.4) 
1.7  
(0.7, 4.0) 
1.7  
(0.7, 4.1) 
GG Referent Referent Referent Referent Referent Referent Referent Referent 
CYP1A1 
rs1048943 
        
CT 1.7  
(0.5, 6.0) 
1.8  
(0.5, 6.8) 
1.9  
(0.5, 7.1) 
2.1  
(0.5, 8.1) 
2.4  
(0.6, 8.7) 
2.4  
(0.6, 9.5) 
1.4  
(0.3, 6.6) 
1.4  
(0.3, 7.0) 
         
Tp53 
rs1042522 
        
GG - - 4.1 
(1.2,14.5) 
5.4 
(1.4, 20.8) 
5.9 
(1.6, 22.1) 
8.0 
(2.0, 33.0) 
4.8 
(1.3, 17.5) 
6.8 
(1.7, 27.7) 
CG - - 1.0 1.0 1.4 1.3 1.1 1.0 
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1. All cases include PV, ET and PMF, confirmed cases  by expert panel include PV, ET, and PMF, confirmed JAK2 V617F  mutation with PV, ET or PMF by expert 
panel, confirmed by expert panel PV only 
2. Adjusted (for age, sex and county) Odds Ratios (95% confidence intervals) 
(0.4, 2.5) (0.4, 2.3) (0.5, 3.6) (0.5, 3.4) (0.4, 2.8) (0.4, 2.6) 
CC - - Referent Referent Referent Referent Referent Referent 
T Referent Referent Referent Referent Referent Referent Referent Referent   
Missing        
rs4646903         
CC 3.8  
(0.4, 38.1) 
4.8  
(0.4, 53.6) 
4.2  
(0.4, 42.3) 
5.1  
(0.5, 57.5) 
-- -- 4.7  
(0.5, 47.5) 
6.8  
(0.6, 80.3) 
CT 2.0  
(0.8, 4.7) 
1.9  
(0.8, 4.7) 
1.6  
(0.6, 4.3) 
1.5  
(0.6, 4.2) 
1.6  
(0.6, 4.7) 
1.6  
(0.5, 4.6) 
1.5  
(0.5, 4.3) 
1.4  
(0.5, 4.0) 
TT Referent Referent Referent Referent Referent Referent Referent Referent 
Missing         
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Table 3.8   Total number deleterious number and frequency 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. AHR, CY1A2, CY1E2, GSTA1, GSTM1, GSTM3, GSTT1, NAT2, TP53 
2. Odds ratio adjusted for age, sex and county 
Number of 
Deleterious genes1 
Number and frequency  
deleterious genes1 
Frequency  
deleterious genes1 
 Cases Controls Cases (%) Controls (%) 
0 0 11 0 3.70 
1 1 99 3.23 33.30 
At least 2 
 
30 182 96.78 63.00 
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Chapter 4:  The Risk of Myeloproliferative Neoplasms Due to the Joint 
Effects of Susceptible Genotypes and Distance of Current Residence from 
Facilities with Known Hazardous Emissions 
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Abstract 
 
Introduction 
The causes of a rare category of myeloproliferative neoplasms (MPN)—a cancer of the 
bone marrow with an excess of blood cells—are currently unknown.  These classical 
MPNs (polycythemia vera (PV), essential thrombocythemia (ET) and primary 
myelofibrosis (PMF)) share the same de novo somatic JAK2 V617F point mutation, but 
are clinically presented differently.  Our recent work identified associations of genetic 
variations that affect toxicity of xenobiotics with risk of MPNs. 
 
Objectives 
To investigate the joint effects of previously identified environmentally sensitive 
genotypes implicated in MPNs and distance of residence from facilities with suspected 
hazardous emissions on risk of PV-related outcomes. 
 
Methods 
We conducted a population-based case-control study among residents of three 
Pennsylvania counties where a cluster of PV was previously described.  Subjects were 
born between 1921 and 1968 and resided in the three counties between 2000 and 2008.  
Cases were identified from the Pennsylvania cancer registry and the previous cluster 
investigation, with multiple case categorizations including all MPNs combined, JAK2 
V617F, and PV.  Controls were selected using random-digit dialling and were screened 
for eligibility.  Blood samples were obtained from participants who consented to blood 
collection (31 cases and 292 controls).  These samples were genotyped for a panel of 
environmentally sensitive genes.  Results from gene-only analysis was used to focus 
current analysis on genotypes that had a 2-4 fold increase in risk of an MPN.  Data was 
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analyzed using logistic regression models that controlled for the design variables (age, 
sex and county) and evaluated one genetic variant at a time.   
 
Information on hazardous waste sites in the tri-county area was obtained directly from 
the US Environmental Protection Agency, CERCLIS database.  To detect the potential for 
existence of gene-environment interaction, the main effects of genes and distance from 
hazardous wastes sites (measure of exposure) as a continuous variable were used in this 
analysis that controlled for design variables (age and sex).  Logistic regression was used 
to estimate odds ratios (OR) and 95% confidence intervals (CI).   
 
Results 
Overall continuous distance to any one of the six hazardous waste/waste-coal plant 
adjusted for age and sex were not associated in MPN risk with adjusted OR=0.97 
(95%CI: 0.93, 1.01).  Adjusted ORs living within 10 miles of a cogeneration plant or 
hazardous waste site had point estimates range here of 1.3 to 1.4 but with wide 
(95%CI:0.5 to 4) including the null.  We also examined nine genotypes that suggested a 
signal when we looked at each risk genotype by distance category, the effect was not 
consistent, greater in some of the genotypes but not for all, compared to looking at the 
distance only model in Table 4.2.  For AHR, GSTA1, GSTM3, and GSTT1 and TP53, these 
results were oscillating back at forth around the null for distances less than or equal to 10 
miles with overlapping confidence intervals. NAT2 and CYP1A2 provided a steady effect 
estimate in the same direction with from a 1 – 20 fold increase of risk of an MPN for both 
distance categories, although it was very imprecise.   
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Conclusions 
Overall distance from one of six hazardous waste/waste-coal plant examined in this 
study was not related to MPN risk.  The sources that were examined maybe incorrect as 
not all sources were included or were characterized with too much error to show an 
effect.  It is also possible that the sensitive genotype associations were due to chance and 
there is no environmental influence.  While the gene-only results did not confirm a gene-
environment interaction effect, it did offer the opportunity to explore the joint effects of 
using distance as a proxy for exposure with respect to NAT2, GST, and CYP gene 
biological pathway and chemical exposures.  
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Introduction 
Myeloproliferative disorders are now called Myeloproliferative neoplasms or (MPNs), 
according to the World Health Organization’s (WHO) new classification of 
hematopoietic tumors.  There are no known causes of MPNs (Seaman et al., 2009).  
These rare cancers are characterized by an overproduction of red blood cells, platelets, 
and white cells.  MPNs include polycythemia vera (PV), essential thrombocythemia (ET), 
and primary myelofibrosis (PMF) (Campbell & Green, 2005).  Patients with PV can 
have>25% above predicted red cell mass (Campbell & Green, 2005).  The overproduction 
of platelets in the bone marrow is seen in ET cases, and scarring of the bone occurs in 
PMF cases (Tefferi et al., 2007). 
 
MPNs were classified as a reportable cancer by the WHO in 2001, and they revised the 
diagnostic criterion in 2008.  The National Cancer Institute estimated the incidence for 
the years 2001-2004 of PV at 2.8 per 100,000 persons per year (Kutti &Ridell, 2001).  
Incidence of 0.4 cases per 100,000 persons per year was estimated for PMF and 1.5 cases 
per 100,000 per year for ET (Kutti &Ridell, 2001).   
 
In 2009, the Centers for Disease Control (CDC) identified a PV cluster in Northeast 
Pennsylvania.  This was first reported cluster for any MPN.  MPNs with an unknown 
etiology create the possibility that the presence of numerous potential environmental 
exposures in the cluster area, with no other known cause, could be associated with the 
cluster. With the etiology of these MPNs unknown, it creates the possibility that the 
presence of numerous potential environmental exposures in the cluster area, with no 
other known cause, could be associated with the cluster (Anderson et al.2012; Hoffman 
&Rondelle, 2007). 
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MPNs and the role of the JAK2 V617F mutation 
  
In 2005 the presence of the JAK2 V617F somatic point mutation was identified with 
these classic MPNs.  The acquired JAK2 V617F mutation is a protein that acts as an on-
and-off switch regulating bone marrow activity and is suspected to be specifically 
characteristic of PV with clinical diagnosis of ET and PMF (Baxter, 2005).  The tyrosine 
kinase complex is activated by the JAK2 V617F protein normally responsible for 
regulating blood cell production through molecular signalling in the bone marrow.  As a 
result of this acquired mutation, the normal inhibition of growth is disrupted, resulting 
in increased blood cell production (Spivak et al., 2010).  This JAK2 V617F mutation is 
not seen in any other cancers to date, but is present in nearly all PV patients (>95%) and 
about half of those with ET or PMF (Kralovics  et al., 2007; Tefferi et al., 2007).  These 
MPNs, PV, ET, and PMF commonly share the same JAK2 V617F somatic mutation, 
which could play a role in disease initiation or progression (Kralovics  et al., 2007).  The 
etiology of the JAK2 V617F mutation is currently unknown (Seaman et al., 2009).   
In 2009, a germ-line haplotype—the 46/1 haplotype—was associated with PV patients 
who were JAK2 V617F, and is now considered to be the only risk factor for the JAK2 
V617F mutation in PV patients (Jones et al., 2009;Andrikovics et al., 2010).  In 
European populations, using genome-wide studies (GWAS), this 46/1 haplotype was 
found in 5-41% of those with JAK2 V617F MPNs (Jones et al., 2009; Olcaydu et al., 
2009; Kilpivaara et al., 2009). 
Familial clustering of PV, ET, and PMF 
A family history of MPNs is associated with an increased risk of developing an MPN 
(Anderson et al., 2012, Landgren et al., 2008).  In 2009, a large population-based study 
in Sweden showed a 5-7-fold increase in risk of developing an MPN for first-degree 
relatives of patients followed in 24,577 first degree relatives of 11,039 MPN patients who 
147 
 
 
were diagnosed with an MPN from 1958 to 2005 (Landgren et al., 2008).  The role of 
inherited genetics is thought to influence both phenotype and susceptibility to MPNs 
(Andrikovics et al., 2010).  
 
Environmental exposures and MPNs 
After identification of the acquired JAK2 V617F mutations in MPN patients, the interest 
in the etiology of the disease has gained interest.  Notably, there has been more research 
into possible links to environmental exposures (Seaman et al., 2009; Seaman et al,2010).  
However, there is limited evidence in the literature to suggest an association with MPNs 
and occupational exposures.  Studies done by Kaplan, (1986), Terreros et al., (1997), and 
Mele et al. (1997) on industry occupations suggests benzene as a risk factor.  Only 
Terreros, with nine cases of myeloproliferative syndrome, reported a significant 
association with assessment of benzene exposure specifically.  Exposure to petroleum 
was found to be associated with an increased risk of PV, ET with an elevated Standard 
Mortality Rate (SMR) of petroleum refiner workers of 455, (95%CI: 120, 1164) when 
compared to the general population with a SMR of 88 (Kaplan, 1986).  Quiroga et al 
(1981) reported an association, p=0.002, with exposure to petroleum.  In this hospital 
based case control study, out of   51, cases, there were only 10 PV cases and four 
myeloproliferative disorders (Quiroga, 1981).  However, Pasqualetti et al. (1991) reported 
a significant risk of hematological malignancies with exposure to aromatic hydrocarbons.  
However, no association was found with only myeloproliferative syndrome cases (n=44, 
ORs not reported).  All of these studies are of limited size and did not use the molecular 
markers such as the JAK2 V617F mutation that have significantly improved the 
identifying of true cases of MPNs (Seaman et al., 2009).  
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In addition, in our study titled The Risk of Myeloproliferative Neoplasms due to 
Exposure to Polycyclic Aromatic Hydrocarbons (described elsewhere in Chapter 2), no 
relationships between MPNs and residential history, diet, lifestyle behaviors, or 
presumed exposure to aromatic and heterocyclic amines was found (Gross-Davis, 
Chapter 2). 
 
Susceptible genotypes associated with MPNs and JAK2 V617F mutation 
Although functional Single Nucleotide Polymorphisms (SNPs) that may modify the 
biological dose of a chemical mutagen are being studied for a wide range of cancers, no 
studies have investigated any combination of these genotypes and the risk of MPNs.   
 
The CYP1A2, NAT2, GSTM3 and GSTA1 SNPs came directly from Aim 2 of this 
dissertation where associations were detected with a 2-5-fold increase of risk of 
developing an MPN.  An additional five SNPs, AHR, GSTA1, GSTM3, and GSTT1 and 
TP53, were included because they also met the biological pathway we are exploring, and 
our results from Aim2 suggested an association with MPNs.  These SNPs are associated 
with the metabolism/detoxification of benzene, and were included based on recent 
publications surround benzene and MPNs (Schnatter et al., 2012). 
 
The Cytochrome P450 superfamily (CYP), Polymorphic N-acetyltransferase (NAT2), and 
the Glutathione S-transferase (GST) polymorphisms have been identified in the 
literature and linked to increased cancer risk and continue to be included in research 
efforts.  With The Human Genome Project at its completion, new methods continue to be 
published to conduct these gene-environment interaction studies.  The candidate-gene 
approach, using a biological pathway hypothesis as its framework, is one of these 
methods used to examine gene-environment interactions (Hunter et al., 2005).  The 
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National Institute of Environmental Health Sciences Environmental Genome Project 
(NIEHS EGP) has built a foundation to explore environmentally sensitive genes (ESG) 
and to categorize them in the human genome.  Included in the NIEHS EGP list are a total 
of 648 genes in the following categories: gene expression; cell structure; cell cycle; 
metabolism; DNA repair; cell division; homeostasis; and cell signalling. 
 
Polymorphisms affecting xenobiotic metabolizing enzymes have been used as markers 
for susceptibility (Their, 2003).  These functional SNPs described below will encode 
enzymes for the biotransformation of chemicals such as PAHs and benzene.  They can be 
genotoxic for cells or cause toxicant-induced damage to cellular DNA (Their, 2003).  
Observed hematologic effects with acute and chronic exposures have been well studied to 
show their direct association of hematologic changes in humans as well as animals 
(Galbraith et al., 2010; Smith, 2010).   
 
Susceptible genotypes associated with MPNs, as reported by Gross-Davis 
(2013) 
 
Cases and controls were similar in all demographic variables, as with the previous 
analysis of this population that investigated the role of genotypes that modify the toxicity 
of chemical mutagens in the risk for MPNs.  As we reported, the prevalence of the 
susceptible genotypes was in agreement with the reported frequency in the literature (see 
Table 3.1 of MPNs Gross-Davis, Chapter 3).  Our analysis of the main effects 14 
environmentally sensitive genes, the presence of CYP1A2 and GSTA1, GSTM3, NAT2 
slow acetylator genotype, and TP53 (point estimates of adjusted (aORs) 2.7 to 4.6, with 
95% C.I.s that excluded 1.0), variants were associated with an increased risk for all MPNs 
.  All but one case harbored at least one deleterious SNP 30/31 (96.7%). out of the initial 
four SNPs, and all 31 cases had at least of the nine SNPs; AHR, CYP1E2, GSTM1, Tp53, 
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GSTT1, GSTM3, CYP1A2, NAT2, and GSTA1.  Because our analysis found a 2 to 5 fold 
increase in developing an MPN associated with it prompted us to further examine the 
interaction hypothesis with respect to NAT2, GST, and CYP, AHR the gene variants with 
distances to industrial facilities.  
 
Demographics  
Tables 3.4 and 3.5 show the study demographics by case and controls status.  31 cases 
and 273 controls were interviewed and consented to genotyping and storage of bio-
sample.  Our cases were diagnosed with one of the following MPNs: PV 27 (90%), 2 (7%) 
with ET and 1 (>3%) PMF.  Genotype data were available for 57% of the total cases and 
62% of controls from the larger study described in Chapter 2 of this dissertation (Gross-
Davis, 2013).  
 
Cases were older (median age=71 vs. 63yrs) (OR=2.9, 95% CI: 1.6, 5.2) and more likely to 
be male (55% vs. 45%) (OR=1.4, 95%0. 8, 2.5) compared to controls but otherwise 
demographically similar (Tables 3.4 and Table 3.5).  The study population was all US 
born and overwhelmingly Caucasian with no cases and few (2%) controls were of Jewish 
ancestry.  Two-thirds of the study population was currently married and cases were more 
likely to be retired (65% versus 47% of controls).   
 
No relationships were found between MPNs and residential history, lifestyle behaviors, 
and diet, with presumed exposure to aromatic and heterocyclic amines.  Participation 
rates of cases were poor but the results do rule out strong associations between 
environmental PAHs and MPNs, with the null result for exposure to cigarette smoke 
(rich in PAH), providing the most convincing evidence.  
 
151 
 
 
 
 
Industrial sources in the Carbon, Luzerne, and Schuylkill Counties with 
potential hazardous emissions 
 
In 2008, the joint efforts by the Pennsylvania Department of Health (PADOH) and the 
Agency for Toxic Substances and Registry (ATSDR) of the CDC confirmed a cancer 
cluster in a tri-county region of Northeast Pennsylvania.  A cluster of cases was identified 
where the incidence of polycythemia vera is 4.3 times (P < 0.001) that of the rest of the 
study area (Seaman et al., 2009).  The area of the cluster of cases in the 2009 report 
identified numerous sources of hazardous material including U.S. Environmental 
Protection Agency (EPA) Superfund sites and waste-coal power plants or co-generation 
plants (Seaman et al., 2009). 
Several hazardous material exposure sources were found in or near the high-rate areas of 
PV.  These plants began operations in the early 1990s, and their emissions are 
characterized by fine particulate matter, including complex hydrocarbons and various 
heavy metals like cadmium (Lui et al., 2008).  There are U.S. EPA Superfund sites 
contained within the cluster area with potential offsite migration in the past (Seaman et 
al., 2009).  These sites are described in more detail below. 
 
Hazardous waste sites/waste-coal power plants  
The Northeastern Power Company operates in McAdoo, PA.  This is a 50-megawatt 
cogeneration station. Known as NEPCO, the plant is located in the eastern, anthracite 
coal-mining region of Pennsylvania.  It uses a circulating fluidized bed boiler to combust 
anthracite coal mining refuse (culm).  Steam from the plant is used in a 20-acre 
greenhouse specializing in flowers. 
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Wheelabrator Frackville Energy Company located in Frackville, PA.  This 42-megawatt 
cogeneration station is located in eastern Pennsylvania.  Steam from the plant is used to 
heat a nearby state correctional facility.  The plant is located on the site of an abandoned 
coal mine and burns anthracite coal mining refuse in a circulating fluidized bed boiler. 
 
WPS Westwood Generation LLC is located in Schuylkill County.  WPS Westwood 
Generation, LLC operates in the Westwood Generating Station located in Tremont, 
Pennsylvania.  The 30-megawatt power plant uses a Circulating Fluidized Bed boiler that 
converts waste coal into low-cost power.  Steam from the plant drives a 40,000 
horsepower generator that produces enough energy to serve 45,000 homes. 
 
Tonolli Corporation is located along Rte. 54 in Nesquehoning, Carbon county 
Pennsylvania.  The Tonolli site operated between 1974 and 1985 as a lead-acid battery 
recycling facility and a secondary lead smelter.  The contaminants found at the site 
included lead, arsenic, cadmium, and chromium from the founder smelter.  These were 
also found in monitoring wells and the soil, and later migrated to Nesquehoning creek. 
Cadmium toxicity is suspected to be genotoxic and is the main environmental exposure 
considered in this study.  This site was formally added to the National Priorities List 
(NPL) in October 1989. 
Eastern Diversified Metals (EDM) is a former recycling facility located in Rush 
Township, Schuylkill County.  This 25-acre site disposed of approximately 350 million 
pounds of waste insulation material in an open pile, called “fluff”.  The fluff pile at this 
site occupied a parcel of land approximately 1,500 feet long, up to 60 feet high and 250 
feet wide.  The threats at the site include polychlorinated biphenyls and dioxin 
compounds, along with other volatile organic compounds that may or may not be site-
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related contaminates.  These compounds contaminated the ground water that serves 
1600 residents living within a one-mile radius.   
McAdoo Associates is a site of interest to the residents of Schuylkill County due to past 
contamination concerns, located in the Borough of McAdoo.  This site is currently still 
under remediation.  Base Neutral Acids, Dioxins/Dibenzofurans, Inorganics, Metals, 
PAH, PCBs, Pesticides, and VOCs were found on site soil and groundwater monitoring 
wells.  Work on McAdoo is not yet complete, as one operable unit continues to create 
groundwater contamination.   
The objective of this study is to explore the identified susceptible genotypes and 
exposure to hazardous waste facilities in the risk for myeloproliferative neoplasms.  
 
Methods 
The study design and data collection were described elsewhere (Chapters 2 & 3) and are 
only briefly summarized below. 
 
Study design 
An unmatched case-control study design was used in this analysis.  The study area was 
located in Northeast Pennsylvania and comprised a tri-county area (Carbon, Luzern, and 
Schuylkill Counties).  Cases were individuals with diagnoses between 2001 and 2010 of 
PV, ET, PMF, with and without JAK2 V617F.  Controls were selected using random digit 
dialling along with age, county, and the amount of time they had resided there.  Both 
cases and controls had their DNA checked for JAK2 V617F mutation and a group of 
genes we were interested in AHR, CY1A2, CY1E2, GSTA1, GSTM1, GSTM3, GSTT1, 
NAT2, and TP53.   
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Participants 
An estimated 500,000 people in 2007 resided in the tri-county region. We restricted the 
study population by age to eliminate younger individuals not at risk for an MPN.  Since 
this study focuses on environmental exposures in the tri-county area, all cases and 
controls were required to reside in the tri-county area for between 2000 and 2008.  
 
Case definition 
 
Cases must have met the clinical criteria for an MPN (PV, ET or PMF), and received a 
diagnosis between the years 2001 and 2010.  They also had to be born between 1/1/ 1921 
and 12/31/1968 to be included.  The following case categorization for eligible cases was 
used in this analysis: all MPNs cases that provided a blood sample for genotyping (see 
Table 2.2).  Cases were identified from two sources.  First, from the Pennsylvania Cancer 
Registry (PCR) using the International Classification of Diseases codes (ICD-O) for 
MPNs (codes M-9950/3, M-9962/3, M-9961/3, and M-9931/3).  Second from a PV 
cluster investigation in 2009 (conducted by the Agency for Toxics Disease Registry 
(ATSDR)).  Cases not confirmed in the ATSDR study were reviewed by either the PA 
DOH expert panel or by a concurrent University of Pittsburgh expert panel funded by PA 
DOH described in Chapter 2. 
 
Controls selection 
Controls were selected from the source population in the tri-county area.  Selection was 
based on eligibility screening questions using random digit dialling.  Residents born 
from 1921-1968 and living in these one of the three counties were eligible.  A stratified 
random sample of controls was selected from the study area and was comparable to the 
population distribution described in the U.S. Census American Community Survey, 
2008. 
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Data collection 
We assessed lifetime residential, smoking, and dietary history by telephone interview.  
The two-phase consent required completion of the phone interview and a blood draw.  A 
$25 gift card was offered as an incentive for each phase (Gross-Davis, Chapter 3, 2013).  
A full description of the consent procedure is described in the role of genotypes that 
modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms 
study (Gross-Davis, Chapter 3, 2013).  
 
A one-time blood draw of peripheral venipuncture of 25-30ml of blood was required to 
get ample blood samples for JAK2 V617F mutation testing, gene susceptibility testing, 
storage, and possible future testing for biomarkers linked to MPN by other studies 
ongoing in the tri-county area (PV Partners studies).  Geisinger Health Systems collected 
the blood samples, and both Mt. Sinai and Geisinger Health Systems completed JAK2 
V617Ftesting. Columbia University Laboratory extracted the DNA and stored the 
samples.  A full description of the genotyping procedure used by Columbia University 
can be found in the original manuscript (Gross-Davis, Chapter 3, 2013).  
 
Distance to hazardous waste/waste-coal sites as a proxy for exposure 
calculation 
 
In order to test for joint effects of distance and susceptible genotype, proximity metric 
was employed.  This proximity metric uses distance as the exposure measure and is 
based on the assumption that people living closer to these hazardous waste sites and 
waste-coal plants with suspected emissions have higher exposures than those living 
farther away.  Each hazardous waste sites and waste-coal plants was analyzed separately 
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and stratified by two categories: <= 10 miles from the hazardous waste sites and waste-
coal plants, and > 10 miles from each hazardous waste sites and waste-coal plants.   
All distance calculations were geocoded using SAS 9.2 mapping function (GeoCode) for 
automated matching.  We used the residents’ current addresses obtained during the 
original study to get latitude and longitude for each location.  The first attempt to convert 
these addresses to a latitude and longitude was fairly successful.  For controls, we had an 
84.6% match of addresses to a latitude and longitude in the three counties, with the 
remaining 15.4 % matching at least for the zip code.  Similarly, our first attempt for 
addresses of cases, matched a latitude and longitude in the 3 county areas for 78.2% of 
the total sample with the remaining (21.8%) matching at least for zip code.  For cases 
that we could not obtain a latitude or longitude from SAS, we address-matched eight 
cases using Google Maps/Google Earth, found two others by using the US Postal Service 
website, and obtained the remaining two using the search engine Google.  For most 
addresses that did not match, the house address was incorrect although all zip codes 
were successfully matched 100% on the first pass.  Where the address obtained from the 
interview did not produce a latitude and longitude, we used the halfway point on street 
names to calculate distances to hazardous waste sites.  The latitude and longitude of the 
hazardous waste sites were inputted directly into SAS.  The CDC (via personal 
communication) gave us the waste-coal power plant latitude and longitude from an 
environmental assessment report that is going through peer review at the CDC.  The 
hazardous waste site latitude and longitudes were obtained directly from the 
Comprehensive Environmental Response, Compensation, and Liability Information 
System (CERCLIS) database, maintained exclusively by the US Environmental 
Protection Agency. 
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Data analysis 
Descriptive analysis was conducted for 31 cases and 273 controls on the characteristics of 
the study population.  SAS version 9.2 logistic regression was used to estimate adjusted 
odds ratios (aOR) and associated 95% confidence intervals (CI) adjusted for design 
variables only, case and sex.  To detect the potential for existence of gene-environment 
interaction, the main effects of genes and distance from hazardous wastes sites and 
waste-coal power plants (measure of exposure) were used.  The measure of distance was 
analyzed by a continuous variable for marginal effects of distance.  To test for joint 
effects of susceptible genotype and distance to hazardous wastes site or a waste-coal 
power plants distance was categorized as near (<= 10 miles) and far (>10 miles).  We 
then stratified these results by each genotype to explore interaction without an 
interaction term, because our sample size was insufficient to accurately estimate cross-
product interaction term in logistic regression.  In addition, analysis of the number of 
deleterious SNPs as a continuous variable was stratified by distance using as near (<= 10 
miles) and far (>10 miles), using logistic regression to estimate crude and adjusted OR s 
with 95% confidence intervals. 
 
Results 
Overall the distance from one of six hazardous waste/waste-coal power plants examined 
in this study was not related to MPN risk.   Approximately one quarter of the cases lived 
within 10 miles of Tonolli Corporation, McAdoo Associates or Eastern Diversified 
Metals, Northeastern Power Company, Westwood generation, and Wheelabrator 
Frackville Energy facilities (Table 4.2).   There is no suggestion in the data that an effect 
was missed using a 10-mile cut off as the near proximity as the mean distance for our 
cases and controls to each site did not dip below 17 .7 miles, with the 25th percentile for 
all cases between 8.8 miles and 23.4 miles away, and 11.1 to 26.8 miles away for controls 
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(Table 4.3).  When all facilities were including in the analysis for living <=10 miles to 
each site was analyzed, there was not much change to the effect estimate, as so few cases 
live near any of these hazardous waste site or waste coal power plants (results not 
shown). 
 
We also examined the effects of residential proximity to three waste-coal plants 
Northeastern Power Company, Westwood Generation, and Wheelabrator Frackville 
Energy and three hazardous waste sites, Tonolli Corporation, McAdoo Associates and 
Eastern Diversified Metals on MPN risk in a three county area (Table 4.2).  There was a 
slight effect detected for all sites except Westwood generation, with no cases living within 
10 miles from the site and no effect was observed for Wheelabrator Frackville Energy, 
(aOR=0.96, 95% CI:0.2, 3.7).  Overall distance to any one of the six hazardous 
waste/waste-coal plants adjusted for age and sex were generally unimpressive.   
 
All three hazardous waste sites showed similar effects, (EDM aOR=1.3, 95% CI: 0.5, 3, 3; 
McAdoo Associates with aOR= 1.5, 95%, CI: 0.6, 3.8 and Tonolli Corporation with an 
aOR= 1.4, 95%CI: 0.5, 3.9), although none reached a magnitude to elicit concern and 
were imprecise. We observed the strongest effect estimate from people living less than or 
equal 10 miles from the Northeastern Power Company, with an aOR=1.6, 95% CI: 0.64, 
4.0). 
 
Susceptible genotype stratified by distance 
We explored nine specific genotypes in this study. Data describing these genotypes 
stratified by distance are presented in Table 4.3.  When we looked at each risk genotype 
by distance category, the effect was not consistent, thus greater in some of the genotypes 
but not for all, compared to looking at the distance only model in Table 4.2.  For AHR, 
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GSTA1, GSTM3, and GSTT1 and TP53, these results were not consistent, oscillating back 
at forth around the null for distances less than or equal to 10 miles with overlapping 
confidence intervals.  The results were not the same for greater than 10 miles for all these 
SNPs.  These dramatic swings in point estimates of the effect are due to small differences 
is the number of cases and controls living less than or equal to 10 miles from any 
particular hazardous waste/waste-coal plants, as shown in Table 4.1.  
 
CYP1A2  
CYP1A2 provided a steady effect estimate in the same direction with from a 2 – 20 fold 
increase of risk of an MPN for both distance categories, although it was very imprecise.  
For resident living <=10 miles of EDM, we also found close to 20 fold increase aOR=21 
(95% CI: 0.6, 710) for CYP1A2 and for greater than 10 miles from Tonolli Corporation an 
aOR of 3.0 (95% CI: 0.8, 11).  Specifically for residents harboring the CYP1A1 genotype 
and living > 10 miles from Tonolli Corporation, aOR=4.9 (95% CI: 1.4, 17.0), adjusted for 
age and county was detected however, the model failed to converge for the<= 10 miles 
category.  Residents living near McAdoo, saw a similar effect size aOR=19 (95% CI: 0.6, 
60) to EDM.  
 
CYP1E2 
Tonolli Corporation as well as Northeastern Power Company both showed an 8-fold 
increase for those subject who have the as risk allele for CY1E2 aOR=7.8 (95% CI: 
0.7,80) and aOR=8.2 (95% CI: 0.3, 189) adjusted for age, and sex respectfully.   
 
GSTM1, GSTA1, GSTM3 
GSTM1 showed consistently a 2-3-fold increase of risk of an MPN for both near and far 
distance.  We observe an adjusted OR of 2.9 (95% CI: 0.4,19.7) for residents living within 
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10 miles of the McAdoo Associates site, as well as an adjusted OR of 1.8 (95% CI:0.7, 4.7) 
for residents living greater than 10 miles from the McAdoo Associate site.  The trend was 
similar for all hazardous waste sites and waste-coal power plants for GSTM1 null 
genotypes.  For GSTM3 at risk genotypes, an effects estimate of 1 to 1.9 was observed 
only in residents living greater than 10 miles from the Tonolli Corporation site. 
 
NAT2 
Similarly for NAT2 slow acetylator subject living > 10 miles from Westwood Generation 
waste-coal power plant, we found an aOR=3.0 (95% CI: 1.1, 7.7) adjusted for age and sex, 
but the model also failed for residents living less than or equal to 10 miles from this 
plant. 
 
Discussion 
While the gene only results did not confirm a gene-environment interaction effect, it did 
offer the opportunity to explore the joint effects of using distance as a proxy for exposure 
with respect to NAT2, GST, and CYP gene and additional AHR, TP53 biological pathway 
and chemical exposures.  
 
Although our results for genotypes associated with modifying benzene exposure is 
consistent with the suggestion by the Schnatter, et al., results for MDS cumulative 
exposure to benzene OR= 4.33 (95% CI: 1.31, 14.3) and 30 MPD cases (OR=1.79, 95% CI: 
0.68, 4.74) (Schnatter, et al., 2012), the cases from both studies are diagnosed with 
different ICD-O coded diseases.  This pooled analysis might have been more useful to 
our study, if when cases (medical records) were reviewed by the hematologists in the 
study, that the WHO 2008 classifications were also used for additional case 
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categorizations.  The misclassification of this classis group of MPNs, still provided 
potential bias in their analysis (Miller, et al., 2010). 
 
An expected limitation of using residential proximity (distance) for the estimated 
exposure is the relevant time frame this represents.  In addition, proximity to hazardous 
waste/industrial sites could indicate multiple chemicals not accounted for in this 
analysis.  All these sites do have potential emissions/releases of chemicals with potential 
mutagenic and/or genotoxic effects. 
 
A potentially more serious problem was the small numbers of "highly exposed" subjects 
in some of the analysis, especially when considering specific industries.  The sample size 
was maximized and distance was used as a continuous measure as opposed to exposed 
and unexposed.  This assumption was critical for our focus which included susceptible 
genotypes where are all cases are considered “exposed” to some amount, but none to 
zero exposure to these ubiquitous chemicals.  This assumption, however might have 
affected usefulness of proximity to these facilities as a measure of exposure.  
 
Residential proximity to a hazardous waste site or an active waste-coal power plant does 
not, alone, indicate exposure, and acknowledging that distance can only weakly 
approximate dose.  Although we did have a mechanism for validating actual distances of 
current addresses using the SAS mapping function, we did not validate actual individual 
exposure since no individual pollutants were identified or measured for this analysis.  
Nonetheless, there was the suggestion of a gradient with distance from reported 
industries.  We did not analyze the duration of residence used in the calculation, as our 
previous findings concerning residence time were not useful.  Thus, it is possible that the 
number of years living in a particular residence could lead to higher exposure than our 
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basic model.  We did not attempt to aggregate durations of exposures to multiple 
industries.  Instead, we evaluated the distance of residence near the each hazardous 
waste site individually.  
 
Our response rate from MPN cases was small and the request for cases to consent to a 
bio-sample could have contributed to this.  This may be a concern for bias.  However, our 
randomized selection of controls for the tri-county area attempted to minimize any 
concern for bias.  We had a 1 to 9 ratio of cases and controls to gain a representative 
comparison population and distribution of genotypes among controls is as can be 
expected in the source population with no significant demographic differences observed 
between case and controls that consented to genotyping and those who did not. 
 
The latency period between possible exposures related to the development of an MPN is 
currently unknown, which complicates identification of potential risk factors when the 
timeframe of effective exposure is not clearly defined.  So using current residence does 
attempt to capture exposure during an unknown window and was used as a simple 
approach to investigate these joint effects.  
 
A strength of the study was the high percentage of cases and controls that were 
successfully geocoded on the first attempt.  Errors were typically due to spelling or 
missing house numbers but there was also perfect matching for zip code for cases and 
controls.  This study was also able to capitalize on the ability to test for JAK2 V617F 
mutation molecular testing to reduce case misclassification that is a concern with MPN 
research.  
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Our study did not showed any consistent relationship with MPNs and joint effects of 
proximity to known hazardous waste site and waste-coal power plants and 
environmentally sensitive genotypes, and the results we did observe were very imprecise.   
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Table 4.1 Distance rounded to the nearest mile for cases and controls to each hazardous/waste-coal site 
 
 EDM McAdoo Northeastern 
Power 
Company 
Tonolli 
Corporation 
Westwood 
Generation 
Wheelabrator 
Frackville Energy 
 Cases 
n=25 
Control 
n=292 
Cases 
n=25 
Control 
n=292 
Cases 
n=25 
Control 
n=292 
Cases 
n=25 
Control 
n=292 
Cases 
n=25 
Control 
n=292 
Cases 
n=25 
Control 
n=292 
             
Mean 17.9 20.7 16.8 19.35 17.7 20.3 18.4 21 36.2 37.9 21.1 23.7 
Minimum 2.4 1.1 3.0 1.5 2.2 4.9 5.5 1.2 10.5 4.8 2.6 2.8 
25th 
percentile 
10.4 12.7 8.8 11.1 9.8 11.6 9.7 12.4 24.3 26.8 10.7 12.9 
Median 16.8 18.6 18.8 18.9 15.2 18.1 19.3 21.6 38.4 39.4 20.1 21.8 
75th 
percentile 
26.3 30.2 30.2 27.1 24.8 29.4 26.0 28.9 49.1 53 31 35.9 
Maximum 36.5 40.6 40.6 37.4 36.2 40.0 33.9 40.4 60.2 63.2 43.1 46.6 
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Table 4.2  Number and frequency of cases and controls with residence near (<= 10 miles) and far (> 10 miles) to Hazardous waste site / waste-coal power plant 
 
Hazardous waste 
site / waste-coal 
power plant 
Number and frequency (%) 
Residence < =10 miles 
Number and frequency (%) 
Residence >10 miles 
Over continuous distance 
measured in miles 
Residence < =10 miles 
 Cases 
n=25 
Controls 
n=292 
Cases 
n=25 
Controls 
n=292 
OR 
(95 % CI) 
Adjusted OR1 
(95 % CI) 
OR 
(95 % CI) 
Adjusted OR1 
(95 % CI) 
EDM 7 (22.5) 48 (16) 24 (77) 244 (83) 0.97 
(0.93, 1.0) 
0.97  (0.93, 1.0) 1.48 
(0.6, 3.6) 
1.3  (0.5, 3.3) 
McAdoo 9 (29) 57 (19.) 22 (70) 235 (80) 0.97 
(0.93, 1.0) 
0.96  (0.93, 1.0) 1.68 
(0.7, 3.8) 
1.5  (0.6, 3.8) 
Northeastern 
Power 
Company 
8  (25) 46  (15) 23  (74) 246   (84) 0.97 
(0.93, 1.1) 
0.97  (0.93, 1.0) 1.86 
(0.78, 4.4) 
1.6  (0.64, 4.0 ) 
Tonolli 
Corporation 
8 (25) 52 (17) 23 (74) 240 (82) 0.97 
(0.93, 1.1) 
0.97  (0.93, 1.1) 1.6  (0.6, 3.7) 1.4  (0.5, 3.9 0 
Westwood 
Generation  
0   (0) 9   (3) 31  (100) 283   (97) 0.99 
(0.97, 1.0) 
1.0  (0.96, 1.0) - - 
Wheelabrator 
Frackville Energy 
7  (22) 55  (19) 24  (78) 237   (82) 0.98 
(0.95, 1.0) 
0.99  (0.94, 1.0) 1.25  (0.5, 
3.0) 
0.96  (0.25,3.7) 
1. Odds ratio adjusted for age and sex and frequency in % 
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Table 4.3  Logistic regression gene and distance to Hazardous/Industrial Site stratified by near (<= 10 miles) and far (>10 miles)  (cont’d) 
 
 
Gene 
 
 
Hazardous waste site/ 
waste-coal power plant 
Residence < =10 miles Residence >10 miles 
    
OR (95% CI) Adjusted OR 1 
(95% CI) 
OR (95% CI) Adjusted OR 1 
(95% CI) 
AHR      
 EDM 0.5   (0.05, 5.0) 0.05  (0.05, 6.2) 1.0  (0.3, 2.9) 1.1  (0.3, 3.3) 
 McAdoo 0.4  (0.04, 3.6) 0.5  (0.05, 6.2) 1.1  (0.4, 3.3) 1.2  (0.4, 3.7) 
 Northeastern Power Company 0.3  (0.04, 3.6) 0.3  (0.03, 3.7) 1.1  (0.4, 3.2) 1.2  (0.4, 3.7) 
 Tonolli Corporation 0.5  (0.06, 5.3) 0.7  (0.06, 8.5) 1.0  (0.3, 2.9) 1.2  (0.4, 3.5) 
 Westwood Generation - - 0.8  (0.3, 2.2) 0.9  (0.3, 2.8) 
 Wheelabrator Frackville Energy 0.5  (0.05, 4.7) 0.5  (0.04, 5.5) 1.0  (0.3, 2.9) 1.1  (0.3, 3.2) 
CY1A2      
 EDM 7.8  (0.4, 142) 20.9  (0.6, 710) 2.5  (0.7, 8.1) 3.0  (0.8, 10.7) 
 McAdoo 3.4  (0.2, 42.4) 15.0  (0.6, 345) 2.8  (0.8, 9.3) 3.4  (0.9, 12) 
 Northeastern Power Company 3.1  (0.2, 39.4) 5.6  (0.6,50) 2.8,  (0.8, 9.2) 2.9  (0.7, 11.8) 
 Tonolli Corporation - - 3.2  (1.0, 9.6) 4.9  (1.4, 17.0) 
 Westwood Generation - - 2.8,  (0.97, 8.2) 3.5  (1.1, 11.2) 
 Wheelabrator Frackville Energy 4.0  (0.6, 26.2) 5.6  (0.6, 50) 2.0  (0.6, 8.5) 2.99  (0.7, 12.2) 
CY1E2      
 EDM 2.4  (0.2, 27.4) 2.9  (0.2, 42.3) 1.1  (0.1, 9.2) 1.2  (0.1, 10.9) 
 McAdoo 1.5  (0.1, 16.1) 2.1  (0.1, 30.8) 1.3  (0.1, 11.1) 1.5  (0.1, 13.6) 
 Northeastern Power Company 3.0  (0.2, 37.6) 2.3  (0.1, 32.8) 1.0  (0.1, 8.6) 1.2  (0.1, 10.4) 
 Tonolli Corporation 5.3  (0.7, 38.6) 7.8  (0.7, 80.8) - - 
 Westwood Generation - - 1.68  (0.3, 7.9) 2.0  (0.4, 10.2) 
 Wheelabrator Frackville Energy - - 1.6  (0.3, 37.9) 1.6  (0.3,8.3) 
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Table 4.3  Logistic regression gene and distance to Hazardous/Industrial Site stratified by near (<= 10 miles) and far (>10 miles)  (cont’d) 
 
 
Gene 
 
 
Hazardous waste site/ 
waste-coal power plant 
Residence < =10 miles Residence >10 miles 
    
OR (95% CI) Adjusted OR 1 
(95% CI) 
OR (95% CI) Adjusted OR 1 
(95% CI) 
GSTA1      
 EDM 0.5  (0.06, 5.1) 0.6  (0.6, 6.2) 2.8  (1.1,7.0) 2.0  (0.7, 5.2) 
 McAdoo 1.1  (0.2, 6.5) 0.9  (0.1, 6.1) 2.6  (1.0, 6.6) 1.8  (0.6, 4.9) 
 Northeastern Power Company 0.9  (0.1, 5.3) 3.3  (0.5, 20.6) 2.6  (0.1, 6.7) 1.3  (0.4, 3.4) 
 Tonolli Corporation 1.4  (0.2, 7.9) 1.1  (0.1, 7.2) 2.4  (0.9, 6.1) 1.7  (0.6, 3.9) 
 WPS - - 2.0  (0.9, 4.6) 1.4  (0.7, 3.9) 
 Wheelabrator Frackville Energy 5.1  (0.9, 27.9) 3.3  (0.5, 20.6) 1.7  (0.6, 4.3) 1.4  (0.5, 3.9) 
GSTM1      
 EDM 2.3  (0.4, 13) 2.2  (0.3, 15) 2.1  (0.8, 5.2) 2.0  (0.8, 5.2) 
 McAdoo 3.1  (0.6, 16.4) 2.9  (0.4, 19.7) 1.8  (0.7, 4.7) 1.8  (0.7, 4.7) 
 Northeastern Power Company 2.7  (0.5, 15.0) 2.3  (0.4, 13.6) 1.9  (0.7, 5.0) 1.8  (0.7, 4.8) 
 Tonolli Corporation 2.0  (0.3, 11.0) 2.0  (0.3, 12.9) 2.1  (0.8, 5.3) 2.0  (0.8, 5.3) 
 Westwood Generation - - 2.1  (0.9, 4.8) 2.0  (0.8, 4.6) 
 Wheelabrator Frackville Energy 2.5  (0.4, 14.0) 2.3  (0.3, 14.0) 2.0  (0.8, 5.1) 1.8  (0.7, 4.7) 
GSTM3      
 EDM 0.8  (0.1, 4.3) 0.9  (0.1, 5.2) 1.4  (0.6, 3.4) 1.4  (0.5, 3.4) 
 McAdoo 0.6  (0.1, 3.0) 0.7  (0.1, 3.9) 1.7  (0.6, 4.5) 1.7  (0.6, 4.6) 
 Northeastern Power Company 0.7  (0.1, 3.6) 0.7 (0.1, 3.6) 1.6 (0.6, 3.9) 1.5  (0.6, 3.9) 
 Tonolli Corporation 0.3  (0.6, 1.9) 0.4  (0.07, 2.3) 2.0  (0.7, 5.0) 1.9  (0.7, 5.0) 
 Westwood Generation - - 1.2  (0.5, 2.6) 1.2  (0.5, 2.7) 
 Wheelabrator Frackville Energy 2.8  (0.4, 15.7) 2.6  (0.4, 16.6) 1.0  (0.4, 2.3) 1.0  (0.4,2.5) 
GSTT1      
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Table 4.3  Logistic regression gene and distance to Hazardous/Industrial Site stratified by near (<= 10 miles) and far (>10 miles)  (cont’d) 
 
 
Gene 
 
 
Hazardous waste site/ 
waste-coal power plant 
Residence < =10 miles Residence >10 miles 
    
OR (95% CI) Adjusted OR 1 
(95% CI) 
OR (95% CI) Adjusted OR 1 
(95% CI) 
 EDM 1.0  (0.1, 6.2) 0.7  (0.1,4.9) 0.9  (0.2, 3.2) 0.9  (0.2, 3.6) 
 McAdoo 0.8  (0.1, 4.2) 0.6  (0.9, 3.8) 1.0  (0.2, 3.7) 1.0  (0.2, 4.0) 
 Northeastern Power Company 1.2   (0.2, 6.8) 0.8  (0.1, 5.4) 0.8  (0.2, 3.0) 0.9  (0.2, 3.5) 
 Tonolli Corporation 0.2  (0.03, 2.5) 0.2  (0.02, 2.6) 1.5  (.4, 4.7) 1.4  (0.4, 4.8) 
 Westwood Generation - - 1.0  (0.3, 2.9) 0.9  (0.2, 2.7) 
 Wheelabrator Frackville Energy 1.1  (0.1, 10.7) 0.7  (0.05,9.3) 1.0  (0.3, 3.1) 0.9  (0.2, 3.0) 
NAT2      
 EDM - - 2.2  (0.8, 5.8) 2.0  (0.7, 5.4) 
 McAdoo - - 2.0  (0.7, 5.4) 1.9  (0.7, 5.3) 
 Northeastern Power Company 5.1  (0.5, 45.1) 4.6  (0.4, 51.9) 2.7  (1.0, 7.7) 2.5  (0.9, 7.8) 
 Tonolli Corporation - - 2.0  (0.7, 5.4) 1.9  (0.7, 5.2) 
 Westwood Generation - - 3.2  (1.3, 8.2) 3.0  (1.1, 7.7) 
 Wheelabrator Frackville Energy 3.7  (0.4, 32.9) 4.6  (0.4, 45) 3.0  (1.1, 8.4) 2.7  (0.9, 7.3) 
p53      
 EDM 0.4  (0.7, 2.2) 0.3  (0.05, 2.0) 1.8  (0.7, 4.2) 1.8  (0.7, 4.4) 
 McAdoo 0.2  (0.05, 1.4) 0.1  (0.02, 1.2) 2.3  (0.9, 5.7) 2.2  (0.8, 5.7) 
 Northeastern Power Company 0.6  (0.12, 2.8) 0.5  (0.09, 3.3) 1.6  (0.7, 3.9) 1.9  (0.6, 3.9) 
 Tonolli Corporation 0.3  (0.07, 2.1) 0.2  (0.03, 1.4) 1.9  (0.8, 4.6) 1.9  (0.7, 4.7) 
 Westwood Generation - - 1.2  (0.6, 2.7) 1.2  (0.5, 2.6) 
 Wheelabrator Frackville Energy 2.9  (0.5, 16.2) 2.2  (0.3, 13.9) 1.0  (0.4, 2.4) 1.0  (0.4, 2.5)
1. Odds ratio (OR) adjusted for age and sex and 95% confidence intervals
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Chapter 5: Summary of Findings 
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Objectives of this dissertation 
The objective of this dissertation was to investigate associations between effects of 
environmental risk factors (including risks associated with aromatic and heterocyclic 
amines) and gene-environment interactions on MPNs and JAK2 V617F mutation.  This 
was accomplished through three specific aims:  
 
1.  evaluate the associations between lifestyle and environmental risk factors for the 
most common MPNs and JAK2 V617F  with a diagnosis of MPN 
2. explore an interaction between known susceptible genotypes for a subset of cases 
and controls and potential mutagenic chemical exposures, including PAHs 
3. explore the joint effects of susceptible genotypes identified in Aim 2 and distance of 
residence from facilities with known hazardous emissions risk of MPNs.  
 
In our study population the cases were older (median age=71 vs. 61yrs) and more likely 
to be male (49% vs. 39%) compared to controls, but they were otherwise 
demographically similar.  Our sample was overwhelmingly Caucasian and none of the 
cases and few (2%) controls were of Jewish ancestry.  All but one control were born in 
the US.  Two-thirds of the subjects were married at the time of the interview.  More cases 
than controls were retired (63% vs. 42%).  Our study had a low response rate. This was 
surprising given the media coverage and the area’s commitment to request and receive 
the CDC funding.  Only 27% of cases consented for the telephone interview and only 56 
% of those also consented to the optional blood draw.  Our controls were slightly better, 
at 41% (which is fair for a Radom Digit Dialling protocol to recruit controls), with 61% of 
those also consenting for the blood draw.  
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The first aim focused on estimation of exposure to PAH as a risk factor for MPNs with 
and without the JAK2 V617F  mutation.  We found no relationships between MPNs and 
diet, lifestyle behaviors with presumed exposure to aromatic and heterocyclic amines, 
and residential history.  This is the first study, to our knowledge, to look at PAH 
exposure from diet and smoking and the risk of developing an MPN. 
 
Our analysis of smoking consistently refuted the existence of a positive association, with 
very small numbers for cases who smoked.  We found an aOR of 0.8 (95% CI: 0.4, 2.0) 
for all MPN cases who were heavy smokers (n=5) and for JAK2- cases alone we found an 
aOR of 0.2 (95% CI: 0.0, 1.4), with only one case.  
Our analysis with smoking was consistently null.  Our findings do not support an 
association between PAHs and an increased risk of getting an MPN, with the null result 
for exposure to cigarette smoke (rich in PAH) providing the most convincing evidence.  .  
No other differences in smoking, home, eating char grilled beef, pork, or chicken or, and 
recreational activities, between the two groups.This finding of no association is 
important and should point future research toward better assessments of other 
ubiquitous mutagenic chemicals, including chemicals such as benzene.  In Aims 2 and 3, 
exposure was to benzene was considered by including susceptible genotypes that modify 
exposures to benzene.  We considered benzene in our study; however, we only included 
susceptible genotypes that modify exposures to benzene—we did not study the exposure 
itself except for self reported exposures.  
 
In the second aim of this dissertation, we explored the potential gene-environment 
interactions in the etiology of MPNs and JAK2 V617F using a biological-pathway 
candidate-gene approach for mutagenic chemicals. 
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After studying the main effects of 14 environmentally sensitive genes, we found 
associations only with the NAT2, CYP1A2, GSTA1, and GSTM3 variants, with an average 
of 3- to 5-fold increased odds of having an MPN.  Our assumption is that a main gene 
effect without exposure is unlikely, based on the biological pathway for disease therefore 
these findings suggest gene-environment interaction. 
 
We also had some interesting findings surrounding our analysis of variants that modify 
enzyme function thereby magnifying the effect of the xenobiotic substrate supporting our 
MPN hypothesis concerning specific genotypes typically associated with benzene 
exposure.  We detected a 2-fold increase for CYP2E1 and GSTM1 null genotypes and an 
8-fold increase for the tumor suppressor gene TP53.  There is a growing body of 
literature suggesting hematopoietic stem-cell toxicity potential (Hirabayashi, 2005).  All 
but one case harbored at least one deleterious (meaning environmentally sensitive) SNP 
30/31, with an adjusted OR of 10 (95% CI: 1.3, 79).  For having two of these four 
compared to none, we found an adjusted OR of 15 (95% CI: 1.7, 123).  For anyone with 
three of the four (4/31 cases), we found an adjusted OR of 43 (95% CI: 4.0, 469). 
 
In this study, we use known biological pathways and candidate-gene polymorphisms 
such as the GSTM3, CYP1A2, and NAT2 gene, these genes modify environmental 
exposures due to increased ability to metabolize or decreased ability to detoxify the 
chemical.  Since this is the first study to explore genetic polymorphisms and MPNs, these 
findings can help target future studies where only ecological environmental exposure 
(not individual exposure) data is available, with both disease and genotype data.  Future 
research in the pathways affected by the NAT2, GST, and CYP genes may be fruitful 
avenues to better assess potential exposures and their association with MPNs. 
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The joint effects of susceptible genotypes and distance of current residence 
from facilities with known hazardous emissions 
 
In the final aim of this dissertation, we studied the joint effects of susceptible genotypes 
and distance of current residence from facilities with known hazardous emissions on risk 
of myeloproliferative neoplasms. 
 
The overall age and sex adjusted odds ratio for distance to any one of the six hazardous 
waste/waste-coal plants generally did not detect an elevated risk of MPNs with distance 
to these sites.  All three hazardous waste sites showed similar effects  Eastern Diversified 
Metals with an aOR of 1.3, 95% CI: 0.5, 3,3; McAdoo Associates with aOR of 1.5, 95%, CI: 
0.6,3.8; Tonolli Corporation with an aOR of 1.4, 95% CI: 0.5, 3.9).  We observed the 
strongest effect estimate from people living less than or equal to 10 miles from the 
Northeastern Power Company, with an aOR of 1.6 (95% CI: 0.64, 4.0), while none were 
of a magnitude to raise concern. 
 
We also examined nine genotypes that suggested a signal when we looked at each risk 
genotype by distance category, the effect was not consistent. It was greater in some of the 
genotypes but not for all, compared to looking at the distance-only model in Table 4.3.  
The results for AHR, GSTA1, GSTM3, GSTT1, and TP53, were fluctuating around the null 
with overlapping confidence intervals for distances less than or equal to 10 miles.  For 
distances greater than 10 miles, we saw a trend with a positive association for most 
SNPs.  These dramatic swings in point estimates of the effect may be due to differences 
in the number of cases and controls living less than or equal to 10 miles from any 
particular hazardous waste/waste-coal plants.  Our study did not show any consistent 
relationship with MPNs and joint effects of proximity to known hazardous waste site and 
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waste-coal power plants and environmentally sensitive genotypes, and the results we did 
observe were very imprecise.   
 
Public health significance 
This research intends to help focus future research to refining exposure assessments and 
yield relevant insights to environmental exposures and risk of MPNs.  This dissertation 
was designed to explore the environmental etiology of polycythemia vera, essential 
thrombocythemia, and primary myelofibrosis.  Results from this dissertation add to the 
limited amount of epidemiological studies looking at environmental exposures as risk 
factors to MPNs.  Hopefully, it will encourage further research for chemical exposures as 
well as susceptible genotypes for these diseases.
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        Drexel University Case-Control Study Northeast Pennsylvania 
Telephone Questionnaire Content for CATI phone script 
February 2011 
 
[Interviewer script in italics] 
 
Greet:  Hello, my name is XXX and I am calling from the Center for Health Research 
at Geisinger. 
 
Hello:  Map I please speak to XX? 
 
Greeting: Hi Mr./Ms. my name is[  and I am calling] from  The Center for Health 
Research at Geisinger.  I am calling to conduct the phone survey for the Drexel 
University School of Public Health – Polycythemia Vera Cluster research study – is 
this a convenient time? 
 
If no, reschedule day and time:  
 
Participant Name:  
 
Last: __________________   Middle: ______________   First: ______________ 
 
Male___ 
Female___ 
 
Telephone:   _________________ 
 
 
 
Date of Interview: /__/__/ /__/__/ /__/__/__/__/     
(Month) (Day) (Year) 
 
 
Standard codes for Yes/No questions: 
1: Yes 
2: No 
997: Don’t know (DK) 
998: Decline to answer (Ref) 
999: Missing data 
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Introduction: Good! During this interview, I will ask you some questions about 
yourself and your family. Some questions may ask about personal information ---- I 
want to remind you that all of your answers will be kept strictly confidential. The 
information you and others provide is very important to this study.  
 
For all questions, answer to the best of your ability, and if you cannot recall or are 
unsure of an answer, please say “I cannot remember or I don’t know”. Ask me to 
repeat any question that you didn’t hear or understand. You may refuse to provide an 
answer to any question – we’ll simply continue on to the next question.  
 
The survey will take between 45 minutes to 1 hour to complete. Please let me know at 
any time if you need to take a short break.   
 
[Note to interviewer] All questions are for the time period: after respondent left 
school or completed education up to the present day with the following exceptions: 
medical conditions history (as specified in section) and residence history (after age 
21).  
 
 
First, I would like to capture your e-mail address in case we need to send you 
information later in the study.   Thank you.  Now, I would like to ask you some 
question about your place of birth and ethnic background 
 
1. Background and Demographics 
First, I’m going to ask some questions about your place of birth and ethnic 
background.  
 
1-1 What is your age? 
 
1-2 And your date of birth? (mo/day/yr):  
 
1-3 Where were you born?  
 
City/State (USA)  ______________ 
 
OR 
 
Country of Birth:______    Year moved to U.S.A._______ 
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1-4.  And what do you consider to be your race or ethnic group? If you belong to 
more than one group, please tell me all the groups you belong to.  
 
White or European American       1 
Black, African American, or African ancestry    2 
Latino/Latina or Hispanic (not including European 
Spanish or Portuguese)      3 
Native American, Alaskan native, or indigenous people    4 
Asian or Pacific Islander        5 
Other (specify: _______________________________________)  6 
Ref          99 
 
For 1-4: If answered “1” ask 1-5 through 1-7: 
If did not answer “1”, skip to 1-8 
 
1-5. What is your father’s ethnic background? [interviewer: asking for 
heritage/nationality, limit two (paternal grandparents)] 
Verbatim: 
DK    98 
Ref    99 
 
1-6. What is your mother’s ethnic background? [interviewer: asking for 
heritage/nationality, limit two (maternal grandparents)] 
Verbatim: 
DK    98 
Ref    99 
 
Continue probe for: 
1-7.  Do you have a Jewish ancestry? 
   Y/N/DK/Ref 
 
1-8. What is the highest level of education you completed?  
 
Less than high school,       1 
High School/GED,            2 
Some college,                    3 
Bachelors degree,              4 
More than Bachelors.        5 
Ref                                    99 
 
1-9. What is your current marital status?  
 
Married           1   
Widowed          2 
Currently Single         3 
Ref           99 
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1-10. Please describe your annual household income from all sources..is it: 
 
Less than $20,000      1 
Between  $20,000 and $35,000    2 
Between  $35,000 and $50,000    3  
Between  $50,000 and $75,000    4 
$75,000 or more?      5 
DK        98 
Ref        99 
 
 
 
 
 
 
Next, I would like to review the residence and job history forms that we mailed to you 
in the original study packet. Could you get these out now?  
 
Section 2 Interviewer Assisted Review of Mail-out Questionnaire Forms. 
 
2-1. Residence History  
 
I’d like to ask you to list each primary residence you’ve lived in for 6 months or 
longer, starting with your current residence (#1) and working backwards to age 21.  
 We will start with your current residence even if you have lived there for less than 6 
months. Please give me the address information to the best of your recollection, even 
if you don’t have a complete address or ZIP Code. Please estimate the time period if 
you cannot remember exact dates. 
 
Key for residence description: 
1) Single Family Home   
2) Apartment  
3) Condominium/Townhouse  
4) Farm (please specify type: dairy, livestock, cash crops, etc.)  
5) Mobile Home 
6) Other (please specify)  
 
Residence 
number 
Time 
period 
 
Mo/Yr to 
Mo/Yr 
Street 
Address 
City/Town State 
and 
ZIP 
Code
How 
would you 
best 
describe 
this 
residence? 
(see key 
above) 
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[Intervie
wer: 
after 
completi
ng each 
line, 
say, 
Thank 
you.  
Now 
still 
working 
backwar
ds, was 
there 
another 
residenc
e that 
you lived in more than six months, going back when you were 21 years old.    
1 
 
(Current) 
 
 
 to 
    
2 
 
 
 
 
 to 
    
3 
 
 
 
 
 to 
    
4 
 
 
 
 
 to 
    
5 
 
 
 
 
 to 
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Thank  you.  We willl continue now with a set of questions for each residence you 
just provided me. 
  
Residence-specific questions (numbered consecutively for each residence) 
 
Water and Heating sources 
Current Address first: 
[Note to Interviewer: Ask the following questions for each residence of 
respondent. Start with current residence (1), and then continue in a reverse 
chronological order according to respondent’s residence list. Maintain number 
coding for each residence: 1, 2, 3, etc.] 
 
Example: Res1_1, Res1_2 …. Res1_22; then continue with Res2_1, Res2_2 … 
Res2_22, etc. 
 
Let me first ask about your [R1] current residence at [interviewer state street 
address]. Use “Since you moved here…” for current address questions. 
 
 
[Interviewer: mark all that apply if applicable] 
Res(#)_1. What is your main [source] of household water? 
 
Municipal Water 1   Private well     2 
River/lake/pond  3                                 Rainwater/cistern         4 
Other   5 
Don’t know                 98   Refused                       99 
 
Res(#)_2. What type of water do you use for drinking? (allow multiple 
answers) 
Tap water - unfiltered  1 
Tap water - filtered  2 
Spring water/bottled water 3 
Well water   4 
Other    5 
Don’t Know   98 
Refused   99 
 
Res(#)_3. What type of water do you use for cooking? 
Tap water - unfiltered  1 
Tap water - filtered  2 
Spring water/bottled water 3 
Well water   4  
Other    5 
Don’t Know   98 
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Refused    99 
 
 
 
Res(#)_4. What are the major sources of heat for this home? (allow multiple 
answers) 
Electricity   1 
Natural Gas/Propane  2 
Kerosene   3 
Fuel Oil   4 
Coal     5 
Wood    6 
Other    7 
DK    98 
Ref    99 
 
Res(#)_5. What fuels do you use for cooking? (allow multiple answers) 
Electricity   1 
Natural Gas/Propane  2 
Kerosene   3 
Fuel Oil   4 
Coal     5 
Wood    6 
Other    7 
DK    98 
Ref    99 
 
 
Res(#)_6. Do you store any of the following fuels in any room or basement or 
in an attached garage or carport? 
Y/N/DK/Ref 
Gasoline        1 
Diesel Fuel        2 
Kerosene        3 
Solvents, turpentine or paints      4 
Other fuel oils        5 
 Verbatim: ________ 
DK         98 
Ref         99 
 
[Probe for each “yes” to 6; if “no” to 6 skip to 8] 
Res(#)_7. About how much do you generally store? Please estimate the size of 
the container(s) in ounces or gallons.  
 Number of ounces ____  OR 
 Number of gallons _____ 
 DK    98 
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 Ref    99 
 
Res(#)_8. Do you burn your trash or yard clippings?   
Y/N/DK/Ref 
 
Res(#)_9. [If yes to 8] How often did you burn your trask or yard clippings?  
 
Weekly         1 
Monthly/    2 
Yearly (few times a year or less)   3 
Don’t know     98 
Ref     99 
 
Location near potential contamination/hazardous sites 
 
Res(#)_10. Do you live within ½ mile (or 10 blocks) of any of the following 
types of facilities: 
 
Y/N/DK/Ref to each 
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Contact with Soils and Garden  
 
 
Res(#)_11   When you lived at ____ in ___, did you grow any fruits or 
vegetables in your yard or in a garden? 
Y/N/DK/Ref 
[If yes, continue to Res_12] 
[If no, skip to question Res_15] 
 
Res(#)_12 Have you eaten fruits and vegetables grown from your garden 
(yard)? 
Y/N/DK/Ref 
[If yes, continue to Res_13 and 14] 
[If no, skip to question Res_15] 
 
Res(#)_13 During the growing season, how often did you eat those home-
grown fruits and vegetables?  
Site If yes, site name 
if known 
Additional Probe 
1 Dump/landfill   
2 Hazardous waste site   
3 Airport   
4 Farm  If yes, what type? (a 
dairy, b livestock, c 
cash crops, d non-
working, e other) 
 
5 Nursery/greenhouse   
6 Golf course   
7 Railroad track used by train   
8 Gas station   
9 High voltage electricity tower 
 
  
10 Incinerator 
 
  
11 Factory/industrial plant 
 
  
12 Quarry/mine 
 
  
13 Coal fired power plant 
 
  
14 Nuclear power plant 
 
  
15 Other 
 
 If yes, [verbatim] 
specify: 
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Daily/Weekly     1 
Less than once per month   2 
Don’t know      98 
Ref      99 
 
Res(#)_14 How regularly did you wash the vegetables and/or fruit before you 
eat/cook them? 
 
Never   0 
Sometimes  1 
Always  2 
DK   98 
Ref   99 
 
Now I’m going to ask about yard and garden work for [re-state residence]. 
 
Res(#)_15 Do you work in soil in your yard (e.g., gardening, digging, 
building, repairing)?  
Y/N/DK/Ref  
 
[If “yes”, continue with 16 and 17; If N/DK/Ref: skip to Res_18, Pesticide 
use] 
 
Res(#)_16 Is the activity:  
 Gardening/Planting  1 
 Building/repairing  2 
 Other     3 
  Verbatim: 
 DK   98 
Ref   99 
 
 
 
 
 
Res(#)_17 How often did you do these activities? 
Weekly (or more)        1 
Monthly    2 
Yearly (few times a year or less)   3 
Don’t know     98 
Ref     99 
 
Pesticide Use  
 
Res(#)_18. Have you or anyone else ever used chemicals in or around your 
house, yard, or garden to control weeds or pests, rodents or other pests?  
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Y/N/DK/Ref 
 
[Prompt examples, if needed: Pesticides or other chemicals used to kill insects, 
weeds, rodents or other pests. (e.g. Raid, Roundup)] 
 
Res(#)_19. Who applied the product? (allow multiple answers) 
Self    1 
Family member  2 
Exterminator   3 
Other    4 
Don’t know   98 
Ref    99  
 
Res(#)_20. What was its purpose? (mark all that apply) 
 To control plants/weeds (herbicide)   1 
 To control insects (insecticide)   2  
 To control rodents (rodenticide)   3 
 Other       4 
  Verbatim: 
 DK     98 
 Ref     99 
 
Res(#)_21. Where was the product used: inside the house, outside the house, 
or both? 
Inside the house  1 
Outside   2 
Both    3 
 
Res(#)_22. How often  were these products used to control plants and weeds? 
(repeat for each answer to Res#20 above) 
Weekly         1 
Monthly    2 
Yearly (few times a year or less)   3 
Don’t know     98 
Ref     99 
 
Thank You.   Now we’ll continue with your next residence at [state street address] 
with the same set of questions. Please remember it’s okay if you don’t know or 
remember the answer for your previous residences. 
 
[Note to interviewer: Repeat Questions R1-R22 for each previous residence 
using past tense in wording of questions] 
 
 
 
Section 2-2.  Work History  
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Now I’m going to ask questions related to your job history form. 
 
Are you currently employed for wages, self-employed, out of work for more 
than 1 year, out of work for less than one year, a homemaker, a student, 
retired, or unable to work?  
 
Employed for wages       1 
Self-employed        2 
Out of work for more than 1 year     3 
Out of work for less than 1 year     4 
Homemaker        5 
Student        6 
Retired        7 
Unable to work       8  
Refused to answer       99 
 
Now we’ll review each job using the mail-out form as a guide, starting with your 
most recent work. 
  
Now, I’d like you to answer the following questions to the best of your ability 
about each job or occupation you held for at least 1 month since you left 
school (completed your education).  Please include full-time, seasonal work, 
part-time, volunteer work and military service (if you worked there at least 1 
month). Also include your current job, even if you have had this for less than 1 
month. 
 
Let’s begin with your most recent (current) job and continue back.  Please 
estimate the time period if you cannot remember exact dates.   
 
a. Job  
number 
(Company 
Name) 
b. Time 
period 
 
Mo/Yr 
to 
Mo/Yr 
c. Job 
Title 
d. Main Job 
Tasks 
e. City and 
State of 
Workplace 
f. Briefly 
describe the 
machines, 
tools and 
materials 
you used on 
the job 
 
g. What did 
your 
company do 
at that site? 
 
1 
 
 
 
 
 
 to 
    
 
 
 
2 
 
 
 
 
 
 to 
    
 
  
 
3 
 
 
 
 
 
 to 
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4 
 
 
 
 
 
 to 
     
5 
 
 
 
 
 
 to 
     
6 
 
 
 
 
 
 to 
     
 
 
 
 
Now I would like you to please describe any gaps in your work history or any 
extended periods of absence from work that were not captured in your job history, 
such as absences for education, illness, pregnancy, care giving (i.e. child or elder 
care), or retirement. [Interviewers to check for existence of gaps before completing 
the interview] 
 
When? (Mo/Yr) How Long? What was the reason for 
the gap or absence? 
 
 
 
  
 
 
 
  
 
 
For any of the jobs you listed, did you perform any of the following tasks or 
activities as part of your normal duties? Please check all that apply. 
 
Task or Activity 
                 (place check-mark if present) 
In which of your jobs did you 
perform this task? List all job 
numbers that apply. 
 
Welding _	
 
 
Painting _	
 
 
Degreasing parts or equipment _	
 
 
Working with glues _	
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Working with solvents or inks _  
 
Working where pesticides were used _ 
    If yes: Purpose of pesticide? (check all that 
apply) 
                   To control plants/weeds (herbicide) 
__ 
       To control insects (insecticide)        
__                                       To control rodents 
(rodenticide) Other
 
Working with or near diesel-powered equipment 
_ 
 
 
Working with or around live animals _ 
 
 
Firefighting _ 
 
 
Working with X-ray or radioactive material _	  
 
 
 
After work history is completed, continue with script below: 
 
Interviewer Script: We’re over half-way through the survey and done with all our 
residence and job related questions – thanks for your patience so far. Would you 
like to take a short break before we continue with the final sections? 
 
 
 
Ok, we’ll continue now with the final sets of questions.  
 
3. Hair Dye Use 
 
3-1. Have you used any hair coloring products?   
Y/N/DK/Ref 
 
[If no, skip to Q4] 
[If yes, continue]  
 
3-2. Is the hair coloring done yourself or by a beautician/hair stylist? (allow 
multiple answers) 
Self     1 
Beautician/hair stylist   2 
Other (specify)   3 
DK     98 
Ref     99 
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3-3. Frequency: How often do you color your hair - Weekly/Monthly/Yearly? 
Weekly (or more)        1 
Monthly    2 
Yearly (few times a year or less)   3 
Don’t know     98 
Ref     99 
 
 
4. Grilled Meat Intake and Local Fish Consumption 
 
The next questions are about your grilled meat intake. 
 
4-1 Have you ever eaten grilled, barbequed, or smoked meats or fish? 
Y/N/DK/Ref 
[If yes, continue to 4-2] 
[If no, skip to 4-6] 
 
KEY for table below:  
Did you eat (type of meat)? 
Y/N/DK/Ref 
 
If yes, continue with A, B, C, as applicable to age of respondent 
 
D. During which seasons (answer all that apply): 
  Winter   1 
  Spring   2 
  Summer   3 
  Fall   4 
  All Year  5  
 
   If yes: 
Have you 
ever eaten 
[type of 
meat] 
A)Between the 
ages of 21 and 
40 how many 
meals in a 
typical 
week/month/or 
year did you 
usually eat 
(type of meat) 
B)Between the 
ages of 41 and 
60, how many 
meals in a 
typical 
week/month/or 
year do/did you 
usually eat 
(type of meat) 
C)After age 60, 
how many 
meals in a 
typical 
week/month/or 
year have you 
usually eaten 
(type of meat) 
D)Which 
seasons of 
the year did 
you usually 
eat (type of 
meat) 
Answer all 
that apply 
4-2 grilled 
or 
barbequed 
beef, lamb 
or pork? 
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4-3 grilled 
or 
barbequed 
poultry or 
fish? 
    
4-4 smoked 
beef, lamb 
or pork 
such as 
bacon or 
ham? 
    
4-5 smoked 
poultry or 
fish such as 
smoked 
turkey or 
lox? 
    
 
Now let’s talk about the local fish consumption.   
 
4-6. Have you ever visited the Still Creek Reservoir?  
Y/N/DK/Ref 
 
[If yes, continue to 4-7; if no skip to 4-10] 
 
4-7. Did you take soil from the Still Creek Reservoir to your garden or 
backyard? 
Y/N/DK/Ref 
 
4-8. Have you ever eaten fish from the Still Creek Reservoir? 
Y/N/DK/Ref 
 
[If yes to 4-8] 
4-9. During which years did you eat fish from the Still Creek Reservoir?     
 
From _____ to _____ 
DK        98 
Ref        99  
-------------------------- 
 
4-10. Have you ever eaten fish from other local creeks or lakes? 
Y/N/DK/Ref 
 
4-11. [If yes] which creeks or lakes? __  Capture creeks or lakes. 
 
[if yes to 4-10] 
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4-12. During which years did you eat fish from these local creeks or lakes?  
 
From ______ to ______ 
DK        98 
Ref        99 
Thank you.  Now I would like to ask you some questions about hobbies.   
 
5. Hobbies  
 
5-1. As an adult (21 or older), have you engaged in any hobbies on a regular 
basis? 
Y/N/DK/Ref 
 
5-2. If yes, what are they? [list each verbatim] 
 
[If require examples prompt: gardening, painting, arts/crafts, auto repairs, 
construction projects, recreational/athletic activities etc.] 
 
[If yes] I’ll ask a couple questions about each hobby: 
5-3. What year (approx.) did you begin this hobby? 
5-4. What year did you stop? 
5-5. How often did you pursue this hobby? 
 
 
 
 
 
6. General health questions 
 
Now I would like to ask you some general health questions. 
 
6-1. How tall are you? (feet and inches):__________ 
 
6-2. How much do you weigh? (lbs.):________ 
 
Hobby 
(verbatim) 
Start Year End Year How often:  
Weekly   1                Yearly or less  3 
Monthly 2                 DK/Ref  98/99 
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Now I’m going to ask about specific medical conditions. If you had any of the 
following illnesses, your doctor would have told you its name. So, if you don't 
recognize the name, we will assume that you’ve never had it.  
 
6-3. [For each item] Has a doctor ever told you that you have [list below]? 
Y/N/DK/Ref 
 
6-4. [For each yes to 6-3] At what age were you diagnosed?____ 
 
List: 
High blood pressure 
Heart Disease 
Stroke 
Diabetes 
Arthritis 
Liver Disease 
Kidney Disease 
 
Multiple Sclerosis 
Lupus  
Fibromyalgia 
Scleroderma 
Reynaud’s Disorder 
Ulcerative Colitis 
Crohn’s Disease 
Parkinson’s Disease 
 
Allergies 
Asthma 
Chronic bronchitis 
Emphysema 
 
Blood disease 
 If yes, what is the disease? [verbatim] 
Cancer 
 What type of cancer? [verbatim] 
  
If yes to Cancer: 
Were you treated with:  
 Chemotherapy   1 
 Radiotherapy   2 
 Immunotherapy  3  
 Surgery   4 
 Other    5 
 DK    98 
 Ref    99 
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6-5. As an adult, have you ever been treated by a doctor or other primary 
caregiver for an infectious disease? (examples: hepatitis, malaria, meningitis, 
influenza/pneumonia, etc)  
Y/N/DK/Ref 
 
If yes, what was the infectious disease [verbatim]? _________ 
Age: 
 
6-6. Have you been diagnosed by a doctor for any other medical conditions 
that we may have not asked you about? 
 If yes, verbatim: 
 Age at diagnosis: 
 
6-7. Have you ever had a blood transfusion (s)? 
Y/N/DK/Ref 
 
[If yes, continue with 6-8 and 6-9; if no, skip to 6-10]  
 
6-8. When was the first time you received blood? (At what age) 
6-9. What medical condition did the transfusion treat? [verbatim] 
 
6-10. Are you currently taking any medicines regularly?   
Y/N/DK/Ref 
 
6-11. [If yes] Which ones (please list names)?  
 
7. Blood Relatives Medical History 
 
Now i’d like to ask several questions about the medical history of your blood 
relatives. A blood elatives would include your Mother, Father, and their siblings, 
any Brothers and Sisters and their children, your Children/Grandchildren and 
Grandparents, who are living or deceased. 
 
 We are asking about your blood or biological relatives only – not step or adopted 
relatives 
 
7-1. To your knowledge, have any of your blood relatives had a blood disease 
or blood cancer?  
Y/N/DK/Ref 
 
[If N/DK/Ref, continue to Section  8] 
[If “yes”, repeat 7-2 through 7-4 for each additional relative] 
 
7-2. 
Which blood relative (of respondent): allow multiple answers 
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Mother          1 
Father           2 
Brother    3 
Sister     4 
Sibling of Mother      5  
Sibling of Father    6 
Parent of Mother   7 
Parent of Father   8 
Child of Brother or Sister      9 
Son                       10 
Daughter     11  
Grandchild       12 
Other     13 
    Specify: 
DK     997 
Ref     998 
 
7-3. What type of blood disease or blood cancer?  
Verbatim: 
DK 
Ref 
 
7-4. At about what age was he/she diagnosed? 
Age: ______ or DK 
 
 
That completes our medical history section and we now have two short sections 
left to complete.  
 
8. Tobacco Use 
The next few questions ask about your use of tobacco products. 
 
8-1 Have you ever smoked any tobacco product 
(at least one cigarette, one cigar or one paper per day for at least six 
months)?   
 1  Yes 2  No (go to 9-1)                  99 Ref 
 
[If yes] Okay, I’m going to ask about specific types of tobacco use. 
 
8-2 Have you ever smoked cigarettes (at least one per day for at least six 
months)?    
 1  Yes 2  No (go to 8-3) 
 
From To Filter (1) Manufactured (1) Average number per day 
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year/age year/age non filter (2) hand rolled (2) 
both types (3) 
Working days Non-working days, 
holidays 
......   |__|__| ......   |__|__| |__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__| |__|__| |__|__| 
 
 
8-3  Have you ever smoked cigars   (at least one per day for at least six 
months)?    
 1  Yes 2  No (go to 8-4) 
 
 
 
From 
year/age 
To 
year/age 
Cigars (1) 
cigarillos (2) 
Average number per day 
Working days Non-working days, 
holidays 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
 
 
8-4 Have you ever smoked a pipe (at least one per day for at least six 
months)?    
 1  Yes 2  No 
 
From 
year/age 
To 
year/age 
Average number of 
pipefuls (bowlfuls) 
of tobacco per week 
......   |__|__| ......   |__|__| |__|__| 
......   |__|__| ......   |__|__| |__|__| 
 
 
 
9. Alcohol Use 
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9-1. Did you ever drink alcoholic beverages such as wine, beer, or other 
liquor - at least one drink per month for 6 months or more? 
 [if prompted: A drink of alcohol is one can or bottle of beer, one glass 
of wine, or a jigger of liquor either alone or in a mixed drink.] Y/N/DK/Ref 
  
If yes,  
From year/age To 
year/age 
Liquor (1) 
Beer (2) 
Wine (3) 
 
Average number of drinks per day on: 
Working days Non-working days, 
holidays 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
......   |__|__| ......   |__|__| |__| |__|__| |__|__| 
  
 
10. Final Questions 
That concludes our phone survey...  
 
10-1. [Open-ended Question] Is there anything you want us to know that we 
did not ask about? 
Y/N/DK/Ref 
[verbatim if “yes”] 
 
 
Thank you again for your time Mr./Ms./Mrs. [ ]. You will receive a gift card in the 
mail within the next month for your contribution to our study.  
 
If YES on biologic specimen consent: 
 
Now I see that you signed a consent form that you will provide a blood sample. 
Thank you for agreeing to do so.  As it mentioned in the consent form if you are 
not a Geisinger patient you will be registered as one to order the blood draw.    
 
 
You can have your blood draw completed at one of the following Geisinger 
Clinics – Frackville, Pottsville, Hazleton, and Geisinger Wyoming Valley.  In 
addition, our research team will send you an information packet regarding your 
blood draw.  Once you schedule and complete your draw you will receive your 
additional $25.00 gift card in the mail.  Should you have any questions or 
201 
Appendix A: 
Study #: 2010-0316    
Version 5 
3.8.2011 
concerns please contact a member of the study team at 1-866-630-0798 and press 
2.   
 
Which of the four clinics would you prefer to complete your blood draw? 
 
If Hazleton, Pottsville, or Frackville:. 
 
Before I transfer you do you have any questions or concerns? 
 
Ok…Thank you for your time today.  Now please stay on the line while I 
connect    you with schedule services. 
 
Transfer Call to Scheduling Services. 
 
If Geisinger Wyoming Valley: 
 
A member of our study team will be in contact with you to arrange for 
your blood draw at Geisinger Wyoming Valley. Please wait for the phone 
call and blood draw packet in the mail (which includes a set of labels) 
prior to completing the blood draw.  
 
Do you have any questions or concerns? 
 
Thank you for your time today. Have a great day/night. 
 
11. For Interviewer only: rate the reliability you assign to this respondent 
 
 
11-1. Respondent Cooperation:  
Good  1 
Fair  2  
Poor  3 
 
11-2. Overall, how reliable was the respondent? 
Highly Reliable 1 
Reliable  2 
Questionable  3 
Low Reliability 4 
 
11-3. Other comments specific to this respondent: _______________ 
 
Interview end time: 
 
 
END 
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Research Proposal: Investigation of a Polycythemia Vera Cluster in Northeast 
Pennsylvania 
 
INTRODUCTION 
In 2008, the initial results of joint efforts by the Pennsylvania Department of 
Health (PADOH) and the Agency for Toxic Substances and Registry (ATSDR) of the 
Centers for Disease Control and Prevention (CDC) confirmed a cancer cluster in a tri-
county region of Northeast Pennsylvania. These investigations found the incidence of 
polycythemia vera – a rare blood disease – to be 4.3 times higher within the cluster 
area than the comparative tri-county region (p <0.001) (1). The close proximity of 
this primary cluster zone – located at the intersection of Carbon, Luzerne, and 
Schuylkill Counties – to known hazardous waste sites and materials might have 
played a role in the disease cluster origin. Follow-up studies in the area were 
proposed by a scientific advisory panel – the Department of Environmental and 
Occupational Health of the Drexel University School of Public Health was tasked 
with undertaking an epidemiological study. The proposed case-control study will be 
the first seeking to identify risk factors of polycythemia vera in this geographic area. 
The study design will be a population-based, case-control study to evaluate possible 
lifestyle and environmental risk factors for the family of BCR/ABL-negative 
myeloproliferative neoplasms (MPN): polycythemia vera (PV), essential 
thrombocythemia (ET) and primary myelofibrosis (PMF).  These diseases differ 
phenotypically but commonly share the same JAK2 V617F point mutation (abbr. 
JAK2) that is thought partly responsible for disease initiation and/or progression (2). 
The etiologies of these MPN and the JAK2 mutation are currently unclear. 
Corresponding subject information – upon informed consent – will be 
obtained through telephone questionnaires by trained interviewers at the Geisinger 
Center for Health Research Survey Unit (Danville, PA). The questionnaire will elicit 
detailed responses from MPN patients and non-MPN referents regarding various 
residential, employment, dietary, and chemical exposure histories. The range of cases 
of PV, ET, and PMF to be ascertained from the tri-county area (based on preliminary 
Pennsylvania Cancer Registry data 2001-2007) is 100-125. Study subjects will be 
recruited from the tri-county population. Approximately four additional subjects 
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(controls) per case will be selected to maximize power.  New cases will be identified 
through a Pennsylvania Department of Health request to the state’s Cancer Registry, 
and through collaborations with ATSDR. Retrospective associations with an 
increased risk for PV, ET, and PMF diseases will be analyzed among the cases 
independently of potential risk factors.  
 
A. Researchers 
 
Principal Investigator: Arthur L. Frank, MD PhD, Professor, Chair 
Co-Investigator: Carol Ann Gross-Davis, MS, Assistant Professor 
 
Drexel University School of Public Health 
Department of Environmental and Occupational Health 
 
Principal Investigator: Porat Erlich, PhD, Research Investigator 
Geisinger Center for Health Research 
 
B. Sponsor  
 
The Centers for Disease Control and Prevention (CDC), Department of Health and 
Human Services.  
CDC Research Grant Number: 1R01EH000640-01 
See award details, attached. 
 
C. Studies Involving Multiple Diseases 
 
The proposed study investigates possible risk factors for polycythemia vera (PV), and 
additionally, essential thrombocythemia (ET) and primary myelofibrosis (PMF). 
Polycythemia vera is the primary disease of interest, and the basis of the disease 
cluster investigation by the CDC (1). The latter two diseases – ET and PMF – share 
many clinical features with PV; all three diseases fall under the 2008 WHO 
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classification scheme of myeloproliferative neoplasms (MPN) (18). Multiple research 
studies review the diseases as a group, commonly termed the Philadelphia 
chromosome negative (Ph-) or BCR/ABL-negative classical MPN referring to their 
shared genetic characteristics (4, 11, 12). 
 
Blood samples from subjects will be tested for the JAK2 V617F mutation, which is 
present in over 95% of primary PV cases and 50-60% of ET and PMF cases (18). 
Allowing the latter two disease categories into our case definition would provide a 
more accurate representation of the JAK2 genetic mutation burden in the affected 
population (17). 
 
The diseases are similar enough that additional protocols and/or informed consents 
are unnecessary – the language contained within this proposal (see research design) 
and the consents are applicable to all disorders under investigation, given the 
considerable overlap. The ability to explore associations with this group of diseases 
that share the JAK2 mutation may provide us the opportunity to test our hypothesis 
since the exact role of the JAK2 mutation in the causal model is still developing. 
 
D. Duration 
 
The project duration, per the CDC grant, lasts two years from the study award date of 
September 1, 2009. 
 
E. Risk 
 
The study activities present minimal risk to participants. Subjects may be 
uncomfortable sharing personal information over the phone for the study 
questionnaire. Subjects who agree to a one-time routine blood draw procedure will 
provide their own transportation to and from the blood clinic site. Any risks for injury 
related to the blood draw are rare. All data will be securely stored in a password 
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protected computer network and locked file cabinets. Data sharing will occur between 
the collaborating research institutions only.  
 
F. Subject Recruitment and Selection 
 
The epidemiological study is a case-control design that will involve subjects with 
specified diseases (cases) and controls without specified diseases. 
 
Cases will be recruited through the Pennsylvania Cancer Registry (PCR) of the 
Pennsylvania Department of Health, and through an existing CDC database (see CDC 
letter for data sharing). Followback activities with cancer patients via the PCR no 
longer require physician consent – only a written first contact by mail to obtain 
informed consent. An application for access to protected data of the PCR will be 
submitted upon final IRB approval. Preliminary data predict between 100-125 total 
eligible cases in the population. 
 
Case Inclusion Criteria: 
1) Diagnosis of polycythemia vera, essential thrombocythemia, or primary 
myelofibrosis between January 1, 2001 and December 31, 2010* and 
a. JAK2 positive, non-MPN from ATSDR 2009 community screening 
also eligible 
2) Born between January 1, 1921 and December 31, 1968  and 
3) Continuous residence within tri-county region (Carbon, Luzerne, or Schuylkill 
County) during 2000-2008 
 
[*July, 2011 protocol amendments: The case inclusion criteria have expanded to 
include the 2009 and partial 2010 PCR case-level data for the tri-county area. 
Originally, these data were not expected to be validated or available for Drexel’s use. 
This expansion is also in response to low participation rates in the study.  
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Additionally, a request has been submitted to ATSDR for the contact information of 
fourteen    JAK2-positive individuals with no presenting MPN that participated in the 
2009 community screening. See also p. 19 case definition.] 
 
Control Inclusion Criteria: 
1) Born between January 1, 1921 and December 31, 1968  and 
2) Continuous residence within tri-county region (Carbon, Luzerne, or Schuylkill 
County) during 2000-2008  
3) No diagnosis of PV-related outcome 
 
Note: The study subjects’ birth year range, 1921 through 1968, screens for an 
approximate 40 to 80 year old age bracket during the years of case diagnosis, 
2001-2010 (median age of PV is 62). Efforts to maintain consistent age 
distributions among cases and controls include monitoring of the control selection 
process, and oversampling of certain demographics, if necessary.  
 
Control Selection: 
A random sample of subjects (400-500 persons) will be selected through Random-
Digit Dialing (RDD), forming the control group of the study. The RDD system 
obtains published residence lists for the specified counties, and residences will be 
contacted at random by phone to seek eligible persons interested in study 
participation. Contacts will continue until the tri-county population is sufficiently 
sampled for the desired control group size (estimated at 400-500, dependent on final 
case numbers). The Geisinger Center for Health Research Survey Unit will conduct 
the RDD recruitment phase. The exact number of controls (selected during RDD and 
consenting to questionnaire) will be determined, in part, by the final number of cases 
recruited for the study.  
 
The recruitment phase is expected to last up to three months, beginning immediately 
after IRB approval of the study protocol. All subjects will receive an informed 
consent document detailing their requirements for participation. Subjects must return 
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the signed consent to the Survey Unit to participate. The phone questionnaire is 
required for participation; the blood draw phase is voluntary.  
 
All subjects will receive a gift card valued at $25 after completion of the phone 
questionnaire; a second $25 gift card will be given to those subjects who also provide 
a blood sample. Incentives will be mailed by the Geisinger Survey Unit after 
completion of each phase. 
 
Basic demographic information will be collected to track refusals and non-
respondents to characterize potential selection bias. Non-respondents will be 
characterized during the RDD and consent procedures. Any differences between 
those subjects who consent to a blood sample and those who decline will be noted.  
 
G. Locations 
 
The following research locations will facilitate the study: 
 
1. Drexel University School of Public Health  
1505 Race Street, Philadelphia, PA, 19102 
 
Tasks: Study coordination, project management, data analysis 
 
 
 2. Drexel Institute for Biotechnology and Virology Research 
     Pennsylvania Biotechnology Center 
     3805 Old Easton Road, Doylestown, PA 18902 
   
    Tasks: Storage of processed blood samples 
 
 3. Geisinger Health System      
100 N. Academy Ave., Danville, PA 17822 
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 a. Geisinger Center for Health Research, Survey Unit  
  
   Tasks: 
 -Selection of controls via RDD 
-Administration of mail-out packages and telephone questionnaires; 
obtain informed consents 
-Data entry and final data transfer to Drexel University upon  
completion of questionnaires 
 
Primary data collection will occur at the Geisinger Center for Health Research 
Survey Unit in Danville, PA. The Survey Unit will administer informed 
consents; select a control group; package mail-out forms; conduct telephone 
questionnaires; mail incentives; and transfer the final electronic database to 
Drexel University School of Public Health.  
 
 b. Geisinger Medical Laboratories 
     Clinic sites: various CAP-accredited (College of American Pathologists) 
Geisinger  
    locations throughout tri-county area 
   
    Tasks: Blood draw collection and shipping sites 
 
 4. Mt. Sinai School of Medicine, Molecular Pathology Laboratory  
     One Gustave L. Levy Place, New York, NY 10029 
  
       Tasks: Genetic testing of blood samples for JAK2 mutation 
 
 5. Columbia University Mailman School of Public Health 
 630 West 168th St, New York, NY 10032 
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Tasks: Process blood samples and test for genetic susceptibility markers in  
extracted DNA; send subset of processed samples to Drexel Institute for 
storage 
 
(See appended flow chart for an overview of study collaborators.) 
 
Note on subjects and study locations: 
The questionnaire data collection component does not require any travel from study 
participants. 
Study subjects who agree to the one-time blood draw are responsible for providing 
their own transportation to the clinic location(s). No repeat or recurring blood draws 
will be performed after the initial visit without further informed consent and IRB 
approval.  
 
 
H. Background 
   Community residents of Tamaqua in Northeast Pennsylvania raised concerns to 
state health department representatives when a group of four unrelated cases of 
polycythemia vera (PV) were documented on one stretch of road. Polycythemia vera 
is a clonal stem cell disorder marked by the proliferation of red blood cell production 
and other blood abnormalities (5). The Pennsylvania Department of Health (PADOH) 
conducted initial investigations of cancer incidence in 2004 and found an increase in 
the rate of PV for the tri-county region of Carbon, Luzerne, and Schuylkill Counties 
(the town of Tamaqua lies at the intersection of the three counties) (1). The initial 
findings by PADOH were corroborated by the Agency for Toxic Substances and 
Disease Registry in 2006 (1).     
PV is a myeloproliferative neoplasm (MPN) of the bone marrow – formerly 
termed myeloproliferative disorder (MPD) – characterized by an overproduction of 
erythrocytes and often platelets and other blood cells (5).  Other MPNs include 
essential thrombocythemia (ET), primary myelofibrosis (PMF), and chronic myeloid 
leukemia (CML) (18).  PV has no known cause and normally occurs in about 1 of 
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every 100,000 people each year in the U.S. (1).  In 2005, an acquired point mutation 
in the Janus-activated kinase-2 (JAK2) gene was discovered, which occurred in 
nearly all PV patients (95%+) and about 50% of those with ET or PMF, but not in 
other cancers (18). The JAK2 V617F mutation activates a tyrosine kinase complex in 
bone marrow normally responsible for regulating blood cell production through 
molecular signaling; the mutation disrupts the normal inhibition of growth, thus 
increasing blood cell production (18). No germ-line associations with the JAK2 
V617F mutation have been made, though familial clustering has been documented – a 
large population-based study in Sweden showed a 5-7 fold increase in risk of 
developing an MPN as a first-degree relative of an MPN patient (30). The median age 
of diagnosis for PV is 62 years, with a slight male predominance.  ET and PMF are 
similar for age and gender frequency (7, 8). The JAK2 mutation was included as a 
major diagnostic criterion for PV, ET and PMF by the World Health Organization 
(WHO) in 2008, and was used by ATSDR to validate cases in their investigation (1, 
12). 
 
Previous ATSDR investigation of polycythemia vera in cluster area 
The main area of concern as identified by the ATSDR in the 2007 study is the area 
around Tamaqua, which also includes the towns of McAdoo, Hometown, Still Creek, 
at the intersection of Luzerne, Carbon and Schuylkill Counties (2007 tri-county 
census population estimate of 521,002). There are a number of potential hazardous 
sources in this compact area including acid mine tailings and drainage, waste-coal 
(cogeneration plants) power plants, and nine U.S. Environmental Protection Agency 
National Priorities Listing (Superfund) sites (1; Appendix B for listing of tri-county 
Superfund sites). 
The goals of the ATSDR investigation which provides the preliminary data for this 
study were to: 1) locate all cases of PV in Carbon, Luzerne, and Schuylkill Counties, 
2) confirm the diagnosis of PV cases using medical records and the JAK2 mutation, 
and 3) describe the characteristics of these individuals. The ATSDR study identified a 
statistically significant (p<0.001) cluster of 15 PV cases (versus ~5 expected) within 
the tri-county region (see Appendix A for graphic) (1). The PV cases did not have any 
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jobs, leisure activities, or other factors in common that may have contributed to their 
disease, although the study was descriptive and thus not designed to compare cases to 
healthy controls nor determine the cluster cause. However, local residents believe that 
it is related to the numerous environmental hazards in the area, which include 
multiple U.S. EPA Superfund sites and waste-coal power plants. The investigation 
also found that a significant number of confirmed PV cases had not been reported to 
the Pennsylvania Cancer Registry (PCR), and that many PV cases reported to the 
PCR during this period did not satisfy the revised 2008 WHO diagnostic criteria for 
PV (1). 
 
JAK2 V617F Mutation 
The 2005 discovery of the acquired point mutation JAK2 V617F yielded insight 
into the genetic basis of BCR/ABL-negative MPNs (1). This recurrent mutation in 
JAK2 occurs in > 90% of patients with polycythemia vera and 50-60% of ET and 
PMF patients (9, 10, 11). As a result of the widespread availability of a quantitative 
molecular test for the JAK2 V617F mutation, the World Health Organization 
formally adopted revised diagnostic criteria for PV, ET, and PMF, which included the 
presence of this point mutation for diagnosis (12, 13). 
      To date no documented external causes of PV, ET, PMF, or the JAK2 V617F 
mutation, have been identified. Weak etiologic associations with radiation and 
benzene occupational exposures were made in smaller studies which were conducted 
prior to JAK2 V617F discovery (1).   
 
 
Genetic Susceptibility to Toxic Effects of Exposure to PAH: A Brief Overview  
Polycyclic aromatic hydrocarbons (PAHs) represent a large chemical class of 
ubiquitous pollutant by-products of partial combustion processes – many of which are 
known or suspected human carcinogens (20). The most established mechanism of 
PAH metabolic activation involves genes, and their variants (polymorphisms), 
including CYP1A1. CYP1A1 has been studied for associations with many cancers – 
notably lung cancer – because CYP1A1’s role in metabolism allows for the body to 
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break down benzo[a]pyrene from its carcinogenic forms (25, 29). Variants of the 
CYP1A1 gene disrupt the metabolic breakdown of PAHs. The susceptibility to PAH 
carcinogenic effects on human cells are heightened in the presence of CYP1A1 
variants, affecting aryl hydrocarbon hydroxylase, the enzymatic activity of the 
CYP1A1 gene (29). In the general population the prevalence of a CYP1A1 variant can 
be up to 45%  (but is not consistent among different ethnicities), and these individuals 
are at an increased risk to PAH related illness (26). Our study base is predominantly 
Caucasian; based on the results of a pooled analysis of 14 case-control studies, the 
prevalence range of the CYP1A1 MspI variant in Caucasian non-smokers is between 
15% and 33% (29).  Using the reasoning of Mendelian randomization discussed by 
Smith (2004), the probability of a particular genotype should not depend on the 
measurement of exposure (27).  This will allow us to test our hypothesis using the 
variation on CYP1A1 genes to see an association of exposure to PAHs on PV, ET and 
PMF outcomes.  
 
PAH Exposure 
 
  Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous by-products of organic 
matter combustion processes. PAHs – which are represented by over 100 distinct 
compounds that may mix together – include chemicals that are known carcinogens in 
humans (20).  
Primary environmental sources of PAHs include (20): 
 - Coal, oil and gas burning 
- Cigarette smoking  
- Dietary sources: intake of charbroiled or barbecued meats; grains and 
vegetables that have been contaminated by ambient PAHs. 
 
  While there is no specific mechanism of action for environmental carcinogens to 
cause polycythemia vera, PAHs represent a burdensome chemical exposure category 
for the geographic region, considering the extensive coal and mining activities. Mt. 
Sinai School of Medicine, another collaborator with the CDC/ATSDR research 
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activities in the tri-county area, is investigating two PAHs as possible genotoxic 
agents to bone marrow: benzo[a]pyrene and benzo[k]fluoranthene (19).  
 
Additional testing of “markers of susceptibility”  
While the CYP1A1 MspI variant is the primary polymorphism of interest for the 
present study, additional tests may genotype other genetic markers of susceptibility 
(performed on the blood samples sent to Columbia University). Proposed markers 
would include variants in xenobiotic metabolizing enzymes, with selections guided 
by the ongoing National Institute of Environmental Health Sciences (NIEHS) 
Environmental Genome Project (35). NIEHS maintains a database of “over 600 
prioritized environmentally relevant genes”, which will be reviewed for genetic 
markers that may support this study (35, 36). The majority of selected polymorphisms 
for genotyping will have a minor allele frequency of at least 5% in a Caucasian 
population. 
 
Tri-County Population Overview 
The tri-county region consists of Carbon, Luzerne, and Schuylkill Counties in 
Northeast Pennsylvania. See Appendix A for tri-county area graphic.  
 
A. Tri-County Population: 
County 
 
Population
 
Percentage  
of population: 
white/Caucasian 
Median 
age 
Carbon 62,937 96.1% 41.4 
Luzerne 311,752 94.4% 42.1 
Schuylkill 147,107 95.3% 42.0 
Total tri-county 521,796 94.9% 42.0 
(Data retrieved from U.S. Census American Community Survey, 2008) 
 
B. County Population Estimates, 2000-2007: 
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Carbon County: 
Total Population:  
July 1, 2000: 58,832 
July 1, 2001: 59,207 
July 1, 2004: 60,653 
July 1, 2007: 63,154 
 
Luzerne County: 
Total Population:  
July 1, 2000: 318,555 
July 1, 2001: 315,487 
July 1, 2004: 311,553 
July 1, 2007: 311,982 
 
Schuylkill County: 
Total Population:  
July 1, 2000: 150,087 
July 1, 2001: 149,114 
July 1, 2004: 146,428 
July 1, 2007: 147,115 
  
Source: U. S Census 2000; ACS 2005-2007 
 
 
 
C. Age Brackets per Control Subject Inclusion Criteria: 
For 1921-1968 year of birth range, study subjects:  
  In 2000: aged 32-79  
  In 2008: aged 40-87   
  In 2010: aged 42-89 (at time of study recruitment) 
 
 
County 35-79 Age Group Total County 
Population 
2000 Census % of total county pop.  
Carbon 53.9% 58,802 
Luzerne  52.8% 319,250 
Schuylkill 53.3% 150,336 
Total 53.1% 528,388 
   
 40-84 Age Group  
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2005-2007 ACS 
(estimates) 
% of total county pop. 
(estimate) 
Total County 
Population Estimate 
Carbon  51.0% 62,326 
Luzerne 50.4% 311,838 
Schuylkill 50.0% 146,838 
Total 50.4% 521,002 
 
Source: U.S. Census Bureau, 2000 Census; 2005-2007 American Community Survey 
Note: Census data age group numbers do not exactly match 1921-1968 DOB study 
cohort due to differences in age intervals. 
 
 
D. Estimated PV annual incidence rate (per 100,000 persons) in: 
U.S. (2001-2004):    1.0 
Pennsylvania (2001-2003):   1.5 
Tri-County (2001-2005):   1.25 (33 cases) 
Tamaqua cluster (2001-2005): 3.47 (15 cases) 
    (From Seaman et al. 2009)  
I. Research Design 
 
Study Overview: The Drexel University unmatched case-control study in Carbon, 
Luzerne, and Schuylkill Counties (tri-county area) in Northeastern Pennsylvania is 
designed to evaluate potential environmental risk factors associated with the cluster 
of PV cases, and additionally ET and PMF cases in northeast Pennsylvania.  To 
determine the presence of effect modification, a 4-to-1 unmatched case-control study 
will be recruited from the tri –county area in Northeast Pennsylvania.  The primary 
exposure assessments will be drawn from residential histories, occupational histories 
and lifestyle factors provided in a questionnaire phase. An optional blood draw phase 
for cases and controls will evaluate JAK2 mutation frequencies and select 
susceptibilities to environmental toxins. Specifically, the primary susceptibility gene 
of interest will be the CYP1A1 MspI variant, which disrupts the metabolic breakdown 
of PAHs. Variations in expression of the CYP1A1 gene influence how PAH 
exposures are “activated” to disease-causing biological intermediates (29).  
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Source Population: The source population for the study is the tri-county population of 
Carbon, Luzerne, and Schuylkill Counties (tri-county area) in Northeastern 
Pennsylvania.  In 2007, an estimated 521,002 people resided in the tri-county region. 
Eligible subjects include those persons born between 1921 and 1968 (inclusive) who 
have resided continuously in the tri-county area between 2000 and 2008. This 
restricted age group in the three counties is estimated to be 244,870 people.  
  A suitable control group from the tri-county population will be selected through 
Random-Digit Dialing (RDD) of retrieved residential phone records. The Geisinger 
Survey Unit will oversee the selection of controls. Those eligible for inclusion as 
controls will be asked for their mailing address to receive and review the informed 
consent form for participation in the study.  
 
Data collection methods: One-time phone interview; and a one-time, routine 
collection of a 25-30 ml blood sample.  
 
Power and Sample Size  
We are planning a study with approximately 130 case patients and 520 control 
patients.   
Minimal detectable effects for gene-environment interaction were assessed at 80% 
power.  The minimal detectable effects were calculated using the program Quanto 
(Version 1.2.4, 2009) for the standard multiplicative interaction for a plausible range 
of the risky allele frequencies and a range of frequencies using data from 14 studies 
on genetic polymorphisms and risk of lung cancer (29, 34). We had assumed that 
main environmental effect and the main genetic effect were both 1.0. Therefore, at the 
high end of the allele frequency range examined, 27%, which is for the CYP1A1 MspI 
allele, in combination with the exposure estimate of 30% for exposure to PAH from 
industrial sources, the minimum detectable interaction odds ratio would be close to 
1.8. Alternatively, at the same exposure estimate for PAH from industrial sources, 
30%, in conjunction with an allele frequency of 15% for the CYP1A1 MspI allele of 
the gene on the minimal detectable interaction, the odds ratio is less than 2.1. 
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SPECIFIC AIMS 
 
Aim 1:  Estimate the effect of polycyclic aromatic hydrocarbon (PAH) 
exposure on polycythemia vera, essential thrombocythemia, and 
primary myelofibrosis risk in the tri-county area, Northeast 
Pennsylvania. 
 
Aim 1a:  Estimate the effect of exposure to polycyclic aromatic 
hydrocarbons on polycythemia vera, essential thrombocythemia, and 
primary myelofibrosis risk from occupational and residential sources, 
diet, and lifestyle behaviors.  
 
Aim 1b: Estimate the effect of exposure to polycyclic aromatic 
hydrocarbons measured by distance from Co-generation Power Plants 
on polycythemia vera, essential thrombocythemia, and primary 
myelofibrosis.  
 
Aim 2: Explore whether the effects of exposure to polycyclic aromatic 
hydrocarbons are modified by polymorphisms in the CYP1A1 gene. 
 
Aim 2a: Investigate the effects of exposure to PAH using CYP1A1 
MspI gene as a proxy for exposure on polycythemia vera, essential 
thrombocythemia, and primary myelofibrosis risk.  
 
Aim 2b: The association will be stronger for people with the enzymatic 
activity of CYP1A1 MspI single nucleotide polymorphism compared to 
people who do not have the environmental susceptibility gene.  
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Aim 3: Explore the role of genotypes susceptible to chemicals on the risk for 
PV, ET and PMF, in the Tri-County area.  
 
Aim 3a: The association will be stronger for people with the 
susceptible genotypes compared to people who do not have the 
genotype.  
  
METHODS 
 
Study Design We propose to construct an unmatched case-control study.  All cases 
must have received a diagnosis of PV, ET, or PMF between January 1, 2001 and 
December 31, 2010 (exception is group of JAK2 positive, MPN negative individuals 
from 2009 ATSDR community screening as separate case series – request submitted 
in July 2011).  Four controls per case will be recruited via Random Digit Dialing 
(RDD) within Carbon, Luzerne, and Schuylkill Counties, meeting inclusion criteria 
for age and residence time without diagnosis of an MPN at time of interview. The 
primary outcomes will be whether or not an individual was diagnosed with PV, ET or 
PMF between 2001 and 2010 in the tri-county area. 
  A suitable control group from the tri-county population will be selected through 
RDD of retrieved residential phone records. The Geisinger Survey Unit will oversee 
the selection of controls. Those eligible for inclusion as controls will be asked for 
their mailing address to receive and review the informed consent form for 
participation in the study. The population in the tri-county area is predominantly 
Caucasian at >95% and roughly equal for males and females. The eligibility criteria 
for inclusion as controls are: 
1) Born between 1921-1968 (inclusively)  and 
2) Continuous residence within tri-county region (Carbon, Luzerne, Schuylkill 
Counties) during 2000-2008  
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   Phone questionnaires will be administered to both cases and control to obtain 
details on residence and job histories, water sources, chemical exposures, and other 
lifestyle factors, including a brief medical and family medical history. The 
questionnaire phase will be followed by an optional blood draw, to test for presence 
of the JAK2 mutation and for toxicologically relevant genetic polymorphisms, 
including the variant of CYP1A1 MspI gene.  
  Data for the individual exposure measurements are not available – therefore 
ecological analyses of ambient environmental exposures will be applied and modeled 
appropriately based on the data available through the efforts of an ATSDR project to 
assemble all the available information into a data warehouse for the PV partners.  
Included in the environmental sampling are air, water, and soil testing parameters that 
provide emissions and ambient (or modeled) data by time and geography. Of note, 
ambient data from the EPA’s National Air Toxics Assessment (NATA) Results and 
National Emission Inventory (NEI) and drinking water data from EPA Safe Drinking 
Water Information System (SDWIS) are available in the Polycythemia Vera (PV) 
Data Warehouse relevant to the tri-county area (ATSDR, pers. comm.).    
 
Questionnaire Methods: A questionnaire will be administered by phone to all 
participants to collect information on lifestyle behaviors as well as detailed residential 
history, chemical exposure history and focused dietary history of homegrown and 
charred food. The phone interview will be preceded by mail-out forms for subjects to 
complete their residence and job histories to be used as reference guides during the 
phone interview. 
 
The required questionnaire phase will include:  
1) Structured and validated telephone questionnaire (~45 min. – 1 hour) to be 
administered by the Geisinger Survey Unit to all study participants  
a. Mail-out questionnaires on residence and employment histories sent 
with initial study packet for interview preparation 
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Upon consent, all eligible participants will be phone-interviewed (Computer Assisted 
Telephone Interview, CATI) by the Geisinger Survey Research Unit whose staff are 
trained to administer the questionnaire in a standardized, unbiased manner. 
Interviewers will be initially blinded to case/control status of participants. The 
questionnaire will elicit detailed information regarding demographic characteristics, 
health behaviors, socioeconomic information, residential and employment history, 
and any past exposures to chemicals and other hazardous materials. Residential and 
occupational histories will be reviewed in advance of the interview by respondents as 
preparation for relevant interview questions. The interview is expected to last 
between 45 minutes and one hour; a gift certificate incentive of $25 for participation 
will be offered. Responses will be stored in an electronic database at Geisinger, 
transferred to Drexel University upon completion, and converted to SAS statistical 
software. 
 
 
 
Blood draw (optional for subjects) includes: 
1) One-time peripheral venipuncture (routine blood draw) of 25-30ml of blood (about 
2 tablespoons) 
 Samples include (maximum volume listed): 
 1) 10ml for JAK2 testing at Mt. Sinai School of Medicine 
2) 10ml for gene susceptibility testing at Columbia University 
3) 10ml for storage and possible future testing for biomarkers linked to 
MPN by other studies ongoing in tri-county area (PV Partners studies) – 
storage at Drexel Institute in Doylestown, PA 
 
Consent to provide blood samples will not be part of the study eligibility criteria; a 
description with a yes/no line at the end of the consent form – in addition to a second 
incentive ($25 gift card) for this phase – are used for blood draw recruitment. This 
will allow us to evaluate if those consenting to a blood draw differ significantly from 
non-consenters. The blood samples will be stored at the Drexel Institute for 
221 
 
Study #: 2010-0316 
Version 2 
10.14.2010 
Biotechnology and Virology Research in Doylestown, PA; Mt. Sinai and Columbia 
Universities will perform the genetic tests. 
  
 Blood samples: Geisinger Medical Laboratories clinics will be available as collection 
sites for blood samples from volunteering study participants. EDTA soft plastic tubes 
will be used to draw blood from each subject (25-30 ml, maximum). Collected tubes 
will be transported to the central Geisinger Medical Laboratories facility for shipping 
within 24-36 hours of collection. Tubes will be shipped with cold-storage packs to 
Mt. Sinai School of Medicine (New York, NY 10029) and Columbia University (New 
York, NY 10032). 
 
Testing Sites 
As part of the overall ATSDR research portfolio of studies occurring in the tri-county 
region (PV Partners studies), Drexel will have its JAK2 blood samples tested at Mt. 
Sinai, which serves all research groups for quantitative JAK2 mutation analysis (see 
Mt. Sinai validation protocol, attached). The remaining blood samples (20-25 ml) will 
be shipped to Columbia University for processing (DNA extraction), testing for 
genetic susceptibility markers, and shipping back to Drexel for storage of extra 
samples for future testing. A separate incentive of $25 will be offered for the blood 
draw.  
 
General Approach: 
The primary goal is to determine the presence (or absence) of increased odds of 
disease using a 4-to-1 unmatched case-control study conducted in the tri –county area 
in Northeast Pennsylvania (Carbon, Luzerne, and Schuylkill Counties). The primary 
exposures under study will be environmental exposures assessed by questionnaires 
eliciting residential histories, occupational histories and other lifestyle/behavioral 
factors including diet. The variable associations will be evaluated using various 
statistical methods. Analysis will control for potential confounding variables as 
appropriate.  Available clinical and environmental data will be reviewed with the 
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study team prior to analysis to determine which variables may warrant exclusion or 
should be considered as potential confounders. 
 
Study Subjects 
Case Definition: The cases will be obtained from the tri-county area through the 
Pennsylvania Cancer Registry and ATSDR records. Clinical criteria for classical 
BCR/ABL-negative MPN: polycythemia vera (PV), essential thrombocythemia (ET), 
and primary myelofibrosis (PMF), diagnosed between 2001-2010 during residence in 
tri-county area. A proposed case series [request submitted to ATSDR for patient 
information in July, 2011] includes the fourteen JAK2 positive persons identified in 
the 2009 ATSDR community screening (16)  
 
Primary outcome variables will be classified as 1) PV 2) ET and 3) PMF.  Primary 
outcomes will be determined via ICD-O codes from Pennsylvania Cancer Registry 
(PCR) for the tri-county area data sources. All potential cases will be reviewed by 
expert panel members for a blinded medical review using WHO diagnostic criteria.  
 
Tri-County MPN Reports to the PA Cancer Registry (PCR)  (Estimates 
provided by PCR) 
PCR Data PV ET PMF Total 
2001-2007 128** 48 23 101* 
2006-2007 30 N/A N/A N/A 
* The total represents ET and PMF cases from 2001-2007 and PV cases from 2006-
2007 reported to the PCR.  
**This 2001-2007 incidence figure (128) is not valid, as determined by the previous 
ATSDR investigation (1), and is not included in the total estimate. Reporting and 
diagnostics prior to 2005 (JAK2 mutation testing available) may be unreliable. Thus, 
the expert panel will review all unverified cases from this period. (The 2008 estimates 
are not yet available to the researchers.)  
N/A = Not applicable      
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ICD-O-3 Codes used for reporting MPN cancer cases to PCR:  
Disease ICD-O-3 code 
Polycythemia vera M-9950/3 
Essential thrombocythemia M-9962/3 
Primary myelofibrosis M-9961/3; M-9931/3 
    (Provided by PADOH, February 2010) 
 
Expert Panel: 
An expert panel has been formed by the Pennsylvania Department of Health to 
systematically review and confirm potential cases for study inclusion. Expert panel 
members will review de-identified medical charts obtained with the permission of 
patient and physician. Potential cases will be recruited through requests by the PCR. 
Potential cases that were previously confirmed by an expert panel will not be 
reviewed again. (1) Diagnostics must agree with the 2008 WHO MPN Classification 
scheme (PV, ET, PMF) for inclusion as cases. The four expert panel members are: 
 
Hamid A. B. Al-Mondhiry, MD  
Professor of Medicine – Hematology Division of Hematology-Oncology  
The Pennsylvania State University College of Medicine  
The Milton S. Hershey Medical Center 
 
Emmanuel Besa, MD 
Professor of Medicine 
Hematologic Malignancies  
Thomas Jefferson University  
Jefferson Medical College  
 
Samuel M. Lesko, MD, MPH 
Medical Director and Director of Research 
Northeast Regional Cancer Institute 
University of Scranton Campus 
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Albert Thomas Quiery Jr., MD 
Director, Hematology/Oncology Geisinger Medical Center 
Geisinger Medical Center Hematology/Oncology  
 
  Summary of Variables 
 
Data Available 
 
Potential Covariate Variable Type Data Source 
Age Continuous and 
Categorical 
Questionnaire  
Gender Binary Questionnaire 
Drinking Water Source Categorical Questionnaire 
Burning trash on property Binary Questionnaire 
Smoking Categorical Questionnaire 
Eating local fish Binary Questionnaire 
Age at diagnosis Continuous and 
Categorical 
Questionnaire 
Proximity to Coal Power 
plants 
Continuous and 
Categorical 
Questionnaire 
Proximity to Superfund 
sites 
Binary Questionnaire 
Family  history of MPN 
disease 
Binary Questionnaire 
Occupation classification Categorical Questionnaire 
PAH dietary exposure 
 
Continuous and 
Categorical 
 
Dietary Questions (grilled 
and barbecued meats) 
JAK2 V617F Binary Blood sample 
 
 
 
Summary of Exposure Variables 
Exposure Period Parameterization Dose Response
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Drinking Water 
Source testing 
Any vs. none Quantiles and/or 
continuous 
Air exposure by 
Cogeneration Plants
Geographical Quantiles  
Lifestyle exposures Questionnaire Quantiles and/or 
continuous 
Genetic 
polymorphisms 
Binary Blood sample 
 
 
 
General approach 
 
Exploratory analysis will be conducted on all data collected from a questionnaire 
developed by Drexel University and administered to both cases and controls. Analysis 
will be conducted on data collected from the questionnaire, genotyping, and regional 
environmental data. Descriptive analysis will be conducted on characteristics for the 
study population. For categorical variables, frequency distributions will be conducted 
for exposure variables, genotype information, and covariates in case and control 
groups.  For continuous exposure variables, central tendency and dispersion of the 
distribution will be conducted.  Bivariate analysis of covariates will be used to find 
unadjusted odds ratios for cases and referents. Unconditional logistic regression will 
be used to estimate adjusted odds ratios and 95% confidence intervals. 
 
Data Analysis 
 
 
 
 
Data Analysis for Aim 1a 
 
Analysis of case-referent data utilizes standard logistic regression; because we have 
multiple outcomes with one referent group, a polytomous regression approach will 
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also be used as this may be more efficient. A polytomous regression model will be 
explored as there is no inherent ordering of the outcome categories.  A stratified 
analysis will be conducted to explore confounding and effect modification. Logistic 
regression will be used to estimate adjusted odds ratios and 95% confidence intervals. 
Categories for exposure variables will be created based on the distribution of 
exposure and time from historical environmental data, and data collected from the 
questionnaire. Potential confounders will be explored using a backward stepwise 
method. If the individual variable changes the effect estimate odds ratio by greater 
than 10%, it will be retained in the model. All variables removed will be added 
individually back to the model to check for joint confounding.  Classic covariate 
adjustment of confounding risk factors will be performed, however no known strong 
confounders have been identified in the literature.   Exposure and outcomes will be 
modeled using multiple logistic regression model and polytomous logistic regression.  
A classical error model will be used to assess measurement error in the model, and a 
sensitivity analysis on variables included in the final model will describe the impact 
of measurement error on the calculated odds ratios. 
 
Data Analysis for Aim 1b 
 
The overall goal is to develop a better appreciation for validity of proxy exposure 
measures used in air pollution exposure modeling, using community exposures to 
PAH from multiple coal-powered plants as a motivating example. Analysis will 
create a model of air pollution in a town with  3-5 coal plants nearby, each with 
different emission rates (Q) and volumes (V) and distances to center of town (D) (a 
circle). Each person in town will live some distance from the city center (r) and 
therefore the plant (d). Assume between-person variance, systematic increase in PAH 
exposure in smokers, and influence of sources on PAH all act together to produce 
exposure X. SAS will simulate one huge dataset of  1,000,000 records and study what 
happens when sampling variation does not matter, i.e. what happens "in probability", 
with infinite sample size.  
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Approach for Aim 2. Explore whether PAH exposure (overall and in specific 
exposures from questionnaire) are modified by polymorphisms in the CYP1A1 MspI 
polymorphism. 
 
Data Analysis for Aim 2 
 
Using genotype as an ‘instrument’, it is possible in principle to distinguish between 
causal and non-causal explanations of a biomarker–disease association, but classical 
methods for instrumental variables are rarely used (37). Classical methods of analysis 
of instrumental variables have some limitations; however, these methods in theory 
can distinguish between non-causal and causal associations with the CYP1A1 MspI 
genotype and PV, ET, and PMF. To use the Mendelian Randomization context, it is 
crucial to have a robust instrument and to use instrumental variable analysis to 
accurately make inferences from the results (38).  In the analysis of gene-environment 
(PAH) interactions, a variable for susceptible genotype will be entered into the 
disease model as the instrumental variable. The relationship we are interested in 
testing is that genetic susceptibility is unique to PAH exposure.  Therefore only if 
there were enough PAH exposure in this population would we see an association 
between genetic susceptibility and risk of PV, ET or PMF.  Using this model is 
appropriated because the exposure in the study area is widespread and there is no 
evidence to support that the genetic susceptibility of the CYP1A1 gene alone is 
associated with the outcomes of interest (28). To test whether factors are causally 
related to diseases, the classical method for instrumental variables, the two-stage 
least-squares (2SLS), will be used.  There are two stages in the computation: in the 
first stage, a new variable from the instruments is created by a phenotype that is 
estimated for each genotypic group; in stage two, this new variable is used in place of 
the problematic variables X (PAH exposure) in the final regression (37). 
 
Using this model is appropriated because the exposure in the study area is widespread 
and there is no evidence to support that the genetic susceptibility of the CYP1A1 gene 
alone is associated with the outcome of interest (28). 
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Data Analysis for Aim 3 
 
This gene-only analysis will use logistic regression to estimate adjusted odds ratios 
and 95% confidence intervals. Classic covariate adjustment of traditional 
confounding risk factors will be performed using multivariate methods.  Exposure 
and outcomes will be modeled using multiple logistic regression model and 
polytomous logistic regression. For genes with more than one functional SNP, 
dummy variables will be created and used in Aim 2 and Aim 3. This gene-only 
analysis will use logistic regression to estimate adjusted odds ratios and 95% 
confidence intervals. Covariates will be added to this model if they were retained in 
the final model in Aim1.  Genotypes and outcomes will be modeled using multiple 
logistic regression model and polytomous logistic regression. In addition to logistic 
regression, case-only approach will be used to test for departure from multiplicative 
effects on disease. Spearman and Peirce correlation coefficients will be calculated to 
determine the assumption of independence for gene and exposure. The assumption 
will be tested to affirm that this assumption is met (39). This approach is more 
statistically efficient than conventional approaches of multiplicative interaction but 
requires an assumption of independence between the exposure and genotype, which 
should be easily met here (39). Here logistic regression is limited to the PV, ET, and 
PMF cases only with the exposure alone, the genotype alone, and their joint effects. 
This is then compared to the odds ratio among the control subjects only. For genes 
with more than one functional SNP, dummy variables will be created and used in 
Aim 2 and Aim 3. An accurate measure of genotype would mean an expected 
decrease in classification error, which would increase our ability to detect an 
association with the disease (40).  So looking at genotypes with 30-50% allele 
frequencies (exposure in population) with high sensitivity and specificity for the test 
makes it much easier to increase the probability of detecting an association with the 
disease (40).   
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Strengths 
 
The case-control study will benefit from being the first of its kind in the tri-county 
area.  The population based sampling approach used to select our controls in 
conjunction with genetic and environmental data make this analysis advantageous. 
Results from this analysis will add to the limited amount of literature on gene-
environmental interaction in regards to environmental exposures and risk for PV.  
The generation of genotype data may provide an important insight on environmental 
exposures for PV in the context of environmental heterogeneity. 
 
Limitations 
The proposed study has several limitations. The principal limitation of the study is the 
maximum number of cases that are expected to be recruited from the area 
(approximately 125 MPN cases).  Another limitation of the study design is its 
inability to detect small relative risks even when associated with widespread 
exposure. This study would be unable to detect very small relative risks <2.0 even if 
the exposure is widespread and large numbers of cases of cancer are occurring in the 
population.  The study will suffer from the difficulty in small studies of detecting 
increased relative risks with the comparatively low power of 80%, even when 
maximizing the number of control per case to five. The latency period between 
possible exposures related to the development of an MPN is currently unknown, 
which complicates identification of potential risk factors when the timeframe of 
effective exposure is not clearly defined. Another possible limitation of this study is 
the potential bias from misclassification of exposure and measurement error in 
exposure assessment for controls.   Sensitivity analysis and imputation techniques 
will be incorporated to quantitatively assess impact of measurement error and other 
exposure covariates on the overall effect estimate.   
 
Ethical Aspects 
 
Informed consent 
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Written informed consent will be obtained from all individuals participating in this 
study.  
 
Involvement of Human Subjects 
The research activities described in this proposal (questionnaires and optional blood 
draw) will be administered to consenting subjects. The study population includes men 
and women living in the tri-county area aged 42 to 89 years old.  No exclusions are 
made based on gender or ethnicity; over 95% of the tri-county population is 
white/Caucasian.  In this analysis we will be using blood samples, which will not be 
de-identified. 
 
Level of Review: 
The level of review for the case-control analysis will go into an expedited IRB review 
at Geisinger Health System, which will also rely on the Drexel University IRB.  
 
J. Risks and Benefits to the Subject 
 
Potential risks and protective measures 
Participants may be uncomfortable answering personal questions on paper or over the 
telephone. Sensitive questions are not included in this protocol. All answers will 
remain private except to the involved researchers. The phone interview will take up to 
an hour to complete. No personal data will be used or shared outside the scientists 
working on this study, unless expressly warranted. 
 
The specimen collection presents minimal risk to the participants. The one-time blood 
draw is a routine non-fasting procedure to collect 25-30 ml of blood from each 
participant. All blood collections will be performed at licensed phlebotomy clinics 
with appropriate supervisions and licensure.  
 
The collaborating clinics will refuse collection from any participant who has 
undergone chemotherapy within the prior two months, is a hemophiliac, or presents 
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with no acceptable peripheral blood draw site (e.g. rashes, burns, wounds on arms) 
(23).  
 
For the registry-based activities, personal identifiers are retained for the purposes of 
the data set linkages.  Study results will always be presented in aggregate form, 
thereby further preventing identification of individual subjects. Secondly, because a 
biological sample may be collected, this could be of moderate concern to the 
participant, but study results will always be presented in aggregate form. No clinical 
diagnosis will be conducted on any stored sample beyond the initial screening for the 
JAK2 V617F mutation, which is not a diagnosis of a disease. 
 
Participation in the study may involve unforeseen risks. In the uncommon event that 
excess bleeding results from the blood draw, the subject will be treated at the time of 
the blood draw. If any problems occur after that time, it will be the subject’s 
responsibility, at their own cost, to seek any treatment or evaluation. Any breach of 
confidentiality will be referred to the Geisinger IRB and Drexel Office of Regulatory 
Research Compliance (ORRC). 
 
All potential risks listed above are also detailed in the consent form. 
 
Benefits 
There are no immediate benefits to the study participants other than the cash 
equivalent incentive, which is modest.  Controls that receive a positive genetic test for 
the JAK2 mutation will be notified and may be eligible to participate in a separate 
prospective study designed to track and detect changes in a subject’s hematological 
profile. The local community may benefit from our improved understanding of the 
causes of these diseases. This information may lead to possible intervention and 
prevention strategies for the local community. These benefits are believed to 
outweigh any minimal risk to individual participants.  
 
K. Protection of Subject Privacy and Confidentiality 
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1. The expert panel may review hematological medical records retrieved from the 
Pennsylvania Cancer Registry (PCR) through the University of Pittsburgh case 
ascertainment study, co-occurring in the tri-county region. The PCR documents 
standardize diagnostic data relevant to the diagnosis. Data from PCR records may be 
viewed by the Drexel investigators. No PHI directly from private medical records will 
be retained or recorded into investigator data collection sheets – the expert panel, 
under authority of the Pennsylvania Department of Health will have access to the 
medical record, but the investigators will not.  
 
2. Research protocols and methodologies will be maintained on-site at Drexel 
University. All data will be de-identified through numeric coding; codes and data will 
be stored in separate files, for up to ten years following completion of the study. 
 
With the exception of disclosure to DHHS, IRB, or collaborating research partners, 
data will not be linked back to individual subjects. Upon completion of a data sharing 
agreement, the University of Pittsburgh Graduate School of Public Health (PI: 
Jeanine Buchanich, PhD), in partnership with the Pennsylvania Department of Health, 
will have access to data sharing as needed to facilitate the aims of their study, also in 
the tri-county area, to prevent unnecessary participation burdens on the study 
population. Only phone questionnaire data for cases consented and enrolled in both 
the University of Pittsburgh case ascertainment study and the Drexel University case-
control study may be transmitted from Drexel to Pittsburgh. Drexel University will be 
responsible for reviewing and matching case lists to determine which individuals 
(cases only) are common to the concurrent studies. No data linked to Drexel's control 
series may be transmitted. Transmitted data may include demographic information 
and relevant environmental and occupational history sections elicited by the phone 
survey. The data sharing is intended to limit redundant study activities (as 
questionnaires) that otherwise would have occurred twice for the same individual. 
The University of Pittsburgh case ascertainment study is funded by the Pennsylvania 
Department of Health.  
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3. No audio/video taping will be recorded. 
 
L. Potential Conflict of Interest 
 
The Principal Investigator, Arthur L. Frank, declares no potential conflict of interest. 
Co-investigator Carol Ann Gross-Davis reports her current status as a paid employee 
of the U.S. Environmental Protection Agency.  
 
M. Compensation for Participation 
 
Study participants will be mailed a gift card voucher worth $25 upon completion of 
the phone questionnaire interview. A separate incentive, also $25 gift card voucher, 
will be provided to the study participants who provide a specimen collection (blood 
draw). The maximum total incentive value for an individual participant is $50; 
incentives are to be issued independently of each other. 
 
No additional compensation for a participant’s contribution to the study will be made. 
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Appendix A: Graphic of Tri-County Region and Environmental Hazards. Area T 
represents the statistically significant cluster of polycythemia vera cases relative to 
the entire tri-county region. 
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From: Seaman et 
al. (2009) 
 
 
 
Appendix B: List of Superfund Sites in Carbon, Luzerne, and Schuylkill Counties 
 
Site Name EPA ID NPL 
Status 
City  County  Zip 
      
Palmerton Zinc 
Piles  
PAD00239588
7 
Final Palmerton Carbon 1807
1 
Tonolli Corp  PAD07361366
3 
Final Nesquehonin
g 
Carbon 1824
0 
      
Butler Mine 
Tunnel  
PAD98050845
1 
Final Pittston TWP Luzerne 1864
0 
C & D Recycling  PAD02144924
4 
Final Freeland Luzerne 1822
4 
Dallas Cleaners 
Site   
PAN00030617
3 
Non Dallas Luzerne 1861
2 
Foster Wheeler 
Energy 
PAD00303178
8 
Propose
d 
Mountaintop Luzerne 1870
7 
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Corporation/Churc
h Road TCE  
Kevak Property  PAD98174012
9 
Non Glen Lyon Luzerne 1861
7 
Lehman MTBE  PA0000057471 Non Lehman Luzerne 1862
7 
Moosic  PA0002008506 Non Avoca Luzerne 1864
1 
Tranguch Gasoline  PA0001409671 Non Hazleton Luzerne 1820
1 
Valmont TCE 
(Former Valmont 
Industrial Park)  
PAD98236397
0 
Final West 
Hazleton 
Luzerne 1820
1 
      
Eastern Diversified 
Metals  
PAD98083053
3 
Final Hometown Schuylkil
l 
1825
2 
McAdoo 
Associates  
PAD98071261
6 
Deleted McAdoo Schuylkil
l 
1823
7 
Metropolitan 
Mirror & Glass  
PAD98236695
7 
Deleted Frackville Schuylkil
l 
1793
1 
      
 
Retrieved from Pennsylvania Superfund Sites: 
<http://www.epa.gov/reg3hwmd/super/pa.htm> Accessed July 2010.  
 
(NPL: National Priorities List) 
 
 
Appendix C: Year Householder Moved into Unit 
Source: 2006-2008 American Community Survey 3-Year Estimates, Data Profile 
Carbon County 
 Estimate Margin of Error Percent Margin of Error 
Occupied 
housing units 
25,747 +/-750 100% (X) 
Moved in 2005 or 
later 
5,517 +/-624 21.4% +/-2.2 
Moved in 2000 to 
2004 
5,816 +/-543 22.6% +/-1.9 
Moved in 1990 to 
1999 
5,991 +/-519 23.3% +/-2.0 
Moved in 1980 to 
1989 
2,783 +/-355 10.8% +/-1.4 
Moved in 1970 to 
1979 
2,361 +/-302 9.2% +/-1.2 
Moved in 1969 or 
earlier 
3,279 +/-305 12.7% +/-1.2 
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Luzerne County 
 
 Estimate Margin of Error Percent Margin of Error 
Occupied 
housing units 
129,204 +/-1,450 99.90% (X) 
Moved in 2005 or 
later 
26,898 +/-1,155 20.8% +/-0.8 
Moved in 2000 to 
2004 
27,157 +/-1,309 21.0% +/-0.9 
Moved in 1990 to 
1999 
25,720 +/-1,097 19.9% +/-0.9 
Moved in 1980 to 
1989 
15,810 +/-947 12.2% +/-0.7 
Moved in 1970 to 
1979 
13,885 +/-723 10.7% +/-0.6 
Moved in 1969 or 
earlier 
19,734 +/-920 15.3% +/-0.7 
 
 
Schuylkill County 
 
 Estimate Margin of Error Percent Margin of Error 
Occupied 
housing units 
60,293 +/-912 100% (X) 
Moved in 2005 or 
later 
11,356 +/-794 18.8% +/-1.2 
Moved in 2000 to 
2004 
12,112 +/-788 20.1% +/-1.2 
Moved in 1990 to 
1999 
12,471 +/-721 20.7% +/-1.2 
Moved in 1980 to 
1989 
7,910 +/-591 13.1% +/-1.0 
Moved in 1970 to 
1979 
6,801 +/-510 11.3% +/-0.8 
Moved in 1969 or 
earlier 
9,643 +/-579 16.0% +/-1.0 
 
 
 
Pennsylvania 
 Estimate Margin of Error Percent Margin of Error 
Occupied 
housing units 
4,877,735 +/-6,828 99.90% (X) 
Moved in 2005 or 
later 
1,141,724 +/-8,691 23.4% +/-0.2 
Moved in 2000 to 
2004 
1,138,851 +/-7,875 23.3% +/-0.2 
Moved in 1990 to 
1999 
1,089,140 +/-7,880 22.3% +/-0.2 
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Moved in 1980 to 
1989 
582,159 +/-6,089 11.9% +/-0.1 
Moved in 1970 to 
1979 
418,614 +/-4,504 8.6% +/-0.1 
Moved in 1969 or 
earlier 
507,247 +/-4,438 10.4% +/-0.1 
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Appendix C: 
Initial Mailed Packet 
Job History (Keep for Reference During Phone Survey)  
 
 
 
To the best of your ability, please briefly tell us about each job or occupation you held for at least 1 month since you left 
school (completed your education).  Include full-time, seasonal work, part-time, volunteer work and military service (if you 
worked there at least 1 month). Also include your current job, even if you have had this for less than 1 month.  Begin with your most 
recent job and continue back.  Please estimate the time period if you cannot remember exact dates. We will review this form during 
the phone survey.  
Job  
number 
Time period 
 
Mo/Yr to Mo/Yr 
Job Title Main Job Tasks Company name 
(optional) 
City and State of 
Workplace 
1 
 
 
 
 
 
 
 
 to 
    
2 
 
 
 
 
 
 
 
 to 
    
3 
 
 
 
 
 
 
 
 to 
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4 
 
 
 
 
 
 
 
 to 
    
Job 
number 
Time period 
 
Mo/Yr to Mo/Yr 
Job Title Main Job Tasks Company name 
(optional) 
City and State of 
Workplace 
5 
 
 
 
 
 
 
 
 to 
    
6 
 
 
 
 
 
 
 
to 
    
7 
to 
    
8 
to 
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9 
to 
    
10 
to 
    
Job 
number 
Time period 
 
Mo/Yr to Mo/Yr 
Job Title Main Job Tasks Company name 
(optional) 
City and State of 
Workplace 
11 
to 
    
12 
to 
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For any of the jobs you listed, did you perform any of the following tasks or activities as part of your normal 
duties? Please check all that apply.  
 
  
Task or Activity 
                 (place check-mark if present) 
In which of your jobs did you perform this 
task? List all job numbers that apply. 
 
Welding _ 
 
 
Painting _ 
 
 
Degreasing parts or equipment _ 
 
 
Working with glues _ 
 
 
Working with solvents or inks _  
 
Working where pesticides were used _ 
    If yes: Purpose of pesticide? (check all that apply) 
                   To control plants/weeds (herbicide) __ 
       To control insects (insecticide)        __                                       To 
control rodents (rodenticide)      __        Other (specify below)            
__ 
 
Working with or near diesel-powered equipment _ 
 
 
Working with or around live animals _ 
 
 
Firefighting _ 
 
 
Working with X-ray or radioactive material _ 
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Appendix D : 
 
 
Telephone script for to determine eligibility and complete questionnaire 
 
 
 
 
Question 1:  Hello my name is _____________ and I am calling from the Geisinger 
Center for Health Research.  May I please speak with  
 
A) If Yes – Continue to Question 2. 
 
 B) If No – Ask for a better time to call back and set call back. 
 
Question 2: I am calling to follow-up with you regarding the Drexel University 
Polycythemia Vera Research Study. Though we have not received your consent by 
mail, we are able to do the consent and questionnaire over the telephone now. May I 
proceed?  
 
A) If Yes – Continue to Question 3. [set callback if necessary]    
  
 B) If No – SKIP to END REFUSAL 
 
Question 3:   Before beginning, I would like to give you some details about the 
study. First, can you confirm that you have continuously resided within the tri-county 
area of Carbon, Luzerne, or Schuylkill County between January 1, 2000 and 
December 31, 2008?   
 
 
A) If Yes – Continue to Question 4. 
 
 B) If No – SKIP to END INELIGIBLE 
 
Question 4:  Thank you. You are being asked to take part in this research study 
because you are a resident of the tri-county region of Northeast Pennsylvania 
(Luzerne, Schuylkill, and Carbon counties).  The purpose of this study is to 
investigate possible risk factors for certain blood diseases that have occurred among 
residents of Northeastern Pennsylvania.   
 Study participants will include those who have certain blood diseases and also 
those who are not known to be affected by any blood disease. 
 Taking part in this research study is voluntary.  You may choose not to be in 
the study or withdraw from the study at any time. 
 Appropriate measures will be made to keep your personal information 
confidential. You should know that according to Federal law the information 
that we are collecting from you is called Protected Health Information and that 
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you have certain rights regarding this information. We will protect the 
confidentiality of your protected health information in accordance with federal 
and state laws.  
 
Do you have any questions about your privacy and confidentiality and your Protected 
Health Information? 
 
A)  If Yes: What questions do you have? (Answer questions). Skip to 
Question 5. 
 
B)  If No: Skip to Question 5. 
 
 
Question 5:  Your decision not to participate or to withdraw from the study will not 
involve any penalty or loss of benefits. It will not affect your access to health care at 
Geisinger Clinic or any other health care system.    
 
Do you agree to participate in this research study by responding to survey questions 
and allowing us to use your Protected Health Information for this study? 
 
If Yes: Great. We can now begin the survey, which will take between 45 
minutes and an hour to complete [set callback if necessary] 
 
 
 If No: Skip to END REFUSED. 
 
 
(Phone Questionnaire Complete) 
 
Question 6: As an optional part of the study we would also like to offer a blood draw. 
We will send you an additional $25.00 Wal Mart gift card to thank you for your 
participation. By having the blood draw, you are giving the research team permission 
to collect, store, and test your blood samples (approximately 2 tablespoons) now or 
for future research studies to learn about, prevent, or treat characteristics related to the 
blood diseases under study. Would you be interested in the blood draw? 
 
If Yes – Great!  For the blood draw, we need a consent form mailed back to us 
in advance, so we will be mailing out a consent form for you to sign to agree 
to the blood draw.  Skip to END   
 
 If No – Skip to END  
 
END:  Thank you again for your participation in the Drexel University Polycythemia 
Vera Research study.  We truly appreciate your efforts.  Should you have any 
questions or concerns please feel free to contact a member of the study team at 1-866-
630-0798 option 2. 
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END REFUSED:  I am sorry to hear that you are not interested in participating in the 
study.  Thank you for your time.  Have a nice day. 
 
END INELIGIBLE: I am sorry that you do not meet the residency requirement for 
this study. If you’d like to speak with a member of the study team, please call 1-866-
630-0798 option 2. Thank you for your time. Have a nice day.  
 
Appendix E 
Initial Mailed Packet  
 Residential History (Keep for Reference During Phone Survey) 
 
 
 
 
To the best of your ability, please list each primary residence you’ve lived in for 6 months or longer. Begin with your current residence (#1) and work 
backwards, listing all residences back to age 21. Include your current residence even if you have lived there for less than 6 months. Fill in the address information 
to the best of your recollection, even if you don’t have a complete address or ZIP Code. Please estimate the time period if you cannot remember exact dates. We will 
review this form during the phone survey.  
 
For the residence description, please write the corresponding number in the space: 
1) Single Family Home   
2) Apartment  
3) Condominium/Townhouse  
4) Farm (please specify type: dairy, livestock, cash crops, etc.)  
5) Mobile Home 
6) Other (please specify)  
 
Please use additional pages if needed.  
 
For the residence description, please write the corresponding number in the space:
Residence 
number 
Time period 
 
Mo/Yr to Mo/Yr 
Street Address City/Town State and ZIP 
Code 
How would you 
best describe 
this residence? 
(see key above) 
1 
 
 
 
 
 
 
 
 to 
    
2 
 
 
 
 
 
 
 
 to 
    
3 
 
 
 
 
 
 
 
 
 to 
    
2
4
8
 
Residence 
number 
Time period 
 
Mo/Yr to Mo/Yr 
Street Address City/Town State and ZIP 
Code 
How would you 
best describe 
this residence? 
(see key above) 
4 
 
 
 
 
 
 
 
 to 
    
5 
 
 
 
 
 
 
 
 to 
    
2
4
9
 
1) Single Family Home   
2) Apartment  
3) Condominium/Townhouse  
4) Farm (please specify: dairy, livestock, cash crops, or other)  
5) Mobile Home 
 
Residence 
number 
Time period 
 
Mo/Yr to Mo/Yr 
Street Address City/Town State and ZIP 
Code 
How would you 
best describe 
this residence? 
(see key above) 
6 
 
 
 
 
 
 
 
 to 
    
7 
 
 
 
 
 
 
 
 to 
    
8 
 
 
 
 
 
 
 
 
 to 
    
9 
 
 
 
 
 
 
 
 to 
    
10 
 
 
 
 
 
 
 
 to 
    
2
5
0
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